---
document_datetime: 2025-07-15 12:58:50
document_pages: 94
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/calquence-h-c-005299-ii-0028-epar-assessment-report-variation_en.pdf
document_name: calquence-h-c-005299-ii-0028-epar-assessment-report-variation_en.pdf
version: success
processing_time: 115.7675457
conversion_datetime: 2025-12-19 06:49:22.646752
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2025 EMA/CHMP/124570/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Calquence

International non-proprietary name: Acalabrutinib

Procedure No. EMEA/H/C/005299/II/0028

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product............................................................................................10      |                                                                                                         |
| 2.1.3. The development programme/scientific advice                                                                          | ....................................................10                                                  |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                             |
| 2.2.2. Discussion on non-clinical aspects......................................................................13           |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................13             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................13    |
| 2.3.1. Introduction....................................................................................................13   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................14      |                                                                                                         |
| 2.3.3. PK/PD modelling..............................................................................................21      |                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................24             |                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................25              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................25    |
| 2.4.1. Dose response study........................................................................................25        |                                                                                                         |
| 2.4.2. Main study......................................................................................................25   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................59        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................63          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................63  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................83                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................86                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................86 |
| 2.6. Risk management plan........................................................................................86         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................88                              |
| 2.7.1. User consultation.............................................................................................88     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................88                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................88           |
| 3.1.1. Disease or condition.........................................................................................88      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................89                  |                                                                                                         |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................89             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................89        |
| 3.3. Uncertainties and limitations about favourable effects.............................................90                  |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................90      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................91                                                             |
| 3.6. Effects Table......................................................................................................91  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................92              |                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................92                    |                                                                                                         |
| 3.7.2. Balance of benefits and risks.............................................................................92         |                                                                                                         |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ...........................................  92

3.8. Conclusions .......................................................................................................  92

4. Recommendations .................................................................................  92

5. EPAR changes  ........................................................................................  93

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADR      | adverse drug reaction                                            |
|----------|------------------------------------------------------------------|
| AE       | adverse event                                                    |
| AESI     | adverse event of special interest                                |
| ALT      | alanine aminotransferase                                         |
| ANC      | absolute neutrophil count                                        |
| AST      | aspartate aminotransferase                                       |
| AUC      | area under the concentration-time curve                          |
| AV       | acalabrutinib and venetoclax                                     |
| AVG      | acalabrutinib, venetoclax, and obinutuzumab                      |
| BCL2     | B-cell leukaemia/lymphoma 2 protein                              |
| BCR      | B-cell receptor                                                  |
| BID      | twice daily                                                      |
| BM       | bone marrow                                                      |
| BOR      | best overall response                                            |
| BR       | bendamustine and rituximab                                       |
| BTK      | Bruton tyrosine kinase                                           |
| BTKi     | Bruton tyrosine kinase inhibitor                                 |
| CI       | confidence interval                                              |
| CLL      | chronic lymphocytic leukaemia                                    |
| COVID-19 | coronavirus disease 2019                                         |
| CR       | complete response/remission                                      |
| CRi      | complete response/remission with incomplete bone marrow recovery |
| CSR      | clinical study report                                            |
| CTCAE    | Common Terminology Criteria for Adverse Events                   |
| DCO      | data cutoff date                                                 |
| DDI      | drug/drug interaction                                            |
| DoR      | duration of response                                             |
| ECI      | event of clinical interest                                       |
| ECOG     | Eastern Cooperative Oncology Group                               |
| EFS      | event-free survival                                              |
| EMA      | European Medicines Agency                                        |
| EORTC    | European Organization for Research and Treatment of Cancer       |

<div style=\"page-break-after: always\"></div>

| EU     | European Union                                         |
|--------|--------------------------------------------------------|
| FACIT  | Functional Assessment of Chronic Illness Therapy       |
| FCR    | fludarabine, cyclophosphamide, and rituximab           |
| FDA    | Food and Drug Administration                           |
| HR     | hazard ratio                                           |
| IGHV   | Immunoglobulin heavy-chain variable region gene        |
| ILD    | interstitial lung disease                              |
| IPTW   | Inverse probability of treatment weighting             |
| IRC    | independent review committee                           |
| IWCLL  | International Workshop on Chronic Lymphocytic Leukemia |
| KM     | Kaplan-Meier                                           |
| mAb    | monoclonal antibody                                    |
| MCL    | mantle cell lymphoma                                   |
| MedDRA | Medical Dictionary of Regulatory Activities            |
| MoA    | Mechanism of action                                    |
| NE     | Not estimated                                          |
| NCCN   | National Comprehensive Cancer Network                  |
| NCI    | National Cancer Institute                              |
| ORR    | overall response rate                                  |
| OS     | overall survival                                       |
| PB     | peripheral blood                                       |
| PD     | progressive disease                                    |
| PFS    | progression-free survival                              |
| PGIC   | Patient Global Impression of Change                    |
| PGIS   | Patient Global Impression of Severity                  |
| PK     | pharmacokinetic                                        |
| PO     | by mouth                                               |
| PopPK  | population pharmacokinetics                            |
| PRO    | patient reported outcome                               |
| PT     | preferred term                                         |
| QD     | once daily                                             |
| R/R    | relapsed or refractory                                 |
| SAE    | serious adverse event                                  |

<div style=\"page-break-after: always\"></div>

| SD   | standard deviation                     |
|------|----------------------------------------|
| SLL  | small lymphocytic lymphoma             |
| SMQ  | standardized MedDRA query              |
| SOC  | system organ class                     |
| SoC  | standard of care                       |
| SPM  | second primary malignancy              |
| sBR  | structured benefit risk                |
| TEAE | treatment-emergent adverse event       |
| TLS  | tumour lysis syndrome                  |
| TN   | treatment naïve (previously untreated) |
| ULN  | upper limit of normal                  |
| uMRD | undetectable minimal residual disease  |
| VAS  | visual analogue scale                  |

Assessment report

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 7 October 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include CALQUENCE in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), based on interim results from study AMPLIFY (D8221C00001). This is a Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation (AMPLIFY). As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8 of the RMP has also been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0111/2023 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received scientific advice from the CHMP on 20 September 2018

(EMEA/H/SA/3090/4/2018/PA/III). The Scientific advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

Co-Rapporteur:

&lt;N/A&gt;

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 7 October 2024   |
| Start of procedure:                                  | 2 November 2024  |
| CHMP Rapporteur Assessment Report                    | 20 December 2024 |
| PRAC Rapporteur Assessment Report                    | 6 January 2025   |
| PRAC members comments                                | 8 January 2025   |
| PRAC Outcome                                         | 16 January 2025  |
| CHMP members comments                                | 20 January 2025  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 23 January 2025  |
| Request for supplementary information (RSI)          | 30 January 2025  |
| CHMP Rapporteur Assessment Report                    | 21 March 2025    |
| PRAC Rapporteur Assessment Report                    | 28 March 2025    |
| PRAC members comments                                | 2 April 2025     |
| Updated PRAC Rapporteur Assessment Report            | Not applicable   |
| PRAC Outcome                                         | 10 April 2025    |
| CHMP members comments                                | 14 April 2025    |
| Updated CHMP Rapporteur Assessment Report            | 16 April 2025    |
| Opinion                                              | 25 April 2025    |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Chronic lymphocytic leukaemia (CLL) is the most prevalent form of adult leukaemia, with an age adjusted incidence of 3.3-6.4 per 100000 person-years and a median age at diagnosis of 70 years.

## Claimed therapeutic indication

Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

## Clinical presentation, diagnosis and stage/prognosis

The diagnosis of CLL is established using peripheral blood counts and immunophenotyping that demonstrates a minimum of 5 x 109 monoclonal B cells that co-express the surface antigens CD5,

<div style=\"page-break-after: always\"></div>

CD19, CD20, and CD23. The clonality of the circulating B lymphocytes needs to be confirmed by demonstrating light chain restriction using flow cytometry.

Treatment of CLL is initiated once there is evidence for progressive or symptomatic/active disease as defined by IWCLL guidelines. While patients with early disease have not been shown to have a survival advantage with early treatment, most patients will eventually require therapy for their disease with the onset of symptoms or cytopenias. Treatment of CLL is therefore often deferred in asymptomatic patients with early-stage disease.

Despite the relatively long-life expectancy for early-stage disease with the recent advent of multiple treatment options including Bruton tyrosine kinase (BTK) and B-cell leukaemia/lymphoma 2 protein (BCL2) inhibitors, CLL remains an incurable disease. The goals of therapy are to improve quality of life and to prolong survival.

## Management

The choice of frontline treatment options for CLL depends on patient characteristics, such as patient's age and overall health, and disease characteristics, including the presence of certain chromosomal abnormalities and mutations. For asymptomatic patients, watchful waiting (observation) remains an option, specifically closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change.

The development of novel molecularly targeted agents, particularly BTK inhibitors (acalabrutinib and ibrutinib) and the apoptosis regulator BCL2 antagonist venetoclax, has transformed the treatment paradigm for patients with CLL, particularly for those with high-risk disease who have inferior outcomes with chemotherapy-based regimens. Targeted treatment (BTKi or venetoclax) with or without anti-CD20 mAbs are the therapy of choice in most front-line CLL settings regardless of mutational status. However, fludarabine, cyclophosphamide, and rituximab (FCR) is also indicated in young and fit patients with mutated IGHV.

Randomised clinical studies had previously established the FCR combination as frontline therapy in a younger, fitter population with few comorbidities. In a head-to-head comparison (CLL10 study) of previously untreated fit patients who received bendamustine and rituximab (BR) versus FCR, the results showed a median Progression Free Survival (PFS) of 42.3 months in BR versus 57.6 months for FCR treated patients. No notable differences were observed in OS benefit between BR and FCR. This study established the combination of FCR as a Standard of Care (SoC) option for front-line therapy in fit patients with CLL. For patients with moderate renal dysfunction, BR is preferred over FCR. Moreover, for patients ≥ 65 years of age, if chemoimmunotherapy is deemed appropriate, BR is a choice of treatment.

In the Phase III ELEVATE TN study, previously untreated CLL patients inclusive of those with high-risk cytogenetics such as 17p deletion, unmutated IGHV or TP53 mutation were randomised to receive acalabrutinib and obinutuzumab, acalabrutinib monotherapy, and obinutuzumab and chlorambucil in 1:1:1 ratio.

After a median follow-up of 28.3 months, the primary analysis showed acalabrutinib + obinutuzumab demonstrated a statistically significant improvement in IRC-assessed PFS compared with obinutuzumab + chlorambucil, with a 90% reduction in risk of disease progression or death (HR = 0.10 [95% CI: 0.06, 0.17]; p &lt; 0.0001). Acalabrutinib monotherapy also demonstrated a statistically significant improvement in IRC-assessed PFS compared with obinutuzumab + chlorambucil, with an 80% reduction in risk of disease progression or death (HR = 0.20 [95% CI: 0.13, 0.30]; p value &lt; 0.0001).

<div style=\"page-break-after: always\"></div>

The combination of acalabrutinib + obinutuzumab as well as acalabrutinib alone, when compared to obinutuzumab + chlorambucil, demonstrated a survival benefit based on the OS HR of 0·47, (95% CI: 0.21, 1.06; p-value = 0.06) and OS HR of 0·60; (95% CI: 0.28, 1.27; p-value = 0·16), respectively. The data from the ELEVATE-TN study supported the approval of acalabrutinib with or without obinutuzumab for the treatment of CLL.

Studies evaluating another second generation BTKi, zanubrutinib, as a monotherapy led to its approval for use in treatment naïve and R/R CLL/SLL patients. SEQUOIA was a randomised Phase III study in previously untreated CLL/SLL patients who were elderly and/or adults with comorbidities which precluded use of FCR. Patients with del(17p) received zanubrutinib as monotherapy and those without del(17p) were randomised to either zanubrutinib alone or BR. At a median follow-up of 26.2 months, in patients without 17p deletion, treatment with zanubrutinib showed improved PFS versus BR (HR = 0.42; 95% CI: 0.28, 0.63; p-value &lt; 0.0001).

In the ALPINE study, patients with R/R CLL/SLL were randomised 1:1 to receive zanubrutinib or ibrutinib. At a median follow-up of 29.6 months, zanubrutinib demonstrated superiority over ibrutinib with PFS that was significantly longer (p-value = 0.002), with a HR of 0.65 (95% CI: 0.49, 0.86). Median PFS for zanubrutinib was not reached and was 34.2 months in the ibrutinib group (95% CI: 33.3 to NE). Based on results from the SEQUOIA and ALPINE studies, zanubrutinib was approved for the treatment of CLL/SLL.

In the EU and other countries outside of the US, ibrutinib in combination with venetoclax is approved as a fixed duration therapy in previously untreated CLL. Ibrutinib plus venetoclax demonstrated superior IRC-assessed PFS compared to obinutuzumab plus chlorambucil in older CLL patients and/or those with comorbidities, but no difference in OS was observed at the GLOW primary analysis.

## 2.1.2. About the product

Acalabrutinib (ACP-196), is a second generation, selective inhibitor of Bruton tyrosine kinase (BTK). Binding of acalabrutinib, and its active metabolite, ACP-5862, to BTK permanently inactivates the enzyme and results in the inhibition of proliferation and survival signals in malignant B-cells.

## Currently approved indications

- Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
- Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

## 2.1.3. The development programme/scientific advice

CHMP Scientific advice was received on the following topics:

- The proposed toxicology package
- It was recommended to power the study for evaluation of both control regimens or perform 2 different studies.
- The Standard of Care (SoC) in the comparator arms were considered acceptable.
- PFS as primary endpoint supported by EFS/DFS (e.g. at 4 years) would need to be provided to

<div style=\"page-break-after: always\"></div>

support regulatory decision making.

- The contribution of acalabrutinib and venetoclax in the regimen would need to be established at time of submission.
- MRD collection and analyses was also supported.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The MAH has provided a revised ERA in accordance with the updated EMA Guidance on the environmental risk assessment of medicinal products for human use (CHMP 2024) in support of this application.

The calculation of the PEC of acalabrutinib, uses a refined Fpen based on European disease prevalence data and the maximum daily dose in the PEC calculation. The resulting estimation of the PEC and environmental risk (PEC:PNEC ratios) are considered conservative.

## Phase I:

The maximum daily dose for the indication MCL is 200 mg/day, resulting in PECSURFACEWATER value of 0.006 μ g/L. For the indication chronic lymphocytic leukaemia with the maximum daily dose of 200 mg/day, the PECSURFACEWATER value was 0.048 μ g/L, using a refined Fpen based on prevalence data as defined in the orphan drug designation. Combining both indications, an updated PECSURFACEWATER-TOTAL was calculated to 0.054 μ g/L.

## Phase II Tier A: updated risk ratios (PEC/PNEC)

New phase II risk ratios are based on the guideline on environmental risk assessment from 2024 and the updated PECSURFACEWATER-TOTAL (0.054 μ g/L) and the PNEC (predicted no-effect concentration) values that were presented for the original ERA submitted for the MAA. The updated risk ratios are presented below.

## Phase II Tier A

| Compartment   | PEC         | PNEC          | PEC/PNEC (action limit)   |
|---------------|-------------|---------------|---------------------------|
| Surface water | 0.054 μ g/L | 120 μ g/L     | 4.5 × 10 -4 (<1)          |
| Groundwater   | 0.014 μ g/L | 12 μ g/L      | 1.1 × 10 -3 (<1)          |
| Microorganism | 0.54 μ g/L  | 100000 μ g/L  | 5.4 × 10-6 (<0.1)         |
| Sediment      | 740 μ g/kg  | 14 400 μ g/kg | 0.051 (<1)                |

## Summary of main study results

<div style=\"page-break-after: always\"></div>

| Substance (INN/Invented Name): Acalabrutinib CAS-number (if available): 1420477-60-6                                                                  | Substance (INN/Invented Name): Acalabrutinib CAS-number (if available): 1420477-60-6   | Substance (INN/Invented Name): Acalabrutinib CAS-number (if available): 1420477-60-6                                                                                     | Substance (INN/Invented Name): Acalabrutinib CAS-number (if available): 1420477-60-6                                                                                     | Substance (INN/Invented Name): Acalabrutinib CAS-number (if available): 1420477-60-6   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| PBT screening                                                                                                                                         |                                                                                        | Result                                                                                                                                                                   |                                                                                                                                                                          | Conclusion                                                                             |
| Bioaccumulation potential- log Dow                                                                                                                    | OECD107                                                                                | log Dow = 1.29 at pH 5 log Dow = 1.96 at pH 7 log Dow = 1.99 at pH 9                                                                                                     | log Dow = 1.29 at pH 5 log Dow = 1.96 at pH 7 log Dow = 1.99 at pH 9                                                                                                     | Potential PBT:N                                                                        |
| PBT-assessment                                                                                                                                        | PBT-assessment                                                                         | PBT-assessment                                                                                                                                                           | PBT-assessment                                                                                                                                                           | PBT-assessment                                                                         |
| Parameter                                                                                                                                             | Result relevant for conclusion                                                         |                                                                                                                                                                          |                                                                                                                                                                          | Conclusion                                                                             |
| Bioaccumulation                                                                                                                                       | log D OW                                                                               | < 3 at pH 5, 7 and 9                                                                                                                                                     | < 3 at pH 5, 7 and 9                                                                                                                                                     | not B                                                                                  |
| Persistence                                                                                                                                           | DT50total system (12 °C) DT50sediment (12 °C)                                          | 216 d 203 d                                                                                                                                                              | 216 d 203 d                                                                                                                                                              | vP                                                                                     |
| Toxicity                                                                                                                                              | NOEC or CMR                                                                            | 1.2 mg/L                                                                                                                                                                 | 1.2 mg/L                                                                                                                                                                 | Not T                                                                                  |
| PBT-statement:                                                                                                                                        | The compound is not considered as PBT nor vPvB                                         | The compound is not considered as PBT nor vPvB                                                                                                                           | The compound is not considered as PBT nor vPvB                                                                                                                           | The compound is not considered as PBT nor vPvB                                         |
| Phase I                                                                                                                                               | Phase I                                                                                | Phase I                                                                                                                                                                  | Phase I                                                                                                                                                                  | Phase I                                                                                |
| Calculation                                                                                                                                           | Value                                                                                  | Unit                                                                                                                                                                     | Unit                                                                                                                                                                     | Conclusion                                                                             |
| PECsurfacewater, refined with prevalence                                                                                                              | 0.054                                                                                  | µ g/L                                                                                                                                                                    | µ g/L                                                                                                                                                                    | > 0.01 threshold: Y N                                                                  |
| Other concerns Phase II Physical-chemical properties and fate                                                                                         | Other concerns Phase II Physical-chemical properties and fate                          | Other concerns Phase II Physical-chemical properties and fate                                                                                                            | Other concerns Phase II Physical-chemical properties and fate                                                                                                            | Other concerns Phase II Physical-chemical properties and fate                          |
| Study type                                                                                                                                            | Test protocol                                                                          | Results                                                                                                                                                                  | Results                                                                                                                                                                  | Remarks                                                                                |
| Dissociation constant, pKa                                                                                                                            |                                                                                        | 3.5 (pyridine), 5.8 (imidazopyrazine), 12.1 (benzamide)                                                                                                                  | 3.5 (pyridine), 5.8 (imidazopyrazine), 12.1 (benzamide)                                                                                                                  |                                                                                        |
| Water solubility                                                                                                                                      |                                                                                        | 70 mg/L at pH 6.8 and 25 o                                                                                                                                               | 70 mg/L at pH 6.8 and 25 o                                                                                                                                               | Not readily biodegradable                                                              |
| Activated sludge die away                                                                                                                             | OECD 314B                                                                              | DT50 (parent) = 0.711 days 3.58% mineralisation over 28                                                                                                                  | DT50 (parent) = 0.711 days 3.58% mineralisation over 28                                                                                                                  | Not readily biodegradable                                                              |
| Adsorption-Desorption Soil 1 = Silty clay loam soil Soil 2 = Loamy sand soil Sediment 1 = Loam sediment Sediment 2 = Sand sediment Sludge [mean, n=2] | OECD 106                                                                               | days K oc, sludge = 5.05 x 10 2 L/kg K oc, sediment 1=1.37 x 10 5 L/kg K oc, sediment2 =1.20 x 10 5 L/kg K oc, soil 1 = 8.79 x 10 5 L/kg K oc, soil 2 = 1.84 x 10 6 L/kg | days K oc, sludge = 5.05 x 10 2 L/kg K oc, sediment 1=1.37 x 10 5 L/kg K oc, sediment2 =1.20 x 10 5 L/kg K oc, soil 1 = 8.79 x 10 5 L/kg K oc, soil 2 = 1.84 x 10 6 L/kg |                                                                                        |
| Phase IIa Effect studies                                                                                                                              | Phase IIa Effect studies                                                               | Phase IIa Effect studies                                                                                                                                                 | Phase IIa Effect studies                                                                                                                                                 | Phase IIa Effect studies                                                               |
| Study type                                                                                                                                            | Test protocol                                                                          | Endpoint                                                                                                                                                                 | value                                                                                                                                                                    | Remarks                                                                                |
| Algae, Growth Inhibition Test/ Pseudokirchneriella subcapitata                                                                                        | OECD 201                                                                               | NOEC EC10 EC50 EC50                                                                                                                                                      | 2700 26000 >41000 29000                                                                                                                                                  | Growth rate Growth rate Yield                                                          |
| Daphnia sp . Reproduction Test                                                                                                                        | OECD 211                                                                               | NOEC LOEC                                                                                                                                                                | 1200 2700                                                                                                                                                                | rate of first brood generation                                                         |
| Fish, Early Life Stage Toxicity Test/ Pimephales promelas                                                                                             | OECD 210                                                                               | NOEC LOEC                                                                                                                                                                | 3800 >3000                                                                                                                                                               | No significant effects observed                                                        |
| Activated Sludge, Respiration Inhibition Test                                                                                                         | OECD 209                                                                               | NOEC                                                                                                                                                                     | 70000                                                                                                                                                                    | solubility limit, total respiration                                                    |
| Sediment dwelling organism/Chironomus riparius                                                                                                        | OECD 218                                                                               | NOEC LOEC                                                                                                                                                                | 244 461                                                                                                                                                                  | Emergence ratio and development rate                                                   |
| Phase IIb Studies                                                                                                                                     |                                                                                        |                                                                                                                                                                          |                                                                                                                                                                          |                                                                                        |

<div style=\"page-break-after: always\"></div>

| Aerobic and Anaerobic Transformation in Aquatic Sediment systems Sediment 1 = Brandywine Creek (HOC) Sediment 2 = Choptank River (LOC)   | OECD 308   | DT 50, water = 3.5 d / 5.8 d DT 50, sediment = 95 d / 53 d DT 50, whole system = 101 d / 54.4 d %shifting to sediment = 77.2 / 40 %CO 2 = 1.7 / 2.4 %NER = 58.4 / 43.2 transformation products > 10%: TP-RT11.5min, 11.4%AR, d7   | I / II, 20 °C at d 14, parent + NER at test end at test end 4-[(pyridin-2- yl)carbamoyl]be nzoic acid   |
|------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|

## 2.2.2. Discussion on non-clinical aspects

An updated ERA was provided but no new non-clinical data was submitted in this application, which is considered acceptable given that the clinical dose intended for treatment of the new indication (untreated CLL) is the same as for the previously authorised indication. No changes in SmPC sections 4.6 or 5.3 are proposed or required.

The MAH has calculated an updated PECSURFACEWATER-TOTAL value (0.054 μ g/L) based on the use of acalabrutinib for the treatment of chronic lymphocytic leukaemia. The risk ratios (PEC/PNEC) were subsequently re-calculated based on considerations in the new ERA guideline implemented 01 September 2024 and the updated PECSURFACEWATER-TOTAL and the PNEC values that were presented for the original ERA submitted for the MAA. The resulting risk ratios remain below the action limits. Therefore, the use of acalabrutinib for the indications considered in the present report (MCL and chronic lymphocytic leukaemia) is not expected to pose a risk for the environment.

## 2.2.3. Conclusion on the non-clinical aspects

Considering the above data, acalabrutinib is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The AMPLIFY study (also referred to as ACE-CL-311) was designed to assess the efficacy and safety of a fixed-duration therapy of acalabrutinib in combination with venetoclax with or without obinutuzumab for the treatment of patients with previously untreated CLL versus investigator's choice of chemoimmunotherapy.

Efficacy data in support of this application, presented in this section, are from the primary PFS analysis (DCO 30 April 2024), unless otherwise stated.

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

<div style=\"page-break-after: always\"></div>

The MAH has provided a statement to the effect that clinical trials conducted outside the European Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study CSR Location                                                                                                                                                                                                                                                                                                                                                                                                         | Study Design                               | Subjects (N; type, ethnicity; age, body weight: median [rangel)                                                                                                                                                                            | Treatments (dose, dosage form, route)                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AMPLIFY Study ACE-CL-311 (D8221C00001),Randomized, Multicenter, Open-Label, Phase IlI Study to Compare the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax (AV) with and without Obinutuzumab (A VG) Compared to Investigator's Choice of Chemoimmunotherapy (Chemo) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation CSR location: Module 5.3.5.1 | Randomized, open- label, multicenter study | Patients with previously untreated CLL; N= 867 Randomized: AV=291; AVG=286; Chemo=290 Sex: Male = 559, Female =308; Age: median (range) 61 yrs (26-86); Race: White = 765 (88.2%), Asian =31 (3.6%), Black or African American = 21 (2.4%) | Acalabrutinib 100 mg. administered twice daily, provided as hard gelatin capsules for oral administration. Venetoclax, administered orally, will begin at Cycle 3 and continue following a 5- week ramp-up at a fixed daily dose until the end of Cycle 14. Obinutuzumab will be administered by intravenous (IV) infusion as an absolute (flat) dose of 1000 mg. starting at Cycle 2 and continue through Cycle 7. |

## 2.3.2. Pharmacokinetics

Study ACE-CL-311 (AMPLIFY) included PK sampling at pre-dose and 1- and 4-hours post-dose on Day 1 of Cycles 1, 5, and 7 (28-day cycle). Acalabrutinib and the active metabolite ACP-5862 were quantified.

The MAH provided graphical and tabular summaries of observed PK data from ACE-CL-311, including comparisons to studies in other populations ( Table 1 and Table 2 )

The baseline characteristics/demographics between the studies included in the PK-comparison are summarized in Table 3 and Table 4 .

Table 1. Observed plasma concentrations (nM) versus time (Steady State) stratified by population/study for acalabrutinib

| Analyte: Acalabrutinib Study ID   | Time (hours)         |                |                      |                     |                     |
|-----------------------------------|----------------------|----------------|----------------------|---------------------|---------------------|
|                                   | 1                    | h 2            | h 4 h                | 6                   | h                   |
| ACE-CL-006                        | N                    | 99             | 102                  | 102                 | 99                  |
| ACE-CL-006                        | GeoMean (GeoCV %)    | 343.27 (235.3) | 290.67 (97)          | 69.01 (114.8)       | 29.85 (124.1)       |
| ACE-CL-006                        | Median (range)558.54 | (4.1 - 2341.6) | 310.42 (18 - 1465.1) | 67.99 (8.6 - 794.8) | 31.36 (4.6 - 476.9) |
|                                   | N                    | 243            | 249                  | 248                 | -                   |

<div style=\"page-break-after: always\"></div>

| ACE-CL-007   | GeoMean (GeoCV %)    | 406.47 (266.8)   | 296.07 (113.8)   | 83.61 (121.9)        | -   |
|--------------|----------------------|------------------|------------------|----------------------|-----|
| ACE-CL-007   | Median (range)604    | (3.3 - 5220)     | 322 (3.7 - 2170) | 72.85 (4.6 - 1620)   | -   |
| ACE-CL-311   | N                    | 531              | -                | 525                  | -   |
| ACE-CL-311   | GeoMean (GeoCV %)    | 266.45 (390.6)   | -                | 96.29 (133.3)        | -   |
| ACE-CL-311   | Median (range)486.47 | (2.4 - 4003.9)   | -                | 97.98 (2.6 - 1472.9) | -   |

Abbreviations: GeoMean, geometric mean; GeoCV, geometric coefficient of variation; h, hour; ID, identifier

Table 2. Observed Plasma Concentrations (nM) Versus Time (Steady State) Stratified by Population/Study for ACP-5862

| Analyte: ACP-5862 Study   | Analyte: ACP-5862 Study   | Time (hours)    | Time (hours)           | Time (hours)           | Time (hours)           |
|---------------------------|---------------------------|-----------------|------------------------|------------------------|------------------------|
| ID                        |                           | 1 h             | 2 h                    | 4 h                    | 6 h                    |
|                           | N                         | 5               | 5                      | 5                      | 6                      |
|                           | GeoMean (GeoCV %)         | 350.97 (78.6)   | 803.67 (24.2)          | 520.58 (32.2)          | 309.4 (35.5)           |
|                           | Median (range)382.14      | (132.9 - 789.2) | 872.27 (529.6 - 957.4) | 452.75 (359.3 - 751.8) | 280.37 (224.3 - 537.9) |
| ACE-CL-007                | N                         | 248             | 251                    | 249                    | -                      |
| ACE-CL-007                | GeoMean (GeoCV %)         | 454.5 (153)     | 606.68 (86.4)          | 395.11 (58.3)          | -                      |
| ACE-CL-007                | Median (range)622         | (26.6 - 3390)   | 690 (37 - 2220)        | 401 (36.8 - 1730)      | -                      |
| ACE-CL-311                | N                         | 532             | -                      | 526                    | -                      |
| ACE-CL-311                | GeoMean (GeoCV %)         | 350.7 (152.3)   | -                      | 406.07 (60)            | -                      |
| ACE-CL-311                | Median (range)483.66      | (14.3 - 2203.8) | -                      | 428.95 (21.6 - 1709.3) | -                      |

Abbreviations: GeoMean, geometric mean; GeoCV, geometric coefficient of variation; h, hour; ID, identifier

Table 3. Comparison of relevant continuous covariates/patient demographics between the populations/ studies

| Parameter           | ACE-CL-006 (N = 117)   | ACE-CL-007 (N = 274)   | ACE-CL-311 (N = 571)   | Overall (N = 962)   |
|---------------------|------------------------|------------------------|------------------------|---------------------|
| Baseline age (year) |                        |                        |                        |                     |
| Mean (SD)           | 65.2 (10.1)            | 69.5 (7.81)            | 60.0 (9.43)            | 63.3 (10.0)         |

<div style=\"page-break-after: always\"></div>

| Median (Min, Max)                         | 66.0 (41.0, 87.0)                         | 70.0 (41.0,88.0)                          | 61.0 (29.0, 84.0)                         | 64.0 (29.0, 88.0)                         |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Baseline weight (kg)                      | Baseline weight (kg)                      | Baseline weight (kg)                      | Baseline weight (kg)                      | Baseline weight (kg)                      |
| Mean (SD)                                 | 79.9 (17.2)                               | 80.4 (18.4)                               | 80.2 (16.3)                               | 80.2 (17.0)                               |
| Median (Min, Max)                         | 79.0 (45.6, 157)                          | 78.5 (44.0, 149)                          | 79.0 (43.0, 140)                          | 79.0 (43.0, 157)                          |
| Baseline height (cm)                      | Baseline height (cm)                      | Baseline height (cm)                      | Baseline height (cm)                      | Baseline height (cm)                      |
| Mean (SD)                                 | 171 (10.6)                                | 169 (9.14)                                | 172 (9.97)                                | 171 (9.87)                                |
| Median (Min, Max)                         | 172 (142, 196)                            | 169 (143, 193)                            | 172 (143, 196)                            | 170 (142, 196)                            |
| Missing                                   | 0                                         | 0                                         | 2 (0.4%)                                  | 2 (0.2%)                                  |
| Baseline body mass index (kg/m 2 )        | Baseline body mass index (kg/m 2 )        | Baseline body mass index (kg/m 2 )        | Baseline body mass index (kg/m 2 )        | Baseline body mass index (kg/m 2 )        |
| Mean (SD)                                 | 27.0 (4.59)                               | 27.9 (5.40)                               | 27.2 (4.78)                               | 27.4 (4.95)                               |
| Median (Min, Max)                         | 26.6 (17.9, 48.3)                         | 27.1 (17.6, 50.5)                         | 26.6 (17.2, 52.6)                         | 26.7 (17.2, 52.6)                         |
| Missing                                   | 0                                         | 0                                         | 2 (0.4%)                                  | 2 (0.2%)                                  |
| Baseline body surface area (m 2 )         | Baseline body surface area (m 2 )         | Baseline body surface area (m 2 )         | Baseline body surface area (m 2 )         | Baseline body surface area (m 2 )         |
| Mean (SD)                                 | 1.92 (0.229)                              | 1.90 (0.228)                              | 1.92 (0.221)                              | 1.92 (0.224)                              |
| Median (Min, Max)                         | 1.92 (1.42, 2.67)                         | 1.90 (1.38, 2.55)                         | 1.91 (1.32, 2.57)                         | 1.91 (1.32, 2.67)                         |
| Missing                                   | 0                                         | 0                                         | 2 (0.4%)                                  | 2 (0.2%)                                  |
| Baseline creatinine clearance (mL/min)    | Baseline creatinine clearance (mL/min)    | Baseline creatinine clearance (mL/min)    | Baseline creatinine clearance (mL/min)    | Baseline creatinine clearance (mL/min)    |
| Mean (SD)                                 | 89.7 (37.2)                               | 81.2 (29.5)                               | 89.2 (27.3)                               | 87.0 (29.5)                               |
| Median (Min, Max)                         | 87.5 (27.2, 264)                          | 77.9 (29.0, 249)                          | 85.2 (36.6, 249)                          | 83.3 (27.2, 264)                          |
| Missing                                   | 0                                         | 0                                         | 1 (0.2%)                                  | 1 (0.1%)                                  |
| Baseline eGFR (mL/min/1.73m 2 )           | Baseline eGFR (mL/min/1.73m 2 )           | Baseline eGFR (mL/min/1.73m 2 )           | Baseline eGFR (mL/min/1.73m 2 )           | Baseline eGFR (mL/min/1.73m 2 )           |
| Mean (SD)                                 | 79.1 (24.8)                               | 74.8 (21.3)                               | 74.3 (16.3)                               | 75.0 (19.1)                               |
| Median (Min, Max)                         | 76.6 (27.8, 168)                          | 73.7 (27.5, 162)                          | 73.1 (26.5, 136)                          | 73.6 (26.5, 168)                          |
| Missing                                   | 0                                         | 0                                         | 1 (0.2%)                                  | 1 (0.1%)                                  |
| Baseline alanine aminotransferase (U/L)   | Baseline alanine aminotransferase (U/L)   | Baseline alanine aminotransferase (U/L)   | Baseline alanine aminotransferase (U/L)   | Baseline alanine aminotransferase (U/L)   |
| Mean (SD)                                 | 19.5 (12.0)                               | 19.9 (17.9)                               | 18.8 (9.48)                               | 19.2 (12.7)                               |
| Median (Min, Max)                         | 17.0 (5.00, 96.0)                         | 16.0 (5.00, 241)                          | 17.0 (5.00, 76.0)                         | 17.0 (5.00, 241)                          |
| Missing                                   | 0                                         | 0                                         | 2 (0.4%)                                  | 2 (0.2%)                                  |
| Baseline aspartate aminotransferase (U/L) | Baseline aspartate aminotransferase (U/L) | Baseline aspartate aminotransferase (U/L) | Baseline aspartate aminotransferase (U/L) | Baseline aspartate aminotransferase (U/L) |
| Mean (SD)                                 | 22.3 (8.92)                               | 22.9 (12.3)                               | 22.2 (8.47)                               | 22.4 (9.75)                               |
| Median (Min, Max)                         | 21.0 (6.00, 73.0)                         | 21.0 (8.00, 164)                          | 21.0 (7.00, 91.0)                         | 21.0 (6.00, 164)                          |
| Missing                                   | 0                                         | 0                                         | 1 (0.2%)                                  | 1 (0.1%)                                  |
| Baseline bilirubin (μmol/L)               |                                           |                                           |                                           |                                           |

<div style=\"page-break-after: always\"></div>

| Mean (SD)         | 9.10 (5.24)       | 8.89 (6.16)       | 9.12 (5.10)       | 9.05 (5.44)       |
|-------------------|-------------------|-------------------|-------------------|-------------------|
| Median (Min, Max) | 7.90 (2.90, 28.2) | 7.45 (2.60, 67.4) | 8.00 (3.00, 44.0) | 7.80 (2.60, 67.4) |
| Missing           | 0                 | 0                 | 14 (2.5%)         | 14 (1.5%)         |

Abbreviations: eGFR, estimated glomerular filtration rate; Max, maximum; Min, minimum; SD, standard deviation.

Table 4. Comparison of relevant continuous covariates/patient demographics between the populations/ studies

| Parameter                                                                                          | ACE-CL-006 (N = 117)   | ACE-CL-007 (N = 274)   | ACE-CL-311 (N = 571)   | Overall (N = 962)   |
|----------------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|---------------------|
| Sex                                                                                                |                        |                        |                        |                     |
| Female                                                                                             | 35 (29.9%)             | 104 (38.0%)            | 198 (34.7%)            | 337 (35.0%)         |
| Male                                                                                               | 82 (70.1%)             | 170 (62.0%)            | 373 (65.3%)            | 625 (65.0%)         |
| Race                                                                                               |                        |                        |                        |                     |
| White                                                                                              | 110 (94.0%)            | 262 (95.6%)            | 508 (89.0%)            | 880 (91.5%)         |
| Black/African American                                                                             | 3 (2.6%)               | 9 (3.3%)               | 14 (2.5%)              | 26 (2.7%)           |
| Asian                                                                                              | 0                      | 3 (1.1%)               | 12 (2.1%)              | 15 (1.6%)           |
| American Indian or Alaska Natives                                                                  | 0                      | 0                      | 1 (0.2%)               | 1 (0.1%)            |
| Other                                                                                              | 4 (3.4%)               | 0                      | 2 (0.4%)               | 6 (0.6%)            |
| Missing                                                                                            | 0                      | 0                      | 34 (6.0%)              | 34 (3.5%)           |
| East asia                                                                                          |                        |                        |                        |                     |
| Non-East asian                                                                                     | 117 (100%)             | 271 (98.9%)            | 562 (98.4%)            | 950 (98.8%)         |
| East asian                                                                                         | 0                      | 3 (1.1%)               | 9 (1.6%)               | 12 (1.2%)           |
| Ethnicity                                                                                          |                        |                        |                        |                     |
| Hispanic/Latino                                                                                    | 2 (1.7%)               | 11 (4.0%)              | 36 (6.3%)              | 49 (5.1%)           |
| Not Hispanic/Latino                                                                                | 100 (85.5%)            | 248 (90.5%)            | 490 (85.8%)            | 838 (87.1%)         |
| Not reported                                                                                       | 15 (12.8%)             | 15 (5.5%)              | 45 (7.9%)              | 75 (7.8%)           |
| Unknown                                                                                            | 0                      | 0                      | 0                      | 0                   |
| Combination                                                                                        |                        |                        |                        |                     |
| Monotherapy                                                                                        | 117 (100%)             | 274 (100%)             | 0                      | 391 (40.6%)         |
| Acala + V                                                                                          | 0                      | 0                      | 289 (50.6%)            | 289 (30.0%)         |
| Acala + VG                                                                                         | 0                      | 0                      | 282 (49.4%)            | 282 (29.3%)         |
| Hepatic impairment status                                                                          |                        |                        |                        |                     |
| Normal (bilirubin ≤ ULN, and AST                                                                   | 104 (88.9%)            | 257 (93.8%)            | 508 (89.0%)            | 869 (90.3%)         |
| ≤ ULN) Mild (bilirubin ≤ ULN, and AST > ULN or bilirubin >1.0 × ULN to ≤ 1.5 × ULN, and AST of any | 13 (11.1%)             | 13 (4.7%)              | 46 (8.1%)              | 72 (7.5%)           |
| Moderate (bilirubin > 1.5 × ULN to ≤ 3 × ULN, and AST of any value)                                | 0                      | 3 (1.1%)               | 3 (0.5%)               | 6 (0.6%)            |
| Severe (bilirubin >3.0 × ULN, and AST of any value)                                                | 0                      | 1 (0.4%)               | 0                      | 1 (0.1%)            |
| Missing                                                                                            | 0                      | 0                      | 14 (2.5%)              | 14 (1.5%)           |

<div style=\"page-break-after: always\"></div>

| Renal impairment status                             |             |             |             |             |
|-----------------------------------------------------|-------------|-------------|-------------|-------------|
| Normal (eGFR ≥ 90 mL/min/1.73 m2)                   | 38 (32.5%)  | 58 (21.2%)  | 84 (14.7%)  | 180 (18.7%) |
| Mild (eGFR 60-89 mL/min/1.73 m2)                    | 62 (53.0%)  | 170 (62.0%) | 385 (67.4%) | 617 (64.1%) |
| Moderate (eGFR 30-59 mL/min/1.73 m2)                | 16 (13.7%)  | 45 (16.4%)  | 100 (17.5%) | 161 (16.7%) |
| Severe (eGFR 15-29 mL/min/1.73 m2)                  | 1 (0.9%)    | 1 (0.4%)    | 1 (0.2%)    | 3 (0.3%)    |
| End stage (eGFR < 15 mL/min/ 1.73 m2 / on dialysis) | 0           | 0           | 1 (0.2%)    | 1 (0.1%)    |
| ECOG performance status                             |             |             |             |             |
| Fully active                                        | 60 (51.3%)  | 141 (51.5%) | 312 (54.6%) | 513 (53.3%) |
| Ambulatory                                          | 52 (44.4%)  | 117 (42.7%) | 216 (37.8%) | 385 (40.0%) |
| Ambulatory but no work                              | 5 (4.3%)    | 16 (5.8%)   | 42 (7.4%)   | 63 (6.5%)   |
| Limited self-care                                   | 0           | 0           | 0           | 0           |
| Completely disabled                                 | 0           | 0           | 0           | 0           |
| Dead                                                | 0           | 0           | 0           | 0           |
| Missing                                             | 0           | 0           | 1 (0.2%)    | 1 (0.1%)    |
| Use of PPI                                          |             |             |             |             |
| Not present                                         | 108 (92.3%) | 262 (95.6%) | 525 (91.9%) | 895 (93.0%) |
| Present                                             | 9 (7.7%)    | 12 (4.4%)   | 45 (7.9%)   | 66 (6.9%)   |
| Imputed present                                     | 0           | 0           | 1 (0.2%)    | 1 (0.1%)    |

Abbreviations: Acala + VG, acalabrutinib + venetoclax + obinutuzumab; Acala +V, acalabrutinib + venetoclax; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; NA, not available; PPI, proton pump inhibitor; ULN, upper limit of normal.

## Population pharmacokinetic (PopPK) analysis

The applicant also provided a popPK analysis to describe PK in the target population.

The pooled PopPK analysis dataset included 13290 acalabrutinib and 7902 ACP-5862 plasma concentrations and relevant covariates from 1569 subjects for acalabrutinib and 1174 subjects for ACP-5862 from studies ACE-CL-001, ACE-CL-003, ACE-CL-006, ACE-CL-007, ACE-LY-004, ACE-WM001, ACE-LY-002, ACE-LY-003, ACE-MY-001, ACE-LY-106 (D8222C00001) and ACE-LY-308 (D8220C00004).

The PopPK dataset included 4039 acalabrutinib observations and 7902 ACP-5862 observations from 571 patients from AMPLIFY.

In this analysis, the previously developed population PK model (Report D8220C00009) was used as a starting point for the current model development.

The structural PK model remained, i.e. a 2-compartment model with a sequential zero-first order absorption and first order elimination on acalabrutinib and a 1 compartment model for ACP-5862 (simultaneously). The previously reported covariate PPI use on relative bioavailability was kept. Indication nor combination were statistically significant covariates using a corresponding p&lt;0.001 threshold.

Final parameter estimates are provided in Table 5 .

<div style=\"page-break-after: always\"></div>

Table 5. Parameter estimates for final model

|                                          | Estimate   | RSE (%)   | 95% CI           | Unit   |
|------------------------------------------|------------|-----------|------------------|--------|
| Population Parameter                     |            |           |                  |        |
| CL/F (Parent)                            | 154        | 1.13      | [150; 157]       | L/hr   |
| V/F central (Parent)                     | 79.9       | 3.58      | [74.3; 85.5]     | L      |
| Q/F (Parent)                             | 19.4       | 3.93      | [17.9; 20.9]     | L/hr   |
| VP/F peripheral (Parent)                 | 186        | 3.30      | [174; 198]       | L      |
| KA                                       | 0.991      | 1.38      | [0.964; 1.02]    | 1/hr   |
| D1                                       | 0.522      | 2.88      | [0.493; 0.552]   | hr     |
| CLM/F (Metabolite)                       | 19.9       | 1.15      | [19.5; 20.4]     | L/hr   |
| VCM/F (Metabolite)                       | 78.5       | 1.57      | [76.1; 80.9]     | L      |
| Covariate                                |            |           |                  |        |
| PPI use on F1 a                          | -0.159     | 10.6      | [-0.192; -0.126] | -      |
| Interindividual Variability              |            |           |                  |        |
| BSV CL/F (Parent) (CV%)                  | 28.3       | 3.14      | [28.3; 28.3]     | -      |
| BSV V/F (Parent) (CV%)                   | 184        | 3.63      | [184; 185]       | -      |
| BSV VP/F (Parent) (CV%)                  | 31.4       | 9.70      | [31.3; 31.4]     | -      |
| BSV KA (CV%)                             | 12.7       | 10.6      | [12.7; 12.8]     | -      |
| BSV CLM/F (Metabolite) (CV%)             | 19.6       | 6.05      | [19.6; 19.7]     | -      |
| BSV on EPS (Parent) (CV%)                | 43.8       | 3.01      | [43.8; 43.8]     | -      |
| Residual Variability                     |            |           |                  |        |
| Proportional component (Parent) (sd)     | 87.1       | 1.55      | [87.1; 87.2]     | -      |
| Proportional component (Metabolite) (sd) | 76.0       | 0.406     | [76.0; 76.0]     | -      |

a relative change (1+estimate)

The Goodness of Fit (GoF) plots and prediction-corrected visual predictive check (pcVPC) for AMPIFLY are  presented in Figure 1 and Figure 2 respectively.

Figure 1. Basic Goodness-of-Fit Plots for the Final Model - Observations Versus Predictions (AMPLIFY; Acalabrutinib)

<div style=\"page-break-after: always\"></div>

<!-- image -->

d822/poppk004/scripts/2.1.AMPLIFY-pk-GOF-FM.Rmd

Grey line is the line of unit. Red line is the linear model smother with 95% CI (shaded area) DVvsPREDonleftandDVvsIPREDonright

Figure 2 . Prediction-Corrected Visual Predictive Check for the Final Model in AMPLIFY Study Patients for Both Acalabrutinib (left) and Metabolite (right) with (top) and without (bottom) Overlaying Observed Data

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

The solid and dashed lines are the median and the 5th and 95th percentiles of the observations. The shaded areas are the 90% CIs of the median and the 5th and 95th percentiles predicted by the model. Data was modelled on the log scale.

## 2.3.3. PK/PD modelling

The applicant has provided exposure-response analyses of efficacy and safety endpoints which was included in the modelling report D8221C00001.

PK exposure was the individual predicted exposure metric (such as Cmax0-24hr, Cmaxss, AUC0-24h, AUCss) of acalabrutinib and ACP-5862, using empirical bayes estimates (EBE) from the updated PopPK model. To account for contribution of the major active metabolite (ACP-5862) to overall response, acalabrutinib and ACP-5862 molar concentrations were adjusted with respective potency and protein binding (shown below) and was used to estimate total active AUC or Cmax (exposure metric for the total active moiety).

<!-- formula-not-decoded -->

Where Cparent and Cmetabolite are molar concentrations of acalabrutinib and ACP-5862, respectively; fuparent (free fraction of acalabrutinib) = 0.025; fumetabolite (free fraction of ACP-5862) = 0.013; and compared to acalabrutinib, ACP-5862 exhibits approximately 0.5-fold potency for inhibition.

Following exclusions, the exposure-response analysis included 571 subjects treated with acalabrutinib (289 in the acalabrutinib+venetoclax arm and 282 in the acalabrutinib+venetoclax+obinutuzumab arm). Regarding exclusions, of the subjects that received acalabrutinib, 6 of them had no acalabrutinib (and ACP-5862) PK concentrations and were not included in the analysis. Data from 290 patients in the reference arm were generally not included in the exposure-response analysis but were used in certain plots for comparison purpose only.

## Exposure-efficacy analysis :

An exploratory Kaplan-Meier analysis evaluated the PFS as function of total active AUCs quartiles ( Figure 3 ) suggest that there is no clear trend in the relationship between PFS and total active AUCss as indicated by the overlap in the Kaplan-Meier curves for all four exposure quartiles over the duration of the assessment.

<div style=\"page-break-after: always\"></div>

Figure 3. Kaplan-Meier plot of AMPLIFY stratified by Total Active AUCss- (Top Panel: AV Arm, Bottom Panel: AVG Arm)

<!-- image -->

<!-- image -->

Time in Month

AV: Acalabrutinib + Venetoclax; AVG: Acalabrutinib + Venetoclax + Obinutuzumab; FCR: Fludarabine, cyclophosphamide, and rituximab; BR: Bendamustine and rituximab; Total active AUCss: total active moiety of the area under the plasma concentration-time curve from time 0 to 24 hours (2 dosing intervals) at steady state. The table below the Kaplan-Meier curves represents the number of patients available for the analyses (i.e., not censored or discontinued).

<div style=\"page-break-after: always\"></div>

A Cox proportional hazard model did not identify a statistically significant exposure-response relationship for PFS (data not shown).

The exploratory graphical analysis using boxplot evaluated the association between total active exposure and ORR and indicated that median total active exposure were similar across all response categories, suggesting a flat relationship in ORR.

## Exposure-safety analysis :

The relationship between acalabrutinib exposure (total active AUC) versus the incidence of any AEs (Grade ≥ 3) and selected safety outcomes of clinical interest (i.e., percentage of subjects with a specific AE) acalabrutinib treated arm of AMPLIFY is shown in Figure 4 . Acalabrutinib exposure (AUCss, and total active AUC) was generally similar regardless of whether the selected safety outcomes of clinical interest were present or absent (data not shown).

Figure 4. Bar Plot of Acalabrutinib Total Active AUCss Stratified by Quartile and Selected Grade ≥3 AEs of Clinical Interest.

AV: Total active AUCss (nM.h)

Grade3orhigher

<!-- image -->

<div style=\"page-break-after: always\"></div>

AVG: Total active AUCss (nM.h)

<!-- image -->

Grade3orhigher

AV: Acalabrutinib + Venetoclax; AVG: Acalabrutinib + Venetoclax + Obinutuzumab; Total active AUCss: total active moiety of the area under the plasma concentration-time curve from time 0 to 24 hours (2 dosing intervals) at steady state. The shaded bars represent the 4 quantiles (quartiles) of total active AUCss with Q1 = first quartile, Q2 = second quartile, Q3 = third quartile, and Q4 = fourth quartile. The numbers on top of the bar plots are the respective percentage of subjects with AEs within each quantile of acalabrutinib exposure.

## 2.3.4. Discussion on clinical pharmacology

The main clinical study (AMPLIFY) supporting this application included collection of PK data.

The objective of the clinical pharmacology data package in the current variation is to describe acalabrutinib PK in first-line CLL patients co-treated with venetoclax (the target population) and to characterise potential PK differences between first-line CLL patients not co-treated with venetoclax.

## Pharmacokinetics

The PK data from AMPLIFY were also analysed using a PopPK approach which however had significant limitations.

From the provided PopPK report, it was unclear which covariates were explored, and which results were used to arrive to the final PK model. A modelling analysis plan and model code would have been helpful for better assessing the covariate model.  However, covariate evaluation of indication and combination treatment on CL/F was described and reported. Combination treatment with venetoclax is considered the most important covariate to explore within this procedure. Acalabrutinib is a P-gP substrate in vitro and venetoclax is a P-gP inhibitor in vitro , thus, a potential PK DDI cannot be excluded. Combination treatment was explored on CL/F which was considered reasonable.  However, it would have been relevant to explore combination treatment as a covariate also on the absorption related parameters KA, D1 and F1 (i.e. relative bioavailability). This is because P-gP is known to be present in the gut which means that a PK DDI involving P-gP may affect rate and extent of absorption.

The goodness-of-fit for the AMPLIFY study based on the final PopPK model is suboptimal. There were signs of major model misspecifications according to the observations vs typical predictions plot for the metabolite ACP-5862. There were also model misspecifications according to CWRES plots for ACP5862. No major model misspecifications were noted for acalabrutinib. The pcVPC did not indicate any obvious model misspecification for neither compound.

<div style=\"page-break-after: always\"></div>

Given these limitations, the PopPK model is not considered acceptable for describing PK in the target population. Nevertheless, an updated PopPK model is not requested since reasonable graphical and tabular summaries of the observed PK data were provided.

The PK in the target population as observed in the AMPLIFY study was compared to previously conducted studies with acalabrutinib in other populations. The results indicated that there are no clinically relevant PK-differences between the target population (CLL patients co-treated with venetoclax) and the currently approved indications of acalabrutinib (CLL patients in Studies ACE-CL006 and ACE-CL-007) as well as second-line MCL patients (Study ACE-LY-004).

The applicants' proposal not to update SmPC Section 5.2 was therefore considered acceptable.

## Exposure-response

Exposure-response analyses of efficacy and safety endpoints were performed by the applicant. No clinically significant exposure-response trends were detected, however, a numerical increase in some safety endpoints such as infections and neutropenia at increasing exposures were noted. The results from the exposure-response analyses should be interpreted with caution; The analyses were based only on patient data from AMPLIFY where only a single dose level of acalabrutinib was explored. This means that the exposure range will be rather limited which does not allow adequate characterisation of the exposure-response relationship.

## 2.3.5. Conclusions on clinical pharmacology

Submitted data indicate that there are no clinically relevant PK-differences between first-line CLL patients co-treated with venetoclax and CLL patients without co-treatment with venetoclax. No updates in the SmPC section 5.2 have been proposed which is acceptable.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Not applicable.

## 2.4.2. Main study

ACE-CL-311 (AMPLIFY): a randomised, multicentre, open-label, Phase III study to compare the efficacy and safety of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemoimmunotherapy in patients with previously untreated CLL without del(17p) or TP53 mutation.

Figure 5 shows the design of the study, the sequence of treatment periods, and the treatment regimens.

<div style=\"page-break-after: always\"></div>

Figure 5. Flowchart of study ACE-CL-311 design

<!-- image -->

- a The 20-mg and 50-mg doses of venetoclax were administered in the hospital for patients who were at high-risk of tumour lysis syndrome (TLS), or if they were indicated to hospitalise, and thereafter at home daily for 7 days. The dose then increased every 7 days to the target dose of 400 mg, and venetoclax was to be administered at home unless a patient was indicated to hospitalise.
- b Only the first dose (1000 mg) of obinutuzumab administration was allowed to be split over 2 days.
- c Patients received either FCR or BR.
- d The first dose could have been given over 2 days at investigator discretion per standard of care.

## Methods

## Study participants

## Key inclusion criteria

<div style=\"page-break-after: always\"></div>

1. Men and women ≥ 18 years of age.
2. ECOG performance status of 0-2.
3. Diagnosis of CLL that meets published diagnostic criteria (Hallek et al 2018):
4. (a) Monoclonal B cells (either kappa or lambda light chain restricted) that are clonally coexpressing B-cell marker (CD19, CD20, and CD23) and CD5.
5. (b) Prolymphocytes may comprise &lt; 55% of blood lymphocytes.
6. (c) Presence of ≥ 5x109 B lymphocytes/L (5000/ μ L) in the peripheral blood (at any point since the initial diagnosis).
4. Active disease per IWCLL 2018 criteria that requires treatment
5. Meet the following laboratory parameters:
9. (a) Adequate bone marrow function independent of growth factor or transfusion support within 1 week of Screening, as follows:
10. (i) ANC ≥ 750 cells/ μ L (0.75x109/L); ANC ≥ 500 cells/ μ L (0.50x109/L) in patients with documented bone marrow involvement of CLL
11. (ii) Platelet count ≥ 50,000 cells/ μ L (50x109/L); platelet count ≥ 30,000 cells/ μ L (30x109/L) in patients with documented bone marrow involvement of CLL
12. (b) Serum AST and ALT ≤ 2.5 x upper limit of normal (ULN)
13. (c) Total bilirubin ≤ 2 x ULN, unless directly attributable to Gilbert ' s syndrome
14. (d) Estimated creatinine clearance of ≥ 50 mL/min, calculated using the Cockcroft and Gault equation (if male, [140-Age] x Mass [kg] / [72 x creatinine mg/dL]; multiply by 0.85 if female); estimated creatinine clearance of ≥ 70 mL/min for patients selected by investigator to receive FCR in Arm C.

## Key exclusion criteria

1. Any prior CLL-specific therapies (except corticosteroid treatment administered due to necessary immediate intervention; within the last 10 days before start of study treatment, only dose equivalents up to 20 mg prednisone daily were permitted).
2. Detected del(17p) or TP53 mutation.
3. Transformation of CLL to aggressive non-Hodgkin lymphoma (e.g., Richter's transformation, PLL, or diffuse large B-cell lymphoma) or CNS involvement by leukaemia.
4. Any comorbidity or organ system impairment rated with a single CIRS-G score of 4 (excluding the eyes/ears/nose/throat/larynx organ system and disease under study) or a total CIRS-G score of &gt; 6.
5. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening. Note: Patients with controlled, asymptomatic atrial fibrillation were allowed to enrol on study.
6. Known history of infection with HIV.

<div style=\"page-break-after: always\"></div>

7. Any active significant infection (e.g., bacterial, viral or fungal, including patients with positive cytomegalovirus DNA PCR).
8. Serologic status reflecting active hepatitis B or C infection.
3. (a) Patients who were hepatitis B core antibody positive and who were hepatitis B surface antigen negative will need to have a negative PCR result before randomisation and must be willing to undergo DNA PCR testing during the study. Those who were H hepatitis B surface antigen-positive or hepatitis B PCR positive will be excluded.
4. (b) Patients who were hepatitis C antibody positive will need to have a negative PCR result before randomisation. Those who were hepatitis C PCR positive will be excluded.
9. History of bleeding diathesis (e.g., haemophilia, von Willebrand disease).
10. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
11. Requires treatment with a strong CYP3A inhibitor. The use of strong or moderate CYP3A inhibitors or inducers within 7 days of the first dose of study drug is prohibited.
12. Breastfeeding or pregnant.

## Treatments

## Arm A (acalabrutinib+venetoclax; AV)

Acalabrutinib 100 mg capsules were orally administered from Cycle 1 at a fixed twice daily (BID) dose for 14 cycles; venetoclax oral dosing was to begin at Cycle 3 and continued following a 5-week rampup at a fixed daily dose of 400 mg until the end of Cycle 14, or until start of new anti-CLL therapy or progression of CLL, or unacceptable toxicity, whichever occurred first.

## Arm B (acalabrutinib+venetoclax+obinutuzumab; AVG)

Acalabrutinib (100 mg capsules) were orally administered from Cycle 1 at a fixed BID dose for 14 cycles; obinutuzumab administered as IV infusion at an absolute (flat) dose of 1000 mg and was to begin at Cycle 2 and continued through Cycle 7; venetoclax dosing was to begin at Cycle 3 and continue following a 5-week ramp-up at a fixed daily dose of 400 mg until the end of Cycle 14, or until start of new anti-CLL therapy or progression of CLL, or unacceptable toxicity, whichever occurred first.

## Arm C (chemoimmunotherapy; investigator's choice of fludarabine+cyclophosphamide+rituximab or bendamustine+rituximab; FCR/BR)

All patients who were randomised to standard chemoimmunotherapy were to receive up to 6 cycles of either FCR or BR as IV infusions, according to standard institutional practice. Patients ≤ 65 years of age with a creatinine clearance of ≥ 70 mL/min were restricted to FCR.

Treatment regimens in ACE-CL-311 are depicted in Figure 6 .

Figure 6. Treatment Regimens in ACE-CL-311

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Objectives

The AMPLIFY study was designed to evaluate whether the finite duration of acalabrutinib in combination with venetoclax with or without obinutuzumab as a first-line treatment setting could improve long-term treatment outcomes in patients with previously untreated CLL without del(17p) or TP53 mutation.

## Outcomes/endpoints

## Primary endpoint

- PFS assessed by IRC (Arm A vs Arm C)

## Key secondary endpoints

- PFS assessed by IRC (Arm B vs Arm C)
- MRD negativity rate (Arm A vs Arm C and Arm B vs Arm C)
- Overall survival (OS, Arm A vs Arm C and Arm B vs Arm C)

Other secondary endpoints (all investigated in Arm A vs Arm C and Arm B vs Arm C)

- PFS by investigator assessment.
- Event-free survival (EFS, IRC and INV)
- Objective response rate (ORR, IRC and INV)
- Duration of response (DoR, IRC and INV)
- Time to next treatment (TTNT)

## Exploratory endpoints

<div style=\"page-break-after: always\"></div>

- PROs by EORTC-QLQ-C30, IL27, FACIT-Fatigue, PGIC, PGIS and EQ-5 D-5 L

## Sample size

According to SAP version 4.0 dated 28 Feb 2024, the study was expected to randomise approximately 260 subjects per arm. With a 1:1:1 randomisation ratio, the study would randomise 780 subjects in total.

Under the exponential model assumptions, the study was sized to achieve approximately 90% power to detect a hazard ratio of 0.62 in PFS at the 2-sided significance level of 0.05 based on 188 events at final analysis, which translates into a 61% improvement in median PFS from 44.7 months in Arm C (FCR/BR) to 72.1 months in Arm A (AV). The hazard ratio of 0.62 was based on the GAIA -CLL13 interim analysis of PFS for venetoclax -obinutuzumab -ibrutinib versus chemoimmunotherapy, in which the upper bound of the 97.5% confidence interval (CI) for the hazard ratio was 0.54 (Eichhorst et al. 2023).

Given that this study was anticipated to have a higher proportion of death due to Coronavirus disease 2019 (COVID-19) than GAIA-CLL13 (at least 24% and 18% of PFS events at interim and final analysis in 3 arms combined, respectively), a more conservative hazard ratio of 0.62 was assumed, which translates to a median PFS of 72.1 months in Arm A (AV) under the exponential distribution and under median PFS of 44.7 months in Arm C (FCR/BR).

## Randomisation

Subjects were randomised in a 1:1:1 ratio to

- Arm A: Acalabrutinib/venetoclax [AV]
- Arm B: Acalabrutinib/venetoclax/obinutuzumab [AVG]
- Arm C: Chemoimmunotherapy - Investigator's choice of

fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR) - [FCR/BR].

All subjects were planned to be centrally assigned to randomised study treatment using an Interactive Voice/Web Response System (IxRS).

After approximately 780 subjects had been randomised into the study, enrolment outside of China (i.e., global enrolment) was planned to be closed and additional Chinese subjects would be recruited into the China extension cohort until approximately 117 Chinese subjects had been randomised (in both the global cohort and the China extension cohort).

For Arm C, approximately 50% of subjects were planned to be treated with FCR and 50% treated with BR per investigator's choice. The investigator must had declared the choice of FCR or BR for a subject before randomisation. When the number of subjects randomised to Arm C with one of the investigatorchosen regimens (FCR or BR) approached 130, future subjects with the same investigator's choice for Arm C would not be eligible to participate in the study. The IxRS was planned to be used to balance the allocation of FCR and BR by region.

## Blinding (masking)

This was an open-label study.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Analysis of primary endpoint

The primary efficacy endpoint IRC-assessed PFS was defined as the time from the date of randomisation until disease progression (assessed per IWCLL 2018 criteria) or death from any cause, whichever occurred first. PFS was planned to be calculated as date of first disease progression or death (censoring date for censored subjects) -randomisation date + 1.

The primary efficacy analysis was planned to be performed on the FAS to compare IRC-assessed PFS between Arms A (AV) and C (FCR/BR) using a stratified 2-sided log rank test and a method that corresponds to the Breslow approach for handling ties (Breslow, 1974). The estimate of the hazard ratio (HR) and its corresponding 95% CI was planned to be computed using a stratified Cox proportional hazards model with Efron's method for ties and the stratification variables included in the strata statement and the CI calculated using the profile likelihood approach.

The four randomisation stratification factors were planned to be used for the stratified analyses: age (&gt;65 or ≤ 65), immunoglobulin heavy-chain variable region gene (IGHV) mutational status (mutated versus unmutated), Rai stage (high risk [ ≥ 3] versus non-high risk [&lt;3]), and geographic region (North America versus Europe versus Other).

If there was at least one stratum that had fewer than two events in either treatment arm or fewer than 10 events across both treatment arms (where a stratum was defined as stratification factor 1 * stratification factor 2 * stratification factor 3 * stratification factor 4), stratification factors would be collapsed until all strata had at minimum two events per treatment arm and 10 events across both treatment arms for the primary endpoint. More details regarding the order in which the stratification factors were planned to be collapsed in the following order: 1. Geographic region (North America versus Europe versus Other) 2. Age (&gt;65 or ≤65) 3. Rai stage (high risk [≥3] versus non -high risk.

The distribution of IRC-assessed PFS was planned to be summarized for each treatment arm using median and its corresponding 95% CI based on Kaplan-Meier (KM) estimates and the BrookmeyerCrowley method for the CI. The proportion of subjects who were progression free and associated 95% CI would be estimated based on KM method at selected timepoints by treatment arm.

## Analyses of secondary endpoints

The same analysis method was planned to be used when analysing key secondary endpoint PFS compared between Arms B and C, where PFS was assessed by IRC review per IWCLL 2018 criteria.

## Timing of Interim and final analysis

According to Protocol version 7 and latest version of the SAP, one interim analysis would be conducted to assess early efficacy of Arm A (AV) versus Arm C (FCR/BR) with respect to the primary efficacy endpoint, IRC-assessed PFS. The interim analysis would occur when approximately 141 IRC-assessed PFS events (75% of the 188 events required for final analysis) in Arm A (AV) and Arm C (FCR/BR) combined had been observed. The interim analysis was anticipated to occur approximately 40 months after the first subject had been randomised (i.e., 14 months after the last subject had been randomised).

The final analysis would be conducted when approximately 188 IRC-assessed PFS events in Arm A (AV) and Arm C (FCR/BR) combined had been observed. The final analysis was anticipated to occur approximately 52 months after the first subject was randomised (i.e., 26 months after the last subject was randomised).

<div style=\"page-break-after: always\"></div>

The crossing boundaries (nominal alpha levels) for the event-driven interim analysis and final analysis for IRC-assessed PFS were 0.019 and 0.044, respectively. The actual crossing boundaries (nominal alpha levels) for the interim and final analyses would be determined based on the actual number of IRC-assessed PFS events observed at the time of data cutoff.

If the criterion for early efficacy was met at the time of the interim analysis, the DMC could recommend stopping the study in accordance with the terms of the DMC charter. At the time of the final analysis for PFS, an interim futility analysis for OS s planned be performed to exclude harm and support the risk-benefit determination. OS is planned to be tested for futility using a non-binding boundary and control for Type I error rate at a 2-sided 0.05 level.

## Multiplicity

For both the interim and final analyses, if the primary endpoint achieved statistical significance, then secondary endpoints (selected secondary endpoints for the interim analysis) were planned to be tested in a manner that would preserve the overall Type I error rate at the 2-sided significance level of 0.05.

To control the overall Type I error, the Lan-DeMets alpha-spending function based on the O'BrienFleming boundaries was planned to be used to split α into α1 and α2 for interim and final analyses of IRC-assessed PFS, respectively.

An alpha-exhaustive recycling strategy (Burman et al 2009) was planned to be utilized to adjust for multiplicity due to multiple endpoints.

If the primary efficacy endpoint, IRC-assessed PFS in Arm A (AV) versus Arm C (FCR/BR), achieved statistical significance at either the PFS IA or PFS FA, then the 5% alpha would be recycled to test the following secondary efficacy endpoints in a fixed sequential hierarchical manner:

1. PFS as assessed by IRC between Arms B (AVG) and C (FCR/BR)
2. MRD negativity rate measured in the peripheral blood by flow cytometry ( 10 -4 ) between Arm A (AV) at Cycle 9 and Arm C (FCR/BR) at 12 weeks after the start of Cycle 6
3. MRD negativity rate measured in the peripheral blood by flow cytometry ( 10 -4 ) between Arm B (AVG) at Cycle 10 and Arm C (FCR/BR) at 12 weeks after the start of Cycle 6
4. OS between Arms A (AV) and C (FCR/BR)
5. OS between Arms B (AVG) and C (FCR/BR)

The hypotheses were planned to be tested using alpha (test mass) recycling, where the test mass that becomes available after each rejected hypothesis is recycled to the secondary hypotheses not yet rejected. This testing procedure stops when the entire test mass is allocated to non-rejected hypotheses.

If the testing procedure stops, the p-value for subsequent tests would be presented as descriptive. If the primary efficacy endpoint, IRC-assessed PFS in Arms A (AV) versus C (FCR/BR), does not cross boundary at the interim analysis, the trial was planned to continue, and the final analysis would be conducted.

## Censoring rules and handling of missing data

Subjects who withdrew from the study or were considered lost to follow-up without prior

<div style=\"page-break-after: always\"></div>

documentation of disease progression were planned to be censored on the date of the last adequate response assessment.

Subjects who started new anticancer therapy would be censored on the date of the last response assessment before start of subsequent anti-CLL therapy.

Subjects who had 2 or more consecutively missed response assessments (without PD or death prior), regardless of whether there is a PD or death afterward would be censored at date of last response assessment before 2 or more consecutively missed response assessments.

For subjects without an adequate post-baseline disease assessment, PFS would be censored on the date of randomisation.

## Sensitivity analyses

According to the SAP, the following sensitivity analyses were planned to be performed for primary endpoint PFS as assessed by IRC between Arms A versus C and Arms B versus C in support of primary and key secondary efficacy analyses:

- Unstratified analysis
- The PFS was planned to be analysed as the time from date of randomization to the date of first disease progression or death due to any cause, whichever came first, regardless of the use of subsequent anticancer therapy, i.e., subjects would not be censored at the last adequate disease assessment prior to the subsequent anticancer therapy. If a subject had neither PD nor death after the initiation of subsequent anticancer therapy prior to data cutoff, the subject would be censored at the last adequate disease assessment prior to data cutoff regardless of initiation of subsequent anticancer therapy.
- Subjects with PFS events after 2 or more consecutively missed visits would not be censored at the last adequate assessment. In particular, PD or death after 2 or more consecutively missed visits will be included as a PFS event.
- To assess for the potential impact of Coronavirus disease 2019 (COVID-19) deaths on PFS, subjects with death related to COVID-19 infection (and without progression prior to death) were planned to be censored at their last evaluable assessment prior to their COVID-19 related death date.
- If &gt;10% of subjects had a discrepancy between the randomization stratum as recorded in IxRS versus in EDC/laboratory data, a sensitivity analysis was planned to be performed using the strata per IxRS for stratification.
- Due to the high number of expected deaths due to COVID-19, a sensitivity analysis may be performed on all randomized subjects in the global cohort plus the China extension cohort (note: the primary analysis is performed on the global cohort only; the global cohort includes the approximately 780 subjects randomized globally.
- If &gt;10% of subjects in any treatment group did not receive any randomised therapy, a \"deviation bias\" sensitivity analysis may be performed based on the per-protocol population, defined in Section 2.1 in the SAP.

## Subgroup analyses

<div style=\"page-break-after: always\"></div>

Subgroup analyses were planned to be performed using potential prognostic variables at screening or baseline listed below to investigate the consistency and robustness of PFS as assessed by IRC between Arms A versus C and Arms B versus C:

- Randomisation stratification factors per EDC/lab data recording. Randomisation stratification factors as presented in the randomisation section.
- Sex (male versus female)
- Race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White)
- Ethnicity (Hispanic or Latino, Not Hispanic or Latino) · ECOG Performance Status (2, ≤ 1)
- Complex karyotype (yes, no)
- CD38 expression (yes, no)
- ZAP-70 expression (yes, no)
- 11q deletion mutation (yes, no)

No adjustment to the significance level for testing was planned to be made since all the subgroup analyses were to be considered exploratory and may only be supportive of the primary analysis of PFS.

## Results

## Participant flow

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Recruitment

First patient enrolled: 25 February 2019.

Last patient was randomised: 21 September 2023.

The clinical cut-off date for presented data was 30 April 2024.

## Conduct of the study

Seven protocol amendments were done during the study and amendments 1, 5 and 6 are considered substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

## · Amendment 1, Version 2.0, 11 July 2019

The protocol was amended to change the treatment duration for acalabrutinib to 14 cycles and venetoclax to 12 cycles. This amendment was introduced to address the evolving treatment landscape for CLL, which is moving towards a fixed duration treatment regimen as opposed to the current treatment paradigm of BTKi treatment to progression. Continued treatment is thought to lead to selection for resistant clones and result in disease progression.

Ongoing studies of BTKi in combination with venetoclax have shown high complete response rates and MRD negativity in contrast to BTKi monotherapy. In view of such deep responses, it is unclear if continuing BTKi therapy beyond completion of combination treatment will yield incremental benefit, acalabrutinib treatment will be completed at the same time as venetoclax.

<div style=\"page-break-after: always\"></div>

Required bone marrow biopsies were reduced to two time points as a result of the shortened combination treatment duration. These will occur at Cycle 9/10 to allow for comparison to the control Arm and at 12 weeks after completion of the experimental combination treatments.

## · Amendment 5.0 Version 6.0/ 22 March 2023

The protocol was amended to extend the timeframe to detect both early and late onset mechanisms for resistance.

## · Amendment 6.0, Version 7.0, 12 October 2023

The primary rationale for this protocol amendment was to include a change to the hazard ratio for the primary endpoint, IRC-assessed PFS of Arm A (AV) versus Arm C (FCR/BR). The PFS hazard ratio was changed from 0.65 to 0.62 based on the results of the GAIA-CLL13 interim analysis and accounting for the high proportion of deaths due to COVID-19 (at least 24% and 18% of PFS events in 3 arms combined at interim and final analysis, respectively) observed in this study. As such, the interim analysis will occur when 141 IRC-assessed PFS events in Arms A (AV) and C (FCR/BR) have been observed, and the final analysis will be conducted when approximately 188 IRC-assessed PFS events in Arm A (AV) and Arm C (FCR/BR) have been observed.

A futility analysis for OS was added at the time of the final analysis for the primary endpoint.

## Protocol deviations

Table 6. Summary of Important Protocol Deviations (FAS), study ACE-CL-311

|                                                                    | ArmA (AV) (N=291) n (%)   | ArmB (AVG) (N =286) n (%)   | ArmC (FCR/BR) (N=290) n (%)   | Total (N =867) n (%)   |
|--------------------------------------------------------------------|---------------------------|-----------------------------|-------------------------------|------------------------|
| Patientswithatleastoneimportantprotocol deviation                  | 66 (22.7)                 | 49 (17.1)                   | 72 (24.8)                     | 187 (21.6)             |
| Inclusioncriteria                                                  | 3 (1.0)                   | 0                           | 1 (0.3)                       | 4 (0.5)                |
| Exclusioncriteria                                                  | 7 (2.4)                   | 3 (1.0)                     | 5 (1.7)                       | 15 (1.7)               |
| Investigationalproductdeviation                                    | 4 (1.4)                   | 5 (1.7)                     | 16 (5.5)                      | 25 (2.9)               |
| Excludedmedicationstaken                                           | 1 (0.3)                   | 4 (1.4)                     | 2 (0.7)                       | 7 (0.8)                |
| Deviationsrelatedtostudyprocedure                                  | 11 (3.8)                  | 17 (5.9)                    | 17 (5.9)                      | 45 (5.2)               |
| Otherimportantprotocoldeviations                                   | 42 (14.4)                 | 23 (8.0)                    | 37 (12.8)                     | 102 (11.8)             |
| Patientswithatleastoneimportantprotocol deviationrelatedtoCOvlD-19 | 0                         | 2 (0.7)                     | 1 (0.3)                       | 3 (0.3)                |
| Investigationalproductdeviation                                    | 0                         | 1 (0.3)                     | 1 (0.3)                       | 2 (0.2)                |
| Deviationsrelatedtostudyprocedure                                  | 0                         | 1 (0.3)                     | 0                             | 1 (0.1)                |

The important protocol deviations category 'Other' included deviations related to informed consent not obtained properly, and incorrect stratification of patients.

## Baseline data

Table 7. Demographic Characteristics (FAS), study ACE-CL-311

|             | Arm A (AV) (N = 291)   | Arm B (AVG) (N= 286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|-------------|------------------------|------------------------|----------------------------|------------------|
| Age (years) |                        |                        |                            |                  |
| Mean (SD)   | 59.9 (9.4)             | 60.1 (9.5)             | 59.8 (9.7)                 | 59.9 (9.5)       |
| Median      | 61.0                   | 61.0                   | 61.0                       | 61.0             |
| Min, Max    | 31, 84                 | 29, 81                 | 26, 86                     | 26, 86           |

<div style=\"page-break-after: always\"></div>

|                                           | Arm A (AV) (N = 291)   | Arm B (AVG) (N= 286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|-------------------------------------------|------------------------|------------------------|----------------------------|------------------|
| Age group , n (%)                         |                        |                        |                            |                  |
| ≤ 65                                      | 212 (72.9)             | 210 (73.4)             | 213 (73.4)                 | 635 (73.2)       |
| > 65                                      | 79 (27.1)              | 76 (26.6)              | 77 (26.6)                  | 232 (26.8)       |
| ≤ 75                                      | 282 (96.9)             | 274 (95.8)             | 280 (96.6)                 | 836 (96.4)       |
| > 75                                      | 9 (3.1)                | 12 (4.2)               | 10 (3.4)                   | 31 (3.6)         |
| Sex , n (%)                               |                        |                        |                            |                  |
| Male                                      | 178 (61.2)             | 198 (69.2)             | 183 (63.1)                 | 559 (64.5)       |
| Female                                    | 113 (38.8)             | 88 (30.8)              | 107 (36.9)                 | 308 (35.5)       |
| Race , n (%)                              |                        |                        |                            |                  |
| American Indian or Alaska Native          | 1 (0.3)                | 0                      | 1 (0.3)                    | 2 (0.2)          |
| Asian                                     | 4 (1.4)                | 9 (3.1)                | 18 (6.2)                   | 31 (3.6)         |
| Black or African American                 | 3 (1.0)                | 11 (3.8)               | 7 (2.4)                    | 21 (2.4)         |
| Native Hawaiian or Other Pacific Islander | 0                      | 0                      | 2 (0.7)                    | 2 (0.2)          |
| White                                     | 265 (91.1)             | 248 (86.7)             | 252 (86.9)                 | 765 (88.2)       |
| Multiple                                  | 0                      | 2 (0.7)                | 0                          | 2 (0.2)          |
| Not reported                              | 18 (6.2)               | 16 (5.6)               | 10 (3.4)                   | 44 (5.1)         |
| Ethnicity , n (%)                         |                        |                        |                            |                  |
| Hispanic or Latino                        | 21 (7.2)               | 15 (5.2)               | 19 (6.6)                   | 55 (6.3)         |
| Not Hispanic or Latino                    | 246 (84.5)             | 250 (87.4)             | 256 (88.3)                 | 752 (86.7)       |
| Not reported                              | 24 (8.2)               | 21 (7.3)               | 15 (5.2)                   | 60 (6.9)         |

Table 8 . Baseline disease characteristics (FAS), study ACE-CL-311

|                                                       | Arm A (AV) (N = 291)   | Arm B (AVG) (N =286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|-------------------------------------------------------|------------------------|------------------------|----------------------------|------------------|
| ECOG performance status, n (%)                        |                        |                        |                            |                  |
| ≤ 1                                                   | 262 (90.0)             | 272 (95.1)             | 262 (90.3)                 | 796 (91.8)       |
| 2                                                     | 28 (9.6)               | 14 (4.9)               | 26 (9.0)                   | 68 (7.8)         |
| Missing                                               | 1 (0.3)                | 0                      | 2 (0.7)                    | 3 (0.3)          |
| Time from initial diagnosis to randomisation (months) |                        |                        |                            |                  |
| Mean (SD)                                             | 42.58 (43.09)          | 41.76 (46.89)          | 41.67 (46.97)              | 42.00 (45.63)    |
| Median                                                | 28.52                  | 26.10                  | 29.55                      | 27.53            |
| Min, Max                                              | 0.8,236.9              | 0.6,234.7              | 0.5,317.1                  | 0.5,317.1        |
| Bulky disease,n(%)                                    |                        |                        |                            |                  |

<div style=\"page-break-after: always\"></div>

|                                    | Arm A (AV) (N = 291)   | Arm B (AVG) (N =286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|------------------------------------|------------------------|------------------------|----------------------------|------------------|
| <5cm                               | 178 (61.2)             | 186 (65.0)             | 166 (57.2)                 | 530 (61.1)       |
| ≥ 5 cm                             | 113 (38.8)             | 100 (35.0)             | 124 (42.8)                 | 337 (38.9)       |
| <10cm                              | 271 (93.1)             | 267 (93.4)             | 269 (92.8)                 | 807 (93.1)       |
| ≥ 10 cm                            | 20 (6.9)               | 19 (6.6)               | 21 (7.2)                   | 60 (6.9)         |
| CIRS-G total score                 |                        |                        |                            |                  |
| Mean (SD)                          | 2.7 (2.1)              | 2.8 (2.1)              | 2.7 (2.0)                  | 2.7 (2.0)        |
| Median                             | 2.0                    | 3.0                    | 2.0                        | 2.0              |
| Min, Max                           | 0,9                    | 0,17                   | 0,8                        | 0,17             |
| CIRS-G total score category, n(%)  |                        |                        |                            |                  |
| 0                                  | 48 (16.5)              | 44 (15.4)              | 52 (17.9)                  | 144 (16.6)       |
| 1-6                                | 237 (81.4)             | 241 (84.3)             | 235 (81.0)                 | 713 (82.2)       |
| >6                                 | 6 (2.1)                | 1 (0.3)                | 3 (1.0)                    | 10 (1.2)         |
| CIRS3+a,n(%)                       |                        |                        |                            |                  |
| Yes                                | 24 (8.2)               | 24 (8.4)               | 26 (9.0)                   | 74 (8.5)         |
| No                                 | 267 (91.8)             | 262 (91.6)             | 264 (91.0)                 | 793 (91.5)       |
| CIRS-G category by age groupb,n(%) |                        |                        |                            |                  |
| Age group ≤ 65 years, n            | 212                    | 210                    | 213                        | 635              |
| ≤ 6                                | 208 (98.1)             | 210 (100)              | 212 (99.5)                 | 630 (99.2)       |
| >6                                 | 4 (1.9)                | 0                      | 1 (0.5)                    | 5 (0.8)          |
| Age group >65years, n              | 79                     | 76                     | 77                         | 232              |
| ≤ 6                                | 77 (97.5)              | 75 (98.7)              | 75 (97.4)                  | 227 (97.8)       |
| >6                                 | 2 (2.5)                | 1 (1.3)                | 2 (2.6)                    | 5 (2.2)          |
| Age group ≤ 75 years, n            | 282                    | 274                    | 280                        | 836              |
| ≤ 6                                | 276 (97.9)             | 273 (99.6)             | 278 (99.3)                 | 827 (98.9)       |
| >6                                 | 6 (2.1)                | 1 (0.4)                | 2 (0.7)                    | 9 (1.1)          |
| Age group >75years, n              | 9                      | 12                     | 10                         | 31               |
| ≤ 6                                | 9 (100)                | 12 (100)               | 9 (90.0)                   | 30 (96.8)        |
| > 6                                | 0                      | 0                      | 1 (10.0)                   | 1 (3.2)          |
| Rai stage, n (%)                   |                        |                        |                            |                  |
| 0                                  | 3 (1.0)                | 1 (0.3)                | 4 (1.4)                    | 8 (0.9)          |
| I                                  | 47 (16.2)              | 61 (21.3)              | 62 (21.4)                  | 170 (19.6)       |
| II                                 | 104 (35.7)             | 108 (37.8)             | 97 (33.4)                  | 309 (35.6)       |
| III                                | 69 (23.7)              | 51 (17.8)              | 59 (20.3)                  | 179 (20.6)       |
| IV                                 | 68 (23.4)              | 65 (22.7)              | 68 (23.4)                  | 201 (23.2)       |
| 11q deletion mutation, n (%)       |                        |                        |                            |                  |
| Yes                                | 51 (17.5)              | 56 (19.6)              | 46 (15.9)                  | 153 (17.6)       |

<div style=\"page-break-after: always\"></div>

|                                       | Arm A (AV) (N = 291)   | Arm B (AVG) (N =286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|---------------------------------------|------------------------|------------------------|----------------------------|------------------|
| No                                    | 238 (81.8)             | 230 (80.4)             | 242 (83.4)                 | 710 (81.9)       |
| Missing                               | 2 (0.7)                | 0                      | 2 (0.7)                    | 4 (0.5)          |
| IGHV mutation, n (%)                  |                        |                        |                            |                  |
| Mutated                               | 124 (42.6)             | 117 (40.9)             | 118 (40.7)                 | 359 (41.4)       |
| Unmutated                             | 167 (57.4)             | 169 (59.1)             | 172 (59.3)                 | 508 (58.6)       |
| Complex karyotype, n (%)              |                        |                        |                            |                  |
| Yes                                   | 45 (15.5)              | 46 (16.1)              | 42 (14.5)                  | 133 (15.3)       |
| Low (3 aberrations)                   | 21 (7.2)               | 14 (4.9)               | 22 (7.6)                   | 57 (6.6)         |
| Medium (4 aberrations)                | 11 (3.8)               | 11 (3.8)               | 7 (2.4)                    | 29 (3.3)         |
| High (≥ 5 aberrations)                | 13 (4.5)               | 21 (7.3)               | 13 (4.5)                   | 47 (5.4)         |
| No                                    | 230 (79.0)             | 223 (78.0)             | 217 (74.8)                 | 670 (77.3)       |
| Missing                               | 16 (5.5)               | 17 (5.9)               | 31 (10.7)                  | 64 (7.4)         |
| CD38 expression, n (%)                |                        |                        |                            |                  |
| Yes                                   | 67 (23.0)              | 70 (24.5)              | 60 (20.7)                  | 197 (22.7)       |
| No                                    | 123 (42.3)             | 116 (40.6)             | 132 (45.5)                 | 371 (42.8)       |
| Missing                               | 101 (34.7)             | 100 (35.0)             | 98 (33.8)                  | 299 (34.5)       |
| Zap-70 expression, n (%)              |                        |                        |                            |                  |
| Yes                                   | 95 (32.6)              | 92 (32.2)              | 89 (30.7)                  | 276 (31.8)       |
| No                                    | 95 (32.6)              | 93 (32.5)              | 102 (35.2)                 | 290 (33.4)       |
| Missing                               | 101 (34.7)             | 101 (35.3)             | 99 (34.1)                  | 301 (34.7)       |
| B2-microglobulin (mg/L), n (%)        |                        |                        |                            |                  |
| ≤ 3.5                                 | 103 (35.4)             | 122 (42.7)             | 107 (36.9)                 | 332 (38.3)       |
| > 3.5                                 | 169 (58.1)             | 151 (52.8)             | 143 (49.3)                 | 463 (53.4)       |
| Missing                               | 19 (6.5)               | 13 (4.5)               | 40 (13.8)                  | 72 (8.3)         |
| Creatine clearance < 60 mL/min, n (%) |                        |                        |                            |                  |
| Yes                                   | 38 (13.1)              | 39 (13.6)              | 30 (10.3)                  | 107 (12.3)       |
| No                                    | 253 (86.9)             | 245 (85.7)             | 260 (89.7)                 | 758 (87.4)       |
| Missing                               | 0                      | 2 (0.7)                | 0                          | 2 (0.2)          |
| Cytopenia, n (%)                      |                        |                        |                            |                  |
| Neutropenia - ANC ≤ 1.5x10 9 /L       |                        |                        |                            |                  |
| Yes                                   | 20 (6.9)               | 25 (8.7)               | 20 (6.9)                   | 65 (7.5)         |
| No                                    | 271 (93.1)             | 261 (91.3)             | 269 (92.8)                 | 801 (92.4)       |
| Missing                               | 0                      | 0                      | 1 (0.3)                    | 1 (0.1)          |
| Anaemia - haemoglobin < 11 g/dL       |                        |                        |                            |                  |

<div style=\"page-break-after: always\"></div>

|                                                                           | Arm A (AV) (N = 291)   | Arm B (AVG) (N =286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|---------------------------------------------------------------------------|------------------------|------------------------|----------------------------|------------------|
| Yes                                                                       | 103 (35.4)             | 85 (29.7)              | 94 (32.4)                  | 282 (32.5)       |
| No                                                                        | 188 (64.6)             | 201 (70.3)             | 195 (67.2)                 | 584 (67.4)       |
| Missing                                                                   | 0                      | 0                      | 1 (0.3)                    | 1 (0.1)          |
| Thrombocytopenia - platelets < 100x10 9 /L                                |                        |                        |                            |                  |
| Yes                                                                       | 66 (22.7)              | 68 (23.8)              | 58 (20.0)                  | 192 (22.1)       |
| No                                                                        | 225 (77.3)             | 218 (76.2)             | 231 (79.7)                 | 674 (77.7)       |
| Missing                                                                   | 0                      | 0                      | 1 (0.3)                    | 1 (0.1)          |
| All of the above                                                          | 5 (1.7)                | 7 (2.4)                | 6 (2.1)                    | 18 (2.1)         |
| Any of the above                                                          | 148 (50.9)             | 128 (44.8)             | 130 (44.8)                 | 406 (46.8)       |
| Prior red blood cell transfusion in 28 days prior to randomisation, n (%) |                        |                        |                            |                  |
| Yes                                                                       | 7 (2.4)                | 3 (1.0)                | 4 (1.4)                    | 14 (1.6)         |
| No                                                                        | 284 (97.6)             | 283 (99.0)             | 286 (98.6)                 | 853 (98.4)       |
| Prior platelet transfusion in 28 days prior to randomization, n (%)       |                        |                        |                            |                  |
| Yes                                                                       | 1 (0.3)                | 0                      | 0                          | 1 (0.1)          |
| No                                                                        | 290 (99.7)             | 286 (100)              | 290 (100)                  | 866 (99.9)       |
| B-symptoms, n (%)                                                         |                        |                        |                            |                  |
| Weight loss                                                               | 37 (12.7)              | 22 (7.7)               | 22 (7.6)                   | 81 (9.3)         |
| Fever                                                                     | 3 (1.0)                | 4 (1.4)                | 4 (1.4)                    | 11 (1.3)         |
| Night sweats                                                              | 122 (41.9)             | 119 (41.6)             | 120 (41.4)                 | 361 (41.6)       |
| All of the above                                                          | 1 (0.3)                | 1 (0.3)                | 1 (0.3)                    | 3 (0.3)          |
| Any of the above                                                          | 131 (45.0)             | 125 (43.7)             | 129 (44.5)                 | 385 (44.4)       |
| ALC (10 9 /L)                                                             |                        |                        |                            |                  |
| Mean (SD)                                                                 | 94.503 (78.514)        | 86.905 (83.669)        | 93.191 (89.445)            | 91.556 (83.952)  |
| Median                                                                    | 71.920                 | 66.285                 | 70.640                     | 70.366           |
| Min, Max                                                                  | 1.09,397.08            | 1.63,553.39            | 1.11,556.11                | 1.09,556.11      |
| ANC (10 9 /L)                                                             |                        |                        |                            |                  |
| Mean (SD)                                                                 | 5.204 (3.165)          | 5.647 (9.268)          | 5.408 (4.136)              | 5.418 (6.115)    |
| Median                                                                    | 4.520                  | 4.645                  | 4.390                      | 4.535            |
| Min, Max                                                                  | 0.00,18.48             | 0.10,152.80            | 0.00,40.11                 | 0.00,152.80      |
| Platelets (10 9 /L)                                                       |                        |                        |                            |                  |
| Mean (SD)                                                                 | 149.4 (67.7)           | 150.8 (65.0)           | 154.6 (69.4)               | 151.6 (67.4)     |
| Median                                                                    | 140.0                  | 142.5                  | 146.0                      | 143.0            |

<div style=\"page-break-after: always\"></div>

|                       | Arm A (AV) (N = 291)   | Arm B (AVG) (N =286)   | Arm C (FCR/BR) (N = 290)   | Total (N =867)   |
|-----------------------|------------------------|------------------------|----------------------------|------------------|
| Min, Max              | 22,546                 | 37,482                 | 9,698                      | 9,698            |
| Haemoglobin (g/dL)    |                        |                        |                            |                  |
| Mean (SD)             | 11.70 (2.08)           | 12.16 (2.09)           | 11.85 (2.12)               | 11.90 (2.10)     |
| Median                | 11.80                  | 12.40                  | 11.90                      | 12.00            |
| Min, Max              | 5.8,16.5               | 5.8,17.0               | 5.9,17.3                   | 5.8,17.3         |
| Current smoker, n (%) |                        |                        |                            |                  |
| Yes                   | 33 (11.3)              | 27 (9.4)               | 31 (10.7)                  | 91 (10.5)        |
| No                    | 68 (23.4)              | 72 (25.2)              | 75 (25.9)                  | 215 (24.8)       |
| Never smoked          | 180 (61.9)             | 174 (60.8)             | 175 (60.3)                 | 529 (61.0)       |
| Missing               | 10 (3.4)               | 13 (4.5)               | 9 (3.1)                    | 32 (3.7)         |

- a. CIRS3+ is defined as CIRS-G score of 3 or 4 in any single organ system.
- b. Percentages are based on the number of patients in the age group.

## Numbers analysed

Table 9 . Description of analysis sets, study ACE-CL-311

| Analysis Set            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full Analysis Set (FAS) | All randomized patients regardless of the treatment actually received. Patients were analysed according to the Arm to which they were randomised, following the 'intent-to-treat' principle. FAS was the primary analysis set used for all efficacy analyses. Additionally, demographic and patient characteristics were summarised among the FAS.                                                                                                                                                         |
| Safety Population       | All randomised patients who received any amount of study drug. Safety data were summarised using the Safety Population, according to the actual treatment that a patient received.                                                                                                                                                                                                                                                                                                                         |
| PK Evaluable Population | All patients who received acalabrutinib or venetoclax with an evaluable post-dose PK value were included in the PK evaluable population.                                                                                                                                                                                                                                                                                                                                                                   |
| Per-protocol Population | All patients in the FAS with exclusion of patients meeting at least one specific criterion or IPD that may have affected the efficacy of the trial therapy, as defined below: • Either did not take or discontinued early from at least one randomised treatment. • Less than 75% RDI for any randomised treatment. • Violated protocol inclusion or exclusion criteria that may affect interpretation of efficacy • At least one important protocol deviation in category 6 (excluded medications taken). |

## Outcomes and estimation

All results presented in this section are based on the data cut-off date of 30 April 2024 unless otherwise specified.

<div style=\"page-break-after: always\"></div>

## Primary endpoint: PFS (Arm A vs Arm C)

Table 10 . Progression-free Survival by Blinded Independent Central Review (FAS), study ACE-CL-311

|                                                                       | Arm A (AV) (N = 291)   | Arm C (FCR/BR) (N = 290)   |
|-----------------------------------------------------------------------|------------------------|----------------------------|
| Event a                                                               |                        |                            |
| Any                                                                   | 89 (30.6)              | 95 (32.8)                  |
| Progression                                                           | 77 (26.5)              | 66 (22.8)                  |
| Death without progression                                             | 12 (4.1)               | 29 (10.0)                  |
| Censored observations                                                 |                        |                            |
| Any                                                                   | 202 (69.4)             | 195 (67.2)                 |
| Censored at Day 1                                                     | 1 (0.3)                | 33 (11.4)                  |
| No baseline disease assessment                                        | 0                      | 1 (0.3)                    |
| No post-baseline response assessment                                  | 1 (0.3)                | 32 (11.0)                  |
| Censored due to 2 or more consecutively missed response assessments b | 20 (6.9)               | 31 (10.7)                  |
| Censored due to subsequent anti-CLL therapy                           | 2 (0.7)                | 5 (1.7)                    |
| Progression-free                                                      | 179 (61.5)             | 126 (43.4)                 |
| Progression-free at time of the analysis                              | 178 (61.2)             | 120 (41.4)                 |
| Early study discontinuation                                           | 1 (0.3)                | 6 (2.1)                    |
| Lost to follow-up                                                     | 0                      | 0                          |
| Withdrew consent                                                      | 1 (0.3)                | 4 (1.4)                    |
| Study exit due to investigator decision or other                      | 0                      | 2 (0.7)                    |
| PFS, months                                                           |                        |                            |
| Median (95% CI)                                                       | NC (51.1, NC)          | 47.6 (43.3, NC)            |
| P25, P75                                                              | 36.8, NC               | 27.7, NC                   |
| Comparison of treatment groups                                        |                        |                            |
| Hazard ratio (95% CI)                                                 | 0.65 (0.49, 0.87)      |                            |
| p-value                                                               | 0.0038                 |                            |
| Progression free survival rate d (%)                                  |                        |                            |
| 12 months (95% CI)                                                    | 94.8 (91.5, 96.8)      | 88.3 (83.6, 91.7)          |
| 24 months (95% CI)                                                    | 87.6 (83.1, 90.9)      | 79.0 (73.2, 83.6)          |
| 36 months (95% CI)                                                    | 76.5 (71.0, 81.1)      | 66.5 (59.8, 72.3)          |
| 48 months (95% CI)                                                    | 63.9 (56.6, 70.3)      | 48.8 (39.5, 57.4)          |

- a. Includes events that occur within 28 weeks of last evaluable assessment (in the first 3 years after randomisation) or within 56 weeks of last evaluable assessment (3 years and later from randomisation).
- b. The threshold for 2 or more consecutively missed response assessments is 28 weeks in the first 3 years after randomisation and 56 weeks thereafter.

Figure 7 . Kaplan-Meier Plot for Progression-free Survival by Blinded Independent Central Review (FAS), study ACE-CL-311

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Sensitivity analyses

Table 11. Progression-free Survival by Blinded Independent Central Review - Sensitivity Analysis (FAS), study ACE-CL-311

|                                                    | Group                  | Patient s with event n (%)   | Median time to event (month s)   | 95% CI   | Comparison of treatment groups   | Comparison of treatment groups   | Comparison of treatment groups   |
|----------------------------------------------------|------------------------|------------------------------|----------------------------------|----------|----------------------------------|----------------------------------|----------------------------------|
|                                                    |                        |                              |                                  |          | HR                               | 95% CI                           | p-value                          |
| Unstratified analysis                              | Arm A (AV) N = 291     | 89 (30.6)                    | NC                               | 51.1, NC | 0.68                             | 0.51, 0.91                       | 0.0080                           |
| Unstratified analysis                              | Arm B (AVG) N = 286    | 56 (19.6)                    | NC                               | NC, NC   | 0.43                             | 0.30, 0.59                       | < 0.0001                         |
| Unstratified analysis                              | Arm C (FCR/BR) N = 290 | 95 (32.8)                    | 47.6                             | 43.3, NC |                                  |                                  |                                  |
| Not censoring due to subsequent anticancer therapy | Arm A (AV) N = 291     | 91 (31.3)                    | NC                               | 51.1, NC | 0.66                             | 0.50, 0.89                       | 0.0054                           |
|                                                    | Arm B (AVG) N = 286    | 56 (19.6)                    | NC                               | NC, NC   | 0.42                             | 0.30, 0.59                       | < 0.0001                         |
|                                                    | Arm C (FCR/BR) N = 290 | 95 (32.8)                    | 47.6                             | 43.3, NC |                                  |                                  |                                  |

<div style=\"page-break-after: always\"></div>

|                                                                   | Group                  | Patient s with event   | Median time to event (month   | 95% CI   | Comparison of treatment groups   | Comparison of treatment groups   | Comparison of treatment groups   |
|-------------------------------------------------------------------|------------------------|------------------------|-------------------------------|----------|----------------------------------|----------------------------------|----------------------------------|
|                                                                   |                        | n (%)                  | s)                            |          | HR                               | 95% CI                           | p-value                          |
| Not censoring due to 2 or more consecutively response assessments | Arm A (AV) N = 291     | 93 (32.0)              | NC                            | 51.5, NC | 0.67                             | 0.50, 0.89                       | 0.0054                           |
|                                                                   | Arm B (AVG) N = 286    | 60 (21.0)              | NC                            | 54.6, NC | 0.45                             | 0.32, 0.62                       | < 0.0001                         |
|                                                                   | Arm C (FCR/BR) N = 290 | 99 (34.1)              | 48.8                          | 43.3, NC |                                  |                                  |                                  |
| Stratification according to IxRS                                  | Arm A (AV) N = 291     | 89 (30.6)              | NC                            | 51.1, NC | 0.66                             | 0.49, 0.88                       | 0.0051                           |
|                                                                   | Arm B (AVG) N = 286    | 56 (19.6)              | NC                            | NC, NC   | 0.41                             | 0.29, 0.57                       | < 0.0001                         |
|                                                                   | Arm C (FCR/BR) N = 290 | 95 (32.8)              | 47.6                          | 43.3, NC |                                  |                                  |                                  |
| Per-protocol Population                                           | Arm A (AV) N = 239     | 66 (27.6)              | NC                            | 51.5, NC | 0.63                             | 0.45, 0.88                       | 0.0071                           |
|                                                                   | Arm B (AVG) N = 186    | 24 (12.9)              | NC                            | NC, NC   | 0.27                             | 0.17, 0.43                       | < 0.0001                         |
|                                                                   | Arm C (FCR/BR) N = 199 | 71 (35.7)              | 48.8                          | 43.7, NC |                                  |                                  |                                  |
| Censoring COVID-19 Deaths                                         | Arm A (AV) N = 291     | 81 (27.8)              | NC                            | 51.5, NC | 0.71                             | 0.52, 0.98                       | 0.0356                           |
|                                                                   | Arm B (AVG) N = 286    | 31 (10.8)              | NC                            | NC, NC   | 0.26                             | 0.17, 0.39                       | < 0.0001                         |
|                                                                   | Arm C (FCR/BR) N = 290 | 77 (26.6)              | 49.2                          | 44.4, NC |                                  |                                  |                                  |

A HR below 1 favours Arm A or Arm B over Arm C, respectively.

The p-value is based on the stratified log-rank test and the HR is based on the stratified Cox proportional hazards model, except for in the \"unstratified\" analysis.

## Subgroup analysis

Figure 8. Forest Plot for Subgroup Analysis of Progression-Free Survival by Blinded Independent Central Review: Arm A (AV) and Arm C (FCR/BR) (FAS), study ACE-CL-311

<div style=\"page-break-after: always\"></div>

|                                      | Number of events/Subjects   | Number of events/Subjects   |                       |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------|
| Variable Category                    | Arm A (AV) (N=291)          | Arm C (FCR/BR) (N=290)      | Hazard ratio (95% CI) |
| Overall                              |                             |                             |                       |
| All subjects                         | 89/291                      | 95/290                      | 0.65 (0.49,0.87)      |
| Age category (year)                  |                             |                             |                       |
| <=65                                 | 66/212                      | 61/213                      | 0.80 (0.56, 1.13)     |
| >65                                  | 23/79                       | 34/77                       | 0.47 (0.27, 0.79)     |
| IGHVmutational status                |                             |                             |                       |
| Mutated                              | 28/124                      | 28/118                      | 0.67 (0.39, 1.14)     |
| Unmutated                            | 61/167                      | 67/172                      | 0.69 (0.48,0.97)      |
| Rai stage                            |                             |                             |                       |
| High risk (>=3)                      | 47/137                      | 45/127                      | 0.66 (0.44,1.00)      |
| Non-high risk(<3)                    | 42/154                      | 50/163                      | 0.67 (0.44,1.00)      |
| Geographic region                    |                             |                             |                       |
| North America                        | 16/50                       | 14/50                       | 0.71 (0.35, 1.48)     |
| Europe                               | 55/184                      | 67/183                      | 0.61 (0.43, 0.87)     |
| Other                                | 18/57                       | 14/57                       | 0.95 (0.47,1.95)      |
| Sex                                  |                             |                             |                       |
| Male                                 | 57/178                      | 64/183                      | 0.66 (0.46,0.95)      |
| Female                               | 32/113                      | 31/107                      | 0.72 (0.44, 1.18)     |
| Race                                 |                             |                             |                       |
| AmericanIndianorAlaskaNative         | 1/1                         | 0/1                         | NC (NC, NC)           |
| Asian                                | 1/4                         | 3/18                        | NC (NC, NC)           |
| BlackorAfricanAmerican               | 0/3                         | 4/7                         | NC (NC, NC)           |
| NativeHawaian orOtherPacificIslander | 0/0                         | 1/2                         | NC (NC, NC)           |
| White                                | 83/265                      | 86/252                      | 0.69 (0.51,0.93)      |
| Multiple                             | 0/0                         | 0/0                         | NC (NC, NC)           |
| Missing                              | 4/18                        | 1/10                        | NC (NC, NC)           |
| Ethnicity                            |                             |                             |                       |
| Hispanic or Latino                   | 9/21                        | 8/19                        | NC (NC, NC)           |
| Not Hispanic or Latino               | 76/246                      | 84/256                      | 0.69 (0.51,0.94)      |
| Missing                              | 4/24                        | 3/15                        | NC (NC, NC)           |
| ECOGPerformanceStatus                |                             |                             |                       |
| <=1                                  | 78/262                      | 84/262                      | 0.68 (0.50,0.93)      |
| 2                                    | 10/28                       | 11/26                       | 0.55 (0.23, 1.31)     |
| Missing                              | 1/1                         | 0/2                         | NC (NC, NC)           |
| 11q deletion mutation                |                             |                             |                       |
| Yes                                  | 18/51                       | 24/46                       | 0.44 (0.24, 0.82)     |
| No                                   | 70/238                      | 71/242                      | 0.75 (0.54,1.04)      |
| Missing                              | 1/2                         | 0/2                         | NC (NC, NC)           |
| Complex karyotype                    |                             |                             |                       |
| Yes                                  | 11/45                       | 12/42                       | 0.50 (0.22, 1.15)     |
| No                                   | 74/230                      | 71/217                      | 0.77 (0.56,1.07)      |
| Missing                              | 4/16                        | 12/31                       | NC (NC, NC)           |
| CD38expression                       |                             |                             |                       |
| Yes                                  | 20/67                       | 21/60                       | 0.57 (0.30,1.05)      |
| No                                   | 37/123                      | 39/132                      | 0.79 (0.50, 1.24)     |
| Missing                              | 32/101                      | 35/98                       | 0.63 (0.39,1.01)      |
| ZAP-70 expression                    |                             |                             |                       |
| Yes                                  | 30/95                       | 38/89                       | 0.45 (0.28, 0.73)     |
| No                                   | 27/95                       | 22/102                      | 1.10 (0.62, 1.94)     |
| Missing                              | 32/101                      | 35/99                       | 0.63 (0.39, 1.02)     |

<div style=\"page-break-after: always\"></div>

## Comparison with FCR only and BR only

Table 12 . PFS by IRC: Arm A (AV) and Arm B (AVG) and Arm C (FCR only) (FAS), study ACE-CL-311

|                                                                       | Arm A (AV) (N = 291)   | Arm B (AVG) (N = 286)   | Arm C (FCR Only) (N = 143)   |
|-----------------------------------------------------------------------|------------------------|-------------------------|------------------------------|
| Event a                                                               |                        |                         |                              |
| Any                                                                   | 89 (30.6)              | 56 (19.6)               | 38 (26.6)                    |
| Progression                                                           | 77 (26.5)              | 23 (8.0)                | 23 (16.1)                    |
| Death without progression                                             | 12 (4.1)               | 33 (11.5)               | 15 (10.5)                    |
| Censored observations                                                 |                        |                         |                              |
| Any                                                                   | 202 (69.4)             | 230 (80.4)              | 105 (73.4)                   |
| Censored at Day 1                                                     | 1 (0.3)                | 2 (0.7)                 | 21 (14.7)                    |
| No baseline disease assessment                                        | 0                      | 1 (0.3)                 | 0                            |
| No post-baseline response assessment                                  | 1 (0.3)                | 1 (0.3)                 | 21 (14.7)                    |
| Censored due to 2 or more consecutively missed response assessments b | 20 (6.9)               | 25 (8.7)                | 15 (10.5)                    |
| Censored due to subsequent anti-CLL therapy                           | 2 (0.7)                | 2 (0.7)                 | 4 (2.8)                      |
| Progression-free c                                                    | 179 (61.5)             | 201 (70.3)              | 65 (45.5)                    |
| Progression-free at time of the analysis                              | 178 (61.2)             | 200 (69.9)              | 62 (43.4)                    |
| Early study discontinuation                                           | 1 (0.3)                | 1 (0.3)                 | 3 (2.1)                      |
| Lost to follow-up                                                     | 0                      | 0                       | 0                            |
| Withdrew consent                                                      | 1 (0.3)                | 1 (0.3)                 | 2 (1.4)                      |
| Study exit due to investigator                                        | 0                      | 0                       | 1 (0.7)                      |
| decision or other PFS, months                                         |                        |                         |                              |
| Median (95% CI)                                                       | NC (51.1, NC)          | NC (NC, NC)             | NC (43.0, NC)                |
| P25, P75                                                              | 36.8, NC               | 51.4, NC                | 27.8, NC                     |
| Comparison of treatment groups                                        |                        |                         |                              |
| Hazard ratio (95% CI)                                                 | 0.69 (0.47, 1.03)      | 0.47 (0.31, 0.73)       | -                            |
| p-value g                                                             | 0.0581                 | 0.0004                  | -                            |
| Progression-free survival rate (%)                                    |                        |                         |                              |
| 12 months (95% CI)                                                    | 94.8 (91.5, 96.8)      | 91.5 (87.6, 94.2)       | 87.1 (79.5, 92.0)            |
| 24 months (95% CI)                                                    | 87.6 (83.1, 90.9)      | 87.1 (82.6, 90.5)       | 79.5 (70.7, 85.9)            |
| 36 months (95% CI)                                                    | 76.5 (71.0, 81.1)      | 83.1 (78.1, 87.1)       | 68.9 (59.0, 76.9)            |
| 48 months (95% CI)                                                    | 63.9 (56.6, 70.3)      | 78.8 (72.7, 83.7)       | 56.1 (42.3, 67.8)            |

<div style=\"page-break-after: always\"></div>

a  Includes events that occur within 28 weeks of last evaluable assessment (in the first 3 years after randomization) or within 56 weeks of last evaluable assessment (3 years and later from randomization).

b  The threshold for 2 or more consecutively missed response assessments is 28 weeks in the first 3 years after randomization and 56 weeks thereafter.

Table 13. PFS by Blinded Independent Central Review: Arm A (AV) and Arm B (AVG) and Arm C (BR only) (FAS)

|                                                                       | Arm A (AV) (N = 291)   | Arm B (AVG) (N = 286)   | Arm C (BR Only) (N = 147)   |
|-----------------------------------------------------------------------|------------------------|-------------------------|-----------------------------|
| Event a                                                               |                        |                         |                             |
| Any                                                                   | 89 (30.6)              | 56 (19.6)               | 57 (38.8)                   |
| Progression                                                           | 77 (26.5)              | 23 (8.0)                | 43 (29.3)                   |
| Death without progression                                             | 12 (4.1)               | 33 (11.5)               | 14 (9.5)                    |
| Censored observations                                                 |                        |                         |                             |
| Any                                                                   | 202 (69.4)             | 230 (80.4)              | 90 (61.2)                   |
| Censored at Day 1                                                     | 1 (0.3)                | 2 (0.7)                 | 12 (8.2)                    |
| No baseline disease assessment                                        | 0                      | 1 (0.3)                 | 1 (0.7)                     |
| No post-baseline response assessment                                  | 1 (0.3)                | 1 (0.3)                 | 11 (7.5)                    |
| Censored due to 2 or more consecutively missed response assessments b | 20 (6.9)               | 25 (8.7)                | 16 (10.9)                   |
| Censored due to subsequent anti-CLL therapy                           | 2 (0.7)                | 2 (0.7)                 | 1 (0.7)                     |
| Progression-free                                                      | 179 (61.5)             | 201 (70.3)              | 61 (41.5)                   |
| Progression-free at time of the analysis                              | 178 (61.2)             | 200 (69.9)              | 58 (39.5)                   |
| Early study discontinuation                                           | 1 (0.3)                | 1 (0.3)                 | 3 (2.0)                     |
| Lost to follow-up                                                     | 0                      | 0                       | 0                           |
| Withdrew consent                                                      | 1 (0.3)                | 1 (0.3)                 | 2 (1.4)                     |
| Study exit due to investigator decision or other                      | 0                      | 0                       | 1 (0.7)                     |
| PFS, months                                                           |                        |                         |                             |
| Median (95% CI)                                                       | NC (51.1, NC)          | NC (NC, NC)             | 46.2 (41.0, NC)             |
| P25, P75                                                              | 36.8, NC               | 51.4, NC                | 27.7, NC                    |
| Comparison of treatment groups                                        |                        |                         |                             |
| Hazard ratio (95% CI)                                                 | 0.63 (0.45, 0.88)      | 0.39 (0.27, 0.57)       | -                           |
| p-value                                                               | 0.0062                 | < 0.0001                | -                           |
| Progression-free rate d (%)                                           |                        |                         |                             |
| 12 months (95% CI)                                                    | 94.8 (91.5, 96.8)      | 91.5 (87.6, 94.2)       | 89.3 (82.7, 93.6)           |

<div style=\"page-break-after: always\"></div>

| 24 months (95% CI)   | 87.6 (83.1, 90.9)   | 87.1 (82.6, 90.5)   | 78.5 (70.2, 84.8)   |
|----------------------|---------------------|---------------------|---------------------|
| 36 months (95% CI)   | 76.5 (71.0, 81.1)   | 83.1 (78.1, 87.1)   | 64.5 (55.1, 72.3)   |
| 48 months (95% CI)   | 63.9 (56.6, 70.3)   | 78.8 (72.7, 83.7)   | 44.3 (32.4, 55.6)   |

a Includes events that occur within 28 weeks of last evaluable assessment (in the first 3 years after randomization) or within 56 weeks of last evaluable assessment (3 years and later from randomization). b The threshold for 2 or more consecutively missed response assessments is 28 weeks in the first 3 years after randomization and 56 weeks thereafter.

## Evaluation of Imbalanced Early Censoring

A tipping point analysis was performed to evaluate the impact of imbalanced early censoring between arms on the PFS by IRC results. In this analysis, the PFS time was imputed for the 75 patients in Arm C (FCR/BR) who were censored informatively, i.e. censored for any reason other than not having an event before the data cutoff date. For the tipping point analysis, it was assumed that these patients had a reduced risk (i.e. reduced hazard rate) compared to all other patients in the arm (i.e. those still in follow-up or who had an event) in Arm C (FCR/BR). A grid search algorithm was used to find the minimal percent reduction of hazard rate needed (in increments of 10%) such that the 95% confidence interval of the hazard ratio would include 1. For each set of imputed PFS data, the Cox model adjusting for the stratification factors was used to generate the logarithm of the hazard ratio and the corresponding standard error. The pooled mean and standard error of the logarithm of the hazard ratio were calculated from 10,000 simulations (assuming an exponential distribution for event time) based on Rubin's rule (Rubin 1987). The estimate and confidence interval for the HR were derived by exponentiating the mean and the corresponding confidence interval of the log (hazard ratio). If the death date was reported, the imputed time was restricted to be shorter than the OS time. Patients who had imputed time after the data cutoff date were censored at the data cutoff date.

Additionally, baseline characteristics of the patients informatively censored vs non-informatively censored were summarised by arm. In Arm C (FCR/BR), a higher proportion of the informatively censored patients compared with the non-informatively censored p atients had Rai stage ≥3 (50.7% vs 36.7%), unmutated IGHV (62.7% vs 48.3%), 11q deletion (16.0% vs 8.3%), and anaemia (41.3% vs 25.8%). Otherwise, baseline characteristics appeared to be well-balanced between the patients informatively censored vs non-informatively censored in Arm C (FCR/BR).

For the comparison of Arm A (AV) vs C (FCR/BR), Figure 9 suggests that the 95% confidence interval of the estimated hazard ratio will include 1 if the 75 patients in Arm C (FCR/BR) were assumed to have at least 40% lower risk of progression or death compared to those still in follow-up or with an event in Arm C (FCR/BR).

Figure 9. Tipping Point Analysis of PFS by IRC in Arm A (AV) vs Arm C (FCR/BR)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## PFS (Arm B vs Arm C)

Table 14. Progression-free Survival by Blinded Independent Central Review: Arm B (AVG) and Arm C (FCR/BR) (FAS), study ACE-CL-311

|                                                                       | Arm B (AVG) (N = 286)   | Arm C (FCR/BR) (N = 290)   |
|-----------------------------------------------------------------------|-------------------------|----------------------------|
| Event a                                                               |                         |                            |
| Any                                                                   | 56 (19.6)               | 95 (32.8)                  |
| Progression                                                           | 23 (8.0)                | 66 (22.8)                  |
| Death without progression                                             | 33 (11.5)               | 29 (10.0)                  |
| Censored observations                                                 |                         |                            |
| Any                                                                   | 230 (80.4)              | 195 (67.2)                 |
| Censored at Day 1                                                     | 2 (0.7)                 | 33 (11.4)                  |
| No baseline disease assessment                                        | 1 (0.3)                 | 1 (0.3)                    |
| No post-baseline response                                             | 1 (0.3)                 | 32 (11.0)                  |
| Censored due to 2 or more consecutively missed response assessments b | 25 (8.7)                | 31 (10.7)                  |
| Censored due to subsequent anti-CLL therapy                           | 2 (0.7)                 | 5 (1.7)                    |
| Progression-free                                                      | 201 (70.3)              | 126 (43.4)                 |
| Progression-free at time of the analysis                              | 200 (69.9)              | 120 (41.4)                 |
| Early study discontinuation                                           | 1 (0.3)                 | 6 (2.1)                    |
| Lost to follow-up                                                     | 0                       | 0                          |
| Withdrew consent                                                      | 1 (0.3)                 | 4 (1.4)                    |
| Study exit due to investigator decision or                            | 0                       | 2 (0.7)                    |
| other                                                                 |                         |                            |

<div style=\"page-break-after: always\"></div>

|                                    | Arm B (AVG) (N = 286)   | Arm C (FCR/BR) (N = 290)   |
|------------------------------------|-------------------------|----------------------------|
| Median (95% CI)                    | NC (NC, NC)             | 47.6 (43.3, NC)            |
| P25, P75                           | 51.4, NC                | 27.7, NC                   |
| Comparison of treatment groups     |                         |                            |
| Hazard ratio (95% CI)              | 0.42 (0.30, 0.59)       |                            |
| p-value                            | < 0.0001                |                            |
| Progression free survival rate (%) |                         |                            |
| 12 months (95% CI)                 | 91.5 (87.6, 94.2)       | 88.3 (83.6, 91.7)          |
| 24 months (95% CI)                 | 87.1 (82.6, 90.5)       | 79.0 (73.2, 83.6)          |
| 36 months (95% CI)                 | 83.1 (78.1, 87.1)       | 66.5 (59.8, 72.3)          |
| 48 months (95% CI)                 | 78.8 (72.7, 83.7)       | 48.8 (39.5, 57.4)          |

- a. Includes events that occur within 28 weeks of last evaluable assessment (in the first 3 years after randomisation) or within 56 weeks of last evaluable assessment (3 years and later from randomisation).
- b. The threshold for 2 or more consecutively missed response assessments is 28 weeks in the first 3 years after randomisation and 56 weeks thereafter.

## MRD negativity rate

Table 15. Flow Cytometry Minimal Residual Disease in Peripheral Blood (Full Analysis Set), study ACECL-311

|                                         | Arm A (AV) N = 291   | Arm B (AVG) N = 286   | Arm C (FCR/BR) N = 290   |
|-----------------------------------------|----------------------|-----------------------|--------------------------|
| Patients with MRD measurement a , n (%) | 244 (83.8)           | 202 (70.6)            | 190 (65.5)               |
| uMRD b , n (%)                          | 78 (26.8)            | 190 (66.4)            | 148 (51.0)               |
| 95% CI                                  | 22.0, 32.1           | 60.8, 71.7            | 45.3, 56.8               |
| Comparison of treatment groups          | 0.5 (0.4, 0.7)       | 1.3 (1.1, 1.5)        | -                        |
| Risk ratio                              | 0.5                  | 1.3                   | -                        |
| 95% CI                                  | 0.4, 0.7             | 1.1, 1.5              | -                        |
| p-value                                 | < 0.0001             | 0.0003                | -                        |
| uMRD and BoR CR/CRi by IRC              | 10 (3.4)             | 35 (12.2)             | 11 (3.8)                 |

a  Patients with an MRD measurement at Cycle 9 (Arm A), Cycle 10 (Arm B), or 12 weeks after the start of Cycle 6 (Arm C).

b uMRD is defined as &lt; 1 CLL cell per 10,000 (10 -4 ) leukocytes unless otherwise indicated. uMRD is based on Arm A at the start of Cycle 9, Arm B at the start of Cycle 10, and Arm C at 12 weeks after the start of Cycle 6.

## Overall Survival

<div style=\"page-break-after: always\"></div>

Table 16. Overall Survival (FAS, cut-off date 30 Oct 2024)), study ACE-CL-311

|                                                  | Arm A (AV) N = 291   | Arm B (AVG) N = 286                | Arm C (FCR/BR) N = 290             |
|--------------------------------------------------|----------------------|------------------------------------|------------------------------------|
| Event, n (%)                                     |                      |                                    |                                    |
| Death                                            | 23 (7.9)             | 37 (12.9)                          | 44 (15.2)                          |
| Censored observations, n (%)                     |                      |                                    |                                    |
| Any                                              | 268 (92.1)           | 249 (87.1)                         | 246 (84.8)                         |
| Still in survival follow up                      | 264 (90.7)           | 246 (86.0)                         | 217 (74.8)                         |
| Early study discontinuation                      | 4 (1.4)              | 3 (1.0)                            | 29 (10.0)                          |
| Lost to follow-up                                | 0                    | 0                                  | 0                                  |
| Withdrew consent                                 | 4 (1.4)              | 1 (0.3)                            | 26 (9.0)                           |
| Study exit due to investigator decision or other | 0                    | 2 (0.7)                            | 3 (1.0)                            |
| Overall survival (months)                        |                      |                                    |                                    |
| Median (95% CI)                                  | NC (NC, NC)          | NC (NC, NC)                        | NC (NC, NC)                        |
| P25, P75                                         | NC, NC               | NC, NC                             | NC, NC                             |
| Comparison of treatment groups                   |                      |                                    |                                    |
| Hazard ratio (95% CI)                            | 0.42 (0.25, 0.70)    | 0.75 (0.48, 1.16)                  |                                    |
| nominal p-value                                  | 0.0006               | 0.1943                             |                                    |
| Overall survival rate b (%)                      |                      |                                    |                                    |
| 6 months (95% CI)                                | 99.0 (96.8, 99.7)    | 96.9 (94.0, 98.4)96.2 (93.1, 98.0) | 96.9 (94.0, 98.4)96.2 (93.1, 98.0) |
| 12 months (95% CI)                               | 97.2 (94.5, 98.6)    | 93.0 (89.4, 95.4)91.7 (87.6, 94.4) | 93.0 (89.4, 95.4)91.7 (87.6, 94.4) |
| 18 months (95% CI)                               | 95.9 (92.8, 97.6)    | 90.6 (86.5, 93.4)89.4 (85.0, 92.6) | 90.6 (86.5, 93.4)89.4 (85.0, 92.6) |
| 24 months (95% CI)                               | 95.5 (92.4, 97.4)    | 89.2 (84.9, 92.2)88.3 (83.7, 91.6) | 89.2 (84.9, 92.2)88.3 (83.7, 91.6) |
| 30 months (95% CI)                               | 94.5 (91.1, 96.6)    | 88.5 (84.1, 91.6)87.1 (82.4, 90.6) | 88.5 (84.1, 91.6)87.1 (82.4, 90.6) |
| 36 months (95% CI)                               | 94.1 (90.7, 96.3)    | 87.7 (83.4, 91.0)85.9 (81.1, 89.6) | 87.7 (83.4, 91.0)85.9 (81.1, 89.6) |
| 42 months (95% CI)                               | 93.7 (90.3, 96.0)    | 87.7 (83.4, 91.0)85.1 (80.2, 88.9) | 87.7 (83.4, 91.0)85.1 (80.2, 88.9) |
| 48 months (95% CI)                               | 91.9 (87.7, 94.7)    | 87.1 (82.4, 90.5)83.4 (78.1, 87.5) | 87.1 (82.4, 90.5)83.4 (78.1, 87.5) |
| 54 months (95% CI)                               | 91.1 (86.4, 94.2)    | 87.1 (82.4, 90.5)81.5 (75.5, 86.1) | 87.1 (82.4, 90.5)81.5 (75.5, 86.1) |
| 60 months (95% CI)                               | 87.4 (76.9, 93.4)    | 85.6 (80.0, 89.8)81.5 (75.5, 86.1) | 85.6 (80.0, 89.8)81.5 (75.5, 86.1) |

<div style=\"page-break-after: always\"></div>

Figure 10. Kaplan-Meier Plot for Overall Survival (Full Analysis Set), study ACE-CL-311

<!-- image -->

## Sensitivity analysis

Table 17. Overall Survival Sensitivity Analysis (FAS), study ACE-CL-311

|                                              | Group                  | Patients with event n (%)   | Median time to event (months)   | 95% CI   | Comparison of treatment groups   | Comparison of treatment groups   | Comparison of treatment groups   |
|----------------------------------------------|------------------------|-----------------------------|---------------------------------|----------|----------------------------------|----------------------------------|----------------------------------|
|                                              |                        |                             |                                 |          | HR                               | 95% CI                           | p-value                          |
| Censoring COVID-19 deaths                    | Arm A (AV) N = 291     | 8 (2.7)                     | 57.8                            | 57.8, NC | 0.27                             | 0.11, 0.60                       | 0.0013                           |
|                                              | Arm B (AVG) N = 286    | 12 (4.2)                    | NC                              | NC, NC   | 0.47                             | 0.22, 0.95                       | 0.0341                           |
|                                              | Arm C (FCR/BR) N = 290 | 21 (7.2)                    | NC                              | NC, NC   |                                  |                                  |                                  |
| Censoring due to subsequent anti-CLL therapy | Arm A (AV) N = 291     | 17 (5.8)                    | NC                              | NC, NC   | 0.35                             | 0.19, 0.62                       | 0.0002                           |

<div style=\"page-break-after: always\"></div>

A HR below 1 favours Arm A or Arm B over Arm C, respectively.

| Group                  | Patients with event n (%)   | Median time to event   | 95% CI   | Comparison of treatment groups   | Comparison of treatment groups   | Comparison of treatment groups   |
|------------------------|-----------------------------|------------------------|----------|----------------------------------|----------------------------------|----------------------------------|
|                        |                             | (months)               |          | HR                               | 95% CI                           | p-value                          |
| Arm B (AVG) N = 286    | 36 (12.6)                   | NC                     | NC, NC   | 0.81                             | 0.51, 1.27                       | 0.3550                           |
| Arm C (FCR/BR) N = 290 | 38 (13.1)                   | NC                     | 43.3, NC |                                  |                                  |                                  |

## Investigator assessed PFS

Table 18 . Progression-free Survival by Investigator Assessment (FAS), DCO date 30 Oct 2024), study ACE-CL-311

|                                                                       | Arm A (AV) N = 291   | Arm B (AVG) N = 286   | Arm C (FCR/BR) N = 290   |
|-----------------------------------------------------------------------|----------------------|-----------------------|--------------------------|
| Event a                                                               |                      |                       |                          |
| Any                                                                   | 102 (35.1)           | 51 (17.8)             | 103 (35.5)               |
| Progression                                                           | 89 (30.6)            | 18 (6.3)              | 72 (24.8)                |
| Death without progression                                             | 13 (4.5)             | 33 (11.5)             | 31 (10.7)                |
| Censored observations                                                 |                      |                       |                          |
| Any                                                                   | 189 (64.9)           | 235 (82.2)            | 187 (64.5)               |
| Censored at Day 1                                                     | 1 (0.3)              | 2 (0.7)               | 33 (11.4)                |
| No baseline disease assessment                                        | 0                    | 1 (0.3)               | 1 (0.3)                  |
| No post-baseline response assessment                                  | 1 (0.3)              | 1 (0.3)               | 32 (11.0)                |
| Censored due to 2 or more consecutively missed response assessments b | 19 (6.5)             | 28 (9.8)              | 29 (10.0)                |
| Censored due to subsequent anti-CLL therapy                           | 4 (1.4)              | 3 (1.0)               | 2 (0.7)                  |
| Progression-free                                                      | 165 (56.7)           | 202 (70.6)            | 123 (42.4)               |
| Progression-free at time of the analysis                              | 164 (56.4)           | 201 (70.3)            | 119 (41.0)               |
| Early study discontinuation                                           | 1 (0.3)              | 1 (0.3)               | 4 (1.4)                  |
| Lost to follow-up                                                     | 0                    | 0                     | 0                        |
| Withdrew consent                                                      | 1 (0.3)              | 1 (0.3)               | 3 (1.0)                  |
| Study exit due to investigator decision or other                      | 0                    | 0                     | 1 (0.3)                  |

<div style=\"page-break-after: always\"></div>

| Progression-free survival (months)   | Progression-free survival (months)   | Progression-free survival (months)   | Progression-free survival (months)   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Median (95% CI)                      | 58.2 (51.7, NC)                      | NC (62.9, NC)                        | 55.6 (45.4, NC)                      |
| P25, P75                             | 38.6, NC                             | 62.9, NC                             | 29.0, NC                             |
| Comparison of treatment groups       | Comparison of treatment groups       | Comparison of treatment groups       | Comparison of treatment groups       |
| Hazard ratio (95% CI)                | 0.68 (0.52, 0.90)                    | 0.36 (0.25, 0.50)                    |                                      |
| nominal p-value                      | 0.0069                               | < 0.0001                             |                                      |
| Progression-free survival rate (%)   | Progression-free survival rate (%)   | Progression-free survival rate (%)   | Progression-free survival rate (%)   |
| 6 months (95% CI)                    | 97.9 (95.4, 99.1)                    | 96.8 (94.0, 98.3)                    | 94.9 (91.4, 97.0)                    |
| 12 months (95% CI)                   | 96.2 (93.2, 97.9)                    | 92.5 (88.8, 95.1)                    | 87.9 (83.2, 91.4)                    |
| 18 months (95% CI)                   | 93.3 (89.7, 95.7)                    | 89.6 (85.4, 92.7)                    | 83.7 (78.4, 87.8)                    |
| 24 months (95% CI)                   | 91.1 (87.2, 93.9)                    | 88.1 (83.7, 91.4)                    | 79.2 (73.5, 83.8)                    |
| 30 months (95% CI)                   | 87.0 (82.5, 90.5)                    | 87.3 (82.8, 90.7)                    | 74.2 (68.0, 79.3)                    |
| 36 months (95% CI)                   | 78.7 (73.4, 83.2)                    | 84.9 (80.1, 88.7)                    | 66.3 (59.8, 72.1)                    |
| 42 months (95% CI)                   | 71.5 (65.7, 76.5)                    | 84.5 (79.6, 88.3)                    | 61.5 (54.8, 67.5)                    |
| 48 months (95% CI)                   | 64.3 (57.8, 70.1)                    | 82.2 (76.8, 86.5)                    | 54.8 (47.6, 61.5)                    |
| 54 months (95% CI)                   | 55.2 (47.1, 62.5)                    | 77.2 (69.8, 83.0)                    | 50.2 (42.2, 57.7)                    |
| 60 months (95% CI)                   | 43.0 (29.1, 56.1)                    | 77.2 (69.8, 83.0)                    | 47.4 (38.1, 56.1)                    |

a    Includes events that occur within 28 weeks of last evaluable assessment (in the first 3 years after randomisation) or within 56 weeks of last evaluable assessment (3 years and later from randomisation).

b  The threshold for 2 or more consecutively missed response assessments is 28 weeks in the first 3 years after randomisation and 56 weeks thereafter.

## Objective response rate

Table 19. Best Overall Response and Overall Response Rate by Blinded Independent Central Review and Investigator Assessment (FAS), study ACE-CL-311

|                                    | IRC assessment       | IRC assessment        | IRC assessment           | Investigator assessment   | Investigator assessment   | Investigator assessment   |
|------------------------------------|----------------------|-----------------------|--------------------------|---------------------------|---------------------------|---------------------------|
|                                    | Arm A (AV) (N = 291) | Arm B (AVG) (N = 286) | Arm C (FCR/BR) (N = 290) | Arm A (AV) (N = 291)      | Arm B (AVG) (N = 286)     | Arm C (FCR/BR) (N = 290)  |
| Response, n (%)                    | 270 (92.8)           | 265 (92.7)            | 218 (75.2)               | 282 (96.9)                | 275 (96.2)                | 238 (82.1)                |
| Estimated risk difference (95% CI) | 17.6 (11.5, 23.6)    | 17.5 (11.4, 23.5)     | -                        | 14.8 (10.0, 20.0)         | 14.1 (9.0, 19.4)          | -                         |

<div style=\"page-break-after: always\"></div>

|                                                        | IRC assessment       | IRC assessment        | IRC assessment           | Investigator assessment   | Investigator assessment   | Investigator assessment   |
|--------------------------------------------------------|----------------------|-----------------------|--------------------------|---------------------------|---------------------------|---------------------------|
|                                                        | Arm A (AV) (N = 291) | Arm B (AVG) (N = 286) | Arm C (FCR/BR) (N = 290) | Arm A (AV) (N = 291)      | Arm B (AVG) (N = 286)     | Arm C (FCR/BR) (N = 290)  |
| Comparison of treatment groups, p-value                | < 0.0001             | < 0.0001              | -                        | < 0.0001                  | < 0.0001                  | -                         |
| Complete response                                      | 26 (8.9)             | 40 (14.0)             | 15 (5.2)                 | 40 (13.7)                 | 69 (24.1)                 | 24 (8.3)                  |
| Complete response with incomplete bone marrow recovery | 0                    | 5 (1.7)               | 1 (0.3)                  | 3 (1.0)                   | 4 (1.4)                   | 6 (2.1)                   |
| Nodular partial response                               | 1 (0.3)              | 0                     | 1 (0.3)                  | 11 (3.8)                  | 1 (0.3)                   | 2 (0.7)                   |
| Partial response                                       | 243 (83.5)           | 220 (76.9)            | 201 (69.3)               | 228 (78.4)                | 201 (70.3)                | 206 (71.0)                |
| Non-response, n (%)                                    |                      |                       |                          |                           |                           |                           |
| Any                                                    | 21 (7.2)             | 21 (7.3)              | 72 (24.8)                | 9 (3.1)                   | 11 (3.8)                  | 52 (17.9)                 |
| Stable disease                                         | 14 (4.8)             | 11 (3.8)              | 26 (9.0)                 | 7 (2.4)                   | 8 (2.8)                   | 14 (4.8)                  |
| Progression                                            | 3 (1.0)              | 2 (0.7)               | 2 (0.7)                  | 0                         | 0                         | 0                         |
| Not evaluable                                          | 0                    | 0                     | 3 (1.0)                  | 0                         | 0                         | 0                         |
| Not done                                               | 4 (1.4)              | 8 (2.8)               | 41 (14.1)                | 2 (0.7)                   | 3 (1.0)                   | 38 (13.1)                 |

## Duration of Response

Table 20. Duration of Response by Blinded Independent Central Review and Investigator Assessment (FAS), study ACE-CL-311

|                                                       | IRC assessment       | IRC assessment        | IRC assessment           | Investigator assessment   | Investigator assessment   | Investigator assessment   |
|-------------------------------------------------------|----------------------|-----------------------|--------------------------|---------------------------|---------------------------|---------------------------|
|                                                       | Arm A (AV) (N = 291) | Arm B (AVG) (N = 286) | Arm C (FCR/BR) (N = 290) | Arm A (AV) (N = 291)      | Arm B (AVG) (N = 286)     | Arm C (FCR/BR) (N = 290)  |
| Patients with response                                | 270 (92.8)           | 265 (92.7)            | 218 (75.2)               | 282 (96.9)                | 275 (96.2)                | 238 (82.1)                |
| Responders who subsequently progressed or died, n (%) | 76 (28.1)            | 40 (15.1)             | 74 (33.9)                | 73 (25.9)                 | 39 (14.2)                 | 83 (34.9)                 |
| Progression                                           | 68 (25.2)            | 19 (7.2)              | 57 (26.1)                | 65 (23.0)                 | 14 (5.1)                  | 62 (26.1)                 |
| Death without progression                             | 8 (3.0)              | 21 (7.9)              | 17 (7.8)                 | 8 (2.8)                   | 25 (9.1)                  | 21 (8.8)                  |

<div style=\"page-break-after: always\"></div>

|                                  | IRC assessment       | IRC assessment        | IRC assessment           | Investigator assessment   | Investigator assessment   | Investigator assessment   |
|----------------------------------|----------------------|-----------------------|--------------------------|---------------------------|---------------------------|---------------------------|
|                                  | Arm A (AV) (N = 291) | Arm B (AVG) (N = 286) | Arm C (FCR/BR) (N = 290) | Arm A (AV) (N = 291)      | Arm B (AVG) (N = 286)     | Arm C (FCR/BR) (N = 290)  |
| Median DoR (95% CI) (months)     | 50.4 (48.5, NC)      | NC (NC, NC)           | 47.6 (44.0, NC)          | NC (49.7, NC)             | NC (NC, NC)               | 48.6 (41.5, NC)           |
| Percentage remaining in response |                      |                       |                          |                           |                           |                           |
| 12 months                        | 97.0                 | 94.7                  | 91.9                     | 96.4                      | 93.4                      | 90.8                      |
| 24 months                        | 88.0                 | 91.0                  | 81.7                     | 89.6                      | 89.8                      | 80.9                      |
| 36 months                        | 73.6                 | 87.9                  | 68.7                     | 76.0                      | 87.2                      | 67.2                      |
| 48 months                        | 62.2                 | 81.4                  | 47.1                     | 64.0                      | 80.7                      | 51.1                      |

DoR is the time from the first documentation of response until the date of progression or death or the last evaluable assessment for patients that do not progress or do not progress within 28 weeks of last evaluable assessment (in the first 3 years after randomisation), or within 56 weeks of last evaluable assessment (3 years and later from randomisation).

## Ancillary analysis

A backdated data cutoff (DCO) date of 08 November 2023 (the date that the originally planned 153 events IRC-PFS events occurred across Arms A [AV] and C [FCR/BR] total) was applied to the interim analysis data. P-value scale boundaries for Arm A (AV) compared to those of Arm C (FCR/BR) and those of Arm B (AVG) compared to those of Arm C (FCR/BR), respectively, were re-calculated based on the observed events at this DCO date in relation to the 229 final analysis events initially planned.

## Primary endpoint: PFS by IRC assessment Arm A (AV) compared to Arm C (FCR/BR)

Based on the originally planned 153 events, the results for PFS, as assessed by the IRC, demonstrated that AV showed statistically significantly superior efficacy compared with that of FCR/BR in previously untreated patients with CLL (HR: 0.61; 95% CI: 0.44, 0.84; p-value: 0.0025 [p-value scale boundary: 0.012]). Median PFS for Arm A was not calculable (NC); the median PFS for Arm C (FCR/BR) was 46.8 months (95% CI: 42.1, NC).

## Key secondary endpoint: PFS by IRC assessment Arm B (AVG) compared to Arm C (FCR/BR)

At the time of 153 observed events across Arm A and Arm C in total, there were 129 events across Arm B and Arm C. The results of this key secondary endpoint analysis for PFS, demonstrated that AVG showed statistically significantly superior efficacy compared to that of FCR/BR in previously untreated patients with CLL (HR: 0.42; 95% CI: 0.29, 0.60; p-value: &lt; 0.0001 [p-value scale boundary: 0.006]). Median PFS for Arm B was 51.7 months (95% CI: 51.7, NC); the median PFS for Arm C was 46.8 months (95% CI: 42.1, NC).

## Supportive studies

In the three-arm, Phase 3 study ELEVATE-TN (originally submitted with the initial Marketing Authorisation Application for Calquence) previously untreated CLL patients were randomised to i) acalabrutinib plus obinutuzumab (AG), ii) acalabrutinib monotherapy (A), or iii) obinutuzumab plus chlorambucil (control arm, CIT). Patients with del17p/TP53 mutation comprised more than 10% of the trial population and the results for both A monotherapy and AG demonstrate improved clinical benefit for this subgroup of patients in terms of PFS.

<div style=\"page-break-after: always\"></div>

In the open-label phase 3 trial CLL14 investigating venetoclax + obinutuzumab (VG) versus obinutuzumab + chlorambucil (control arm, CIT) in patients with previously untreated CLL, 14% of the patients had a del17p or/and TP53 mutation. Efficacy in terms of investigator assessed PFS was established in the primary analysis and subgroup analyses demonstrated less, but still beneficial, efficacy of VG therapy in patients with TP53 mutation or del17).

The AVG regimen is being studied in the SAT NCT03580928 enriched for patients with TP53 aberrancy. In this ongoing SAT, 10 out of 27 randomised patients (27%) had del17p and concomitant TP53 mutation.

Results from these studies are summarised in Table 22 .

Table 21. Clinical trials with acalabrutinib and TP53 aberrations

|                                                                 | ELEVATE-TN                                                              | ELEVATE-TN                                             | ELEVATE-TN                                               |
|-----------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|
|                                                                 | Acalabrutinib + obinutuzumab                                            | Acalabrutinib monotherapy                              | Obinutuzumab + chlorambucil                              |
| Number of patients Total TP53 aberration                        | 179 25                                                                  | 179 23                                                 | 177 25                                                   |
| IRC PFS HR (95% CI) All patients Del17p or/and TP53 mut: Yes No | 0.10 (0.06, 0.17) 0.10 (0.03, 0.34) 0.10 (0.05, 0.18)                   | 0.20 (0.13, 0.30) 0.23 (0.09, 0.61) 0.19 (0.11, 0.31)  | - - -                                                    |
| IRC-ORR %(95% CI) All patients Del17p or/and TP53 mut: Yes No   | 93.9% (89.3, 96.5) 84.0 (65.3, 93.6) 95.5 (90.9, 97.8)                  | 85.5% (79.6, 89.9) 82.6 (62.9, 93.0) 85.9 (79.6, 90.5) | 78.5% (71.9, 83.9) 56.0% (37.1, 73.3) 82.1% (75.2, 87.4) |
|                                                                 | CLL-14                                                                  | CLL-14                                                 | CLL-14                                                   |
|                                                                 | Venetoclax + obinutuzumab                                               | Obinutuzumab + chlorambucil                            |                                                          |
| Number of patients Total del17p TP53 mut TP53 unmutated         | 216 17 19 152                                                           | 216 14 13 144                                          |                                                          |
| INV-PFS HR (95% CI) All patients Del17p TP53 mut Tp53 unmutated | 0.32 (0.21, 0.49) 0.35 (0.13, 0.94) 0.31 (0.11, 0.88) 0.22 (0.12, 0.40) | - - - -                                                |                                                          |
| INV-ORR %(95% CI) All patients Del17p TP53 mut Tp53 unmutated   | 84.7% (79.2, 89.2) 82.4% 84.2% 86.8%                                    | 71.3% (64.8, 77.2) 35.7% 53.8% 71.5%                   |                                                          |
|                                                                 | NCT03580928 (SAT)                                                       | NCT03580928 (SAT)                                      | NCT03580928 (SAT)                                        |
|                                                                 | Acalabrutinib + venetoclax + obinutuzumab                               |                                                        |                                                          |
| Number of patients TP53 aberration                              | 37 10                                                                   |                                                        |                                                          |
| ORR at cycle 25 (%) All patients                                | 97%                                                                     |                                                        |                                                          |
| TP53 aberration                                                 | 100%                                                                    |                                                        |                                                          |

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 22. Summary of Efficacy for trial study ACE-CL-311 (AMPLIFY)

| Title: AMPLIFY            | Title: AMPLIFY                                                                                                                                                                                                                                                                                                           | Title: AMPLIFY                                                                                                                                                                                                                                                                                                           | Title: AMPLIFY                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | Study Code: ACE-CL-311 (D8221C00001) EudraCT/EU CT Number: 2018-002443-28 NCT Number: 2023-505867-35                                                                                                                                                                                                                     | Study Code: ACE-CL-311 (D8221C00001) EudraCT/EU CT Number: 2018-002443-28 NCT Number: 2023-505867-35                                                                                                                                                                                                                     | Study Code: ACE-CL-311 (D8221C00001) EudraCT/EU CT Number: 2018-002443-28 NCT Number: 2023-505867-35                                                                                                                                                                                                                                                                                                                                                                         |
| Design                    | AMPLIFY is a randomized, multicenter, open-label, Phase III study to compare the efficacy and safety of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemo-immunotherapy in patients with previously untreated CLL without del(17p) or TP53 mutation. | AMPLIFY is a randomized, multicenter, open-label, Phase III study to compare the efficacy and safety of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemo-immunotherapy in patients with previously untreated CLL without del(17p) or TP53 mutation. | AMPLIFY is a randomized, multicenter, open-label, Phase III study to compare the efficacy and safety of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemo-immunotherapy in patients with previously untreated CLL without del(17p) or TP53 mutation.                                                                                                                                                     |
|                           | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                        | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                        | <time> <time> <not applicable> <time> <not applicable>                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hypothesis                | Duration of Extension phase: Superiority                                                                                                                                                                                                                                                                                 | Duration of Extension phase: Superiority                                                                                                                                                                                                                                                                                 | Duration of Extension phase: Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Treatments groups         | Arm A (acalabrutinib+venetoclax; AV)                                                                                                                                                                                                                                                                                     | Arm A (acalabrutinib+venetoclax; AV)                                                                                                                                                                                                                                                                                     | Acalabrutinib 100 mg capsules were orally administered from Cycle 1 at a fixed twice daily (BID) dose for 14 cycles; venetoclax oral dosing was to begin at Cycle 3 and continued following a 5-week ramp-up at a fixed daily dose of 400 mg until the end of Cycle 14, or until start of new anti-CLL therapy or progression of CLL, or unacceptable toxicity, whichever occurred first. Acalabrutinib (100 mg capsules) were                                               |
|                           | Arm B (acalabrutinib+venetoclax+ obinutuzumab; AVG)                                                                                                                                                                                                                                                                      | Arm B (acalabrutinib+venetoclax+ obinutuzumab; AVG)                                                                                                                                                                                                                                                                      | orally administered from Cycle 1 at a fixed BID dose for 14 cycles; obinutuzumab administered as IV infusion at an absolute (flat) dose of 1000 mg and was to begin at Cycle 2 and continued through Cycle 7; venetoclax dosing was to begin at Cycle 3 and continue following a 5-week ramp-up at a fixed daily dose of 400 mg until the end of Cycle 14, or until start of new anti-CLL therapy or progression of CLL, or unacceptable toxicity, whichever occurred first. |
|                           | Arm C (chemoimmunotherapy; Investigator's choice of fludarabine+cyclophosphamid e+rituximab or bendamustine+rituximab; FCR/BR)                                                                                                                                                                                           | Arm C (chemoimmunotherapy; Investigator's choice of fludarabine+cyclophosphamid e+rituximab or bendamustine+rituximab; FCR/BR)                                                                                                                                                                                           | All patients who were randomized to standard chemoimmunotherapy were to receive up to 6 cycles of either FCR or BR as IV infusions, according to standard institutional practice. Patients ≤ 65 years of age with a creatinine clearance of ≥ 70 mL/min were restricted to FCR.                                                                                                                                                                                              |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                                                                         | PFS                                                                                                                                                                                                                                                                                                                      | Determined by IRC assessment for the primary efficacy objective (Arm A vs Arm C); by investigator assessment for the secondary efficacy objective (Arm A vs Arm C)                                                                                                                                                                                                                                                                                                           |
|                           | Secondary endpoint                                                                                                                                                                                                                                                                                                       | PFS                                                                                                                                                                                                                                                                                                                      | By both IRC and investigator assessment for the secondary efficacy objective (Arm B vs arm C).                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                                                                                                               | MRD negativity rate                                                                                                                                              | Determined as the proportion of patients with MRD negativity, measured in the peripheral blood by flow cytometry (10-4) at the start of Cycle 9 (in Arm A), the start of Cycle 10 (in Arm B), and 12 weeks after the start of Cycle 6 (in Arm C)   | Determined as the proportion of patients with MRD negativity, measured in the peripheral blood by flow cytometry (10-4) at the start of Cycle 9 (in Arm A), the start of Cycle 10 (in Arm B), and 12 weeks after the start of Cycle 6 (in Arm C)   | Determined as the proportion of patients with MRD negativity, measured in the peripheral blood by flow cytometry (10-4) at the start of Cycle 9 (in Arm A), the start of Cycle 10 (in Arm B), and 12 weeks after the start of Cycle 6 (in Arm C)   |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                                                                                                                               | OS                                                                                                                                                               | Time from randomization to death from any cause.                                                                                                                                                                                                   | Time from randomization to death from any cause.                                                                                                                                                                                                   | Time from randomization to death from any cause.                                                                                                                                                                                                   |
| Database lock                                   | 30 April 2024                                                                                                                                                    | 30 April 2024                                                                                                                                                    | 30 April 2024                                                                                                                                                                                                                                      | 30 April 2024                                                                                                                                                                                                                                      | 30 April 2024                                                                                                                                                                                                                                      |
| Results and Analysis                            | Results and Analysis                                                                                                                                             | Results and Analysis                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                               |
| Analysis description                            | Primary Analysis                                                                                                                                                 | Primary Analysis                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                   |
| Analysis population and time point description  | Full Analysis Set (FAS)                                                                                                                                          | Full Analysis Set (FAS)                                                                                                                                          | Full Analysis Set (FAS)                                                                                                                                                                                                                            | Full Analysis Set (FAS)                                                                                                                                                                                                                            | Full Analysis Set (FAS)                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability |                                                                                                                                                                  |                                                                                                                                                                  |                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                    |
|                                                 | Treatment group Arm A (AV)                                                                                                                                       | Treatment group Arm A (AV)                                                                                                                                       | Treatment group Arm A (AV)                                                                                                                                                                                                                         | Arm B (AVG)                                                                                                                                                                                                                                        | Arm C (FCR/BR)                                                                                                                                                                                                                                     |
|                                                 | Number of subject 291                                                                                                                                            | Number of subject 291                                                                                                                                            | Number of subject 291                                                                                                                                                                                                                              | 286                                                                                                                                                                                                                                                | 290                                                                                                                                                                                                                                                |
|                                                 | (%) Median PFS NC (51.1, NC)                                                                                                                                     | (%) Median PFS NC (51.1, NC)                                                                                                                                     | (%) Median PFS NC (51.1, NC)                                                                                                                                                                                                                       | NC (NC, NC)                                                                                                                                                                                                                                        | 47.6 (43.3, NC)                                                                                                                                                                                                                                    |
|                                                 | (months) HR (95% CI), p- value 0.65 (0.49,                                                                                                                       | 0.87),                                                                                                                                                           | (months) HR (95% CI), p- value 0.65 (0.49,                                                                                                                                                                                                         | 0.42 (0.30, 0.59), < 0.0001                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                  |
|                                                 | MRD Negativity Rate uMRD, n (%) 78 (26.8)                                                                                                                        | MRD Negativity Rate uMRD, n (%) 78 (26.8)                                                                                                                        | MRD Negativity Rate uMRD, n (%) 78 (26.8)                                                                                                                                                                                                          | 190 (66.4)                                                                                                                                                                                                                                         | 148 (51.0)                                                                                                                                                                                                                                         |
|                                                 | Patient with                                                                                                                                                     | MRD 244 (83.8)                                                                                                                                                   |                                                                                                                                                                                                                                                    | 202 (70.6)                                                                                                                                                                                                                                         | 190 (65.5)                                                                                                                                                                                                                                         |
|                                                 | measurement Risk ratio (95% CI), p-value 0.5 (0.4, 0.7), <0.0001                                                                                                 | measurement Risk ratio (95% CI), p-value 0.5 (0.4, 0.7), <0.0001                                                                                                 | measurement Risk ratio (95% CI), p-value 0.5 (0.4, 0.7), <0.0001                                                                                                                                                                                   | 1.3 (1.1, 1.5), 0.0003                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                  |
|                                                 | OS Death events, n (%) 23 (7.9)                                                                                                                                  | OS Death events, n (%) 23 (7.9)                                                                                                                                  | OS Death events, n (%) 23 (7.9)                                                                                                                                                                                                                    | 37 (12.9)                                                                                                                                                                                                                                          | 44 (15.2)                                                                                                                                                                                                                                          |
|                                                 | Median OS (months) (95% NC (NC, NC)                                                                                                                              | Median OS (months) (95% NC (NC, NC)                                                                                                                              | Median OS (months) (95% NC (NC, NC)                                                                                                                                                                                                                | NC (NC, NC)                                                                                                                                                                                                                                        | NC (NC, NC)                                                                                                                                                                                                                                        |
|                                                 | CI) HR (95% CI), p- value 0.42 (0.25, 0.70)                                                                                                                      | CI) HR (95% CI), p- value 0.42 (0.25, 0.70)                                                                                                                      | CI) HR (95% CI), p- value 0.42 (0.25, 0.70)                                                                                                                                                                                                        | 0.75 (0.48, 1.16)                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                  |
| Notes                                           | OS maturity rate 10% (Arm A vs Arm C) and 14% (Arm B vs Arm C) at DCO for the interim analysis. The study is not powered to detect statistically significant OS. | OS maturity rate 10% (Arm A vs Arm C) and 14% (Arm B vs Arm C) at DCO for the interim analysis. The study is not powered to detect statistically significant OS. | OS maturity rate 10% (Arm A vs Arm C) and 14% (Arm B vs Arm C) at DCO for the interim analysis. The study is not powered to detect statistically significant OS.                                                                                   | OS maturity rate 10% (Arm A vs Arm C) and 14% (Arm B vs Arm C) at DCO for the interim analysis. The study is not powered to detect statistically significant OS.                                                                                   | OS maturity rate 10% (Arm A vs Arm C) and 14% (Arm B vs Arm C) at DCO for the interim analysis. The study is not powered to detect statistically significant OS.                                                                                   |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

AMPLIFY is a randomised, open-label, Phase III study designed to evaluate whether fixed duration of acalabrutinib in combination with venetoclax with or without obinutuzumab as a first-line treatment setting could improve long-term treatment outcomes in patients with previously untreated CLL without del(17p) or TP53 mutation.

<div style=\"page-break-after: always\"></div>

A total of 867 patients were randomised in the global cohort in 1:1:1 ratio into 3 Arms (Arm A, Arm B, and Arm C). In the experimental arms A and B, participants received acalabrutinib (A) 100 mg BID for 14 cycles with the addition of venetoclax (V) from cycle 3 through cycle 7. In addition, patients in Arm B received IV obinutuzumab (G, cycle 2-7).

The primary endpoint was PFS assessed by IRC (Arm A vs Arm C) and key secondary endpoint was PFS assessed by IRC (Arm B vs Arm C). Other secondary endpoints included MRD negativity rate, OS, and ORR (all tested in Arm A vs Arm C and Arm B vs Arm C, respectively).

Overall, the sample size calculation, randomisation procedure, application of analysis population sets in analyses, multiplicity control as well as the handling of stratification factors (used during randomisation) in the analyses were pre-specified and done in accordance with pre-specification.

Seven protocol amendments were done during the study and amendments 1, 5 and 6 were considered substantial. According to Amendment 6.0, the HR in the sample size calculation for the primary endpoint was changed from 0.65 to 0.62. This change in assumed HR was based on the results from the interim analysis of the GAIA-CLL13 trial. Additionally, the information fraction at interim analysis was updated from 67% to 75% to ensure sufficient data maturity. As a result of these changes, the required number of PFS events changed from 153 (67% information fraction) to 141 (75% information fraction) for the PFS interim analysis and from 229 to 188 for the final analysis. The analysis submitted in this application (data cut-off 30 April 2024) included 184 PFS events, (98% of the information fraction of the 188 PFS events required for the final analysis).

The rationale behind the changes in the assumed HR is understood, however it is not clear why the analysis was performed at 184 PFS events instead of the 188 that was concluded in the updated calculations. Nevertheless, this issue is not considered to impact the overall conclusions of the study, as the MAH provided results for the PFS analyses based on the originally planned interim at 153 PFS events which were consistent with the results submitted as the primary analysis of the study.

The MAH has also confirmed that the IRC stopped assessing disease progression following the positive interim analyses. The reason for discontinuing IRC assessments on disease progression was that the interim analysis met its primary objective (IRC-assessed PFS of AV versus PFS of FCR/BR) thereby serving as the final analysis of the study. Patients are still being followed for investigator-assessed (INV) PFS events.

At the data cut-off for the PFS interim analysis, 30 April 2024, none of the patients randomised into the global cohort were on study treatment. The majority of patients (83.6%) were in follow-up phase: 269 patients (92.4%) in Arm A, 245 patients (85.7%) in Arm B and 211 patients (72.8%) in Arm C.

## Efficacy data and additional analyses

Among 867 patients randomised in the global cohort, the FAS included 291 patients in Arm A, 286 patients in the Arm B, and 290 patients in the Arm C.  Median age was 61 years in all trial arms and two-thirds of participants were men. Median time from diagnosis to randomisation was similar between arms: 28.5 months in Arm A, 26.1 months in Arm B and 29.6 months in Arm C. Baseline characteristics are balanced between the three study arms.

Statistically significant IRC-assessed PFS was shown for Arm A as compared with Arm C, with HR 0.65 (95% CI [0.49, 0.87]). Median PFS was 47.6 months in Arm C and, at the DCO, not yet reached in Arm A. A PFS event was registered for 30.6% of patients in Arm A and 32.8% in Arm C.

<div style=\"page-break-after: always\"></div>

It is noted that the proportion of deaths in the PFS analysis is higher in Arm C (10.0%) compared with Arm A (4.1%), whereas disease progression was a more frequently observed event among patients in Arm A (26.5% vs 22.8% among patients in Arm C).

In sensitivity analyses, inclusion of events after subsequent anticancer therapy and inclusion of events after &gt;2 consecutively missed visits (according to EMA censoring rules) resulted in HR of 0.66 and 0.67 respectively and was consistent with the primary analysis result. The sensitivity analyses performed are, overall, deemed adequate to evaluate the robustness of the primary analysis of PFS and are considered acceptable. The sensitivity analysis censoring for Covid-19 related deaths is of limited value since these are informative censorings.

For the primary endpoint, relevant subgroup results are mainly consistent.

Post-hoc tipping point analyses of PFS was performed to evaluate the impact of imbalanced early censoring between arms on the PFS results, imputing the time for PFS for the 75 patients in Arm C (FCR/BR) who were censored informatively and assuming that they were at a reduced risk of progression or death compared to all other patients in the arm. In addition, the MAH provided baseline characteristics enabling comparison of patients with informative censoring and the other patients in each treatment arm. Overall, the baseline data indicate a trend toward more advanced disease and worse prognosis among informatively censored patients of the control arm, compared to those in the same arm that were not informatively censored.

For the primary endpoint, PFS in Arm A vs Arm C, the tipping point analysis demonstrates that if the 75 patients in Arm C were assumed to have at least 40% lower risk of progression or death compared to those still in follow-up or with an event in Arm C, the 95% CI of the estimated HR would include 1.

Given the comparison of baseline characteristics depending on censoring status, the tipping point analyses, and the PFS results from comparison of Arm A and Arm C are deemed robust.

Statistically significant IRC-assessed PFS was shown for Arm B (AVG) as compared with Arm C (FCR/BR), with HR 0.42 (95% CI [0.30, 0.59]. Median PFS was 47.6 months in Arm C and, at the DCO, not yet reached in Arm B. A PFS event was registered for 19.6% of patients in Arm B and 32.8% in Arm C.

Progression was more prevalent in Arm C than in Arm B (22.8% and 8.0%, respectively). It is, however, noted that the proportion of deaths is higher in Arm B (11.5%) as compared with Arm C (10.0%).

In subgroup analyses based on the upfront choice of treatment in Arm C (FCR or BR), PFS analyses of Arm A and Arm B against the FCR subgroup resulted in HRs of 0.69 (95% CI [0.47, 1.03], p=0.0581) and 0.47 (95% CI [0.31, 0.73], p=0.0004), respectively. PFS analyses of Arm A and Arm B against the BR subgroup resulted in HRs of 0.63 (95% CI [0.45, 0.88], p=0.0062) and 0.39 (95% CI [0.27, 0.57], p&lt;0.0001), respectively. The FCR regimen is used in younger, more fit patients with less comorbidities and, as expected, a higher number of PFS events were observed in the BR subgroup of Arm C.

The MAH has provided updated INV-PFS analyses with DCO date 30 October 2024. In the Arm A vs Arm C analysis, 102 (35.1%) INV-PFS events were reported in Arm A, and 103 (35.5%) INV-PFS events were reported in Arm C (HR: 0.68; 95% CI; 0.52, 0.90). The median PFS was 58.2 months and 55.6 months for patients in Arm A and Arm C, respectively. In the Arm B versus Arm C analysis, 51 (17.8%) INV-PFS events were reported in Arm B and 103 (35.5%) INV-PFS events were reported in Arm C (HR: 0.36; 95% CI: 0.25, 0.50). Both AV and AVG continues to show improvement in PFS over FCR/BR.

<div style=\"page-break-after: always\"></div>

A total of 78 patients (26.8%) in Arm A (AV), 190 patients (66.4%) in Arm B and 148 patients (51.0%) in Arm C (FCR/BR) achieved MRD negativity at Cycle 9 and at 12 weeks post Cycle 6, respectively. In comparison between Arm A and Arm C, the risk ratio was 0.5 (95% CI: 0.4, 0.7; pvalue &lt; 0.0001). This translates to an inverse association, with decreased chance of MRD negativity among participants treated with AV (Arm A) as compared with participants in the control arm. Between Arm B and Arm C, the risk ratio was 1.3 (95% CI: 1.1, 1.5; nominal p-value = 0.0003), favouring treatment with AVG. Thus, the addition of obinutuzumab to the AV combination appeared to increase the likelihood of MRD negativity.

Of note, MRD measurement was missing for &gt;30% of patients in both Arm B and Arm C lot and this large proportion of missing data may influence the results.  Patients randomised to Arm C had a higher rate of withdrawal or were lost to follow-up (12.41%) compared to those in Arm A (0.69%) and Arm B (1.40%). Also, there were more patients with death before reaching the MRD timepoint in Arm B and Arm C compared to those in Arm A. The most common reason for missing data was however missing sample collection for various reasons.

It is, however, noted that MRD sampling is performed at different time points in Arm A (cycle 9), Arm B (cycle 10) and that the MRD sample at PTFU1 in the control arm (i.e. 12 weeks after cycle 6, corresponding to cycle 9) is used as reference in both analyses. As expected, a progressive increase in MRD negativity is seen over time (i.e. between each sampling). It is therefore possible that the later sampling in Arm B has an impact on the result of the MRD analysis.

At time of the interim analysis, 18 (6.2%) patients had died in Arm A, 37 (12.9%) had died in Arm B (AVG), and 42 (14.5%) ha died in Arm C (FCR/BR). Median OS was 57.8 months in Arm A but not met in either Arm B or Arm C. Upon request, the MAH provided updated OS analyses with DCO of 30 October 2024. With 7 additional deaths since the previous DCO of 30 April 2024 (5 in Arm A, 0 in Arm B and 2 in Arm C), data maturity was 12% in the Arm A versus Arm C analysis, and 14% in the Arm B vs Arm C analysis. In the analysis of Arm A versus Arm C, the OS HR was 0.42 (95% CI: 0.25, 0.70). The OS HR for Arm B versus Arm C was 0.75 (95% CI: 0.48, 1.16). It is agreed that the treatment benefit with both AV and AVG remains stable and consistent with the primary OS analysis.

In the updated OS data, the median OS in Arm A was updated from the 57.8 months (95% CI [57.8, NC]) stated in the original analysis with DCO of 30 Apr 2024, to NC (NC, NC).

Of note, in the control arm, 11.0% of patients were censored due to withdrawal of consent. In Arm A and B, 1.4% and 0.3% of patients were censored due to consent withdrawal. This may impact the OS analysis.

Nonetheless, OS data demonstrate a trend towards improvement in OS for patients treated with AV and AVG as compared with FCR/BR. It is, however, emphasized that OS data are very immature and thus the CHMP recommend that the final OS results should be submitted when available.

Numerically higher ORR per IRC assessment were observed for both Arm A (92.8%) and Arm B (92.7%) as compared with Arm C (75.2%). An assessment of ORR by investigator assessment was consistent with the IRC assessment for both Arm A and Arm B vs Arm C.

Scarce evidence was provided by the MAH to support the contribution of both acalabrutinib and venetoclax to the observed treatment effect, based on cross study comparisons between the AMPLIFY and ELEVATE-TN studies. It is noted that the ORR was higher with AV compared with acalabrutinib monotherapy (96.9% [282/291] vs 91.7% [143/156]), when excluding del(17p) and TP53 mutated patients.

However, acalabrutinib and venetoclax target B-cells by two different and complementary mechanisms, which renders additive effects likely. The concept of combining a BTKi and venetoclax has

<div style=\"page-break-after: always\"></div>

previously been accepted by the CHMP in the approval of combination use with ibrutinib. Moreover, time-limited use of a BTKi and venetoclax is presently a recommended treatment alternative for all patients in need of a first line therapy regardless of del(17p)/TP53 mutation status (ESMO Guidelines, Eichhorst et al 2024). Thus, the rationale for the combination was accepted by the CHMP.

With this submission, the MAH seeks approval of the following indication: ' Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). '

Due to the choice of chemoimmunotherapy (BR/FCR) as control arm, patients with a detected del17p or TP53 mutation were excluded from study enrolment as BTK inhibitors and venetoclax-based therapy are considered SoC over chemoimmunotherapy combination for these high-risk patients.  Thus, to support the proposed indication (i.e. all-comer, previously untreated CLL), the MAH provided data from 3 additional studies to extrapolate efficacy to patients with del(17p) and/or TP53.

In the Phase 3 study ELEVATE-TN, among patients receiving the AG combination, ORR was higher in the del17p/TP53 mutation-negative subgroup (95%) than in the patients with TP53 aberration (84%), while similar for the subgroups with A monotherapy. Among patients without TP53 aberration, the ORR of the control regimen is roughly similar to A monotherapy but considerably lower than both experimental arms in del17p/TP53 positive disease (56%).

In the open-label phase 3 trial CLL14, for the VG regimen, investigator-assessed ORR was close to 85% irrespective of TP53 or del17p status.

Preliminary data from the ongoing SAT NCT03580928 have showed that at cycle 25 all patients with TP53 aberrations had achieved CR or PR.

Results from these studies are considered sufficient of bridging the obtained efficacy results in the pivotal AMPLIFY study to patients with TP53 aberrations.

## 2.4.4. Conclusions on the clinical efficacy

Efficacy has been established in the form of a clinically meaningful prolongation of PFS with both AV and AVG treatment. OS data are very immature but trending towards improvement in OS for patients treated with the experimental treatments.

## 2.5. Clinical safety

## Introduction

Acalabrutinib is a second generation BTKi. Common AEs associated with BTKi treatment include GI disturbances (diarrhoea, nausea, and vomiting), cytopenias, bleeding events, and infections. Other toxicities that have been associated with BTKi include atrial fibrillation and hypertension.

## Patient exposure

The Pivotal Safety Dataset supporting the proposed indication is based on the PFS interim analysis data (DCO 30 April 2024) from the AMPLIFY study. A total of 867 patients were enrolled from 25 February 2019 up to the 31 March 2021, including 291 patients in AV arm, 286 patients in AVG arm, and 290 patients in the FCR/BR arm. Of these, 834 patients (291, 284, and 259 patients, respectively)

<div style=\"page-break-after: always\"></div>

received at least one dose of any study treatment and are included in this safety summary referred as the Safety Population ( Table 24 -Table 26 ).

Table 23. Exposure, Arm A, acalabrutinib and venetoclax (AV), Safety population, study ACE-CL-311

|                             | Arm A(AV) (N=291)   | Arm A(AV) (N=291)   |
|-----------------------------|---------------------|---------------------|
|                             | Acalabrutinib       | Venetoclax          |
| Durationof exposure(month)  |                     |                     |
| Mean (SD)                   | 12.7 (2.2)          | 10.9 (1.6)          |
| Median                      | 12.9                | 11.1                |
| Min, Max                    | 1, 18               | 2,14                |
| Actual cumulative dose (g)  |                     |                     |
| Mcan (SD)                   | 73.70 (13.32)       | 115.194 (25.174)    |
| Median                      | 78.00               | 125.330             |
| Min, Max                    | 5.8,93.6            | 1.98, 138.99        |
| Average daily dose (mg/day) |                     |                     |
| Mean (SD)                   | 191.249 (16.037)    | 344.071 (60.212)    |
| Median                      | 196.835             | 346.994             |
| Min, Max                    | 77.71,200.00        | 20.00, 376.54       |
| Rclative dose intensity (%) |                     |                     |
| Mean (SD)                   | 94.008 (16.993)     | 91.577 (20.013)     |
| Median                      | 99.490              | 99.635              |
| Min, Max                    | 7.40, 119.39        | 1.57,110.49         |

Table 24. Exposure Arm B, acalabrutinib, venetoclax and obinutuzumab (AVG), Safety population, study ACE-CL-311

Table 25. Exposure, Arm C, FCR and BR, Safety population, study ACE-CL-311

|                             | ArmB(AVG)(N=284)   | ArmB(AVG)(N=284)   | ArmB(AVG)(N=284)   |
|-----------------------------|--------------------|--------------------|--------------------|
|                             | Acalabrutinib      | Venetoclax         | Obinutuzumab       |
| Durationofexposure(month)   |                    |                    |                    |
| Mean (SD)                   | 12.2 (3.0)         | 10.5 (2.5)         | 5.4 (1.1)          |
| Median                      | 12.9               | 11.0               | 5.5                |
| Min, Max                    | 0,18               | 0,15               | 1, 8               |
| Actual cumulative dose (g)  |                    |                    |                    |
| Mean (SD)                   | 68.78 (17.68)      | 106.117 (32.853)   | 7.538 (1.348)      |
| Median                      | 76.90              | 123.910            | 8.000              |
| Min, Max                    | 2.2,85.4           | 0.12,129.74        | 0.04, 8.90         |
| Average daily dose (mg/day) |                    |                    |                    |
| Mean (SD)                   | 186.123 (20.725)   | 327.487 (75.406)   |                    |
| Median                      | 195.385            | 320.538            |                    |
| Min, Max                    | 93.80,200.00       | 19.70, 375.51      |                    |
| Relative dose intensity (%) |                    |                    |                    |
| Mean (SD)                   | 87.734 (22.555)    | 84.360 (26.117)    | 94.221 (16.852)    |
| Median                      | 98.090             | 98.505             | 100.000            |
| Min, Max                    | 2.81, 108.93       | 0.10, 103.14       | 111.25             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                             | Arm C(FCR/BR)   | Arm C(FCR/BR)     | Arm C(FCR/BR)   | Arm C(FCR/BR)   | Arm C(FCR/BR)   |
|-----------------------------|-----------------|-------------------|-----------------|-----------------|-----------------|
|                             | FCR (N = 122)   | FCR (N = 122)     | FCR (N = 122)   | BR (N = 137)    | BR (N = 137)    |
|                             | Fludarabine     | Cyclophosph amide | Rituximab       | Bendamustine    | Rituximab       |
| Durationofexposure(month)   |                 |                   |                 |                 |                 |
| Mean (SD)                   | 5.2 (1.4)       | 5.2 (1.4)         | 5.2 (1.4)       | 5.4 (1.4)       | 5.4 (1.3)       |
| Median                      | 5.6             | 5.6               | 5.5             | 5.6             | 5.6             |
| Min, Max                    | 1,8             | 1,8               | 1,8             | 1,11            | 1, 11           |
| Actual cumulative dose (g)  |                 |                   |                 |                 |                 |
| Mean (SD)                   | 0.778 (0.250)   | 7.568 (2.269)     | 4.954 (1.531)   | 1.775 (0.503)   | 4.983 (1.342)   |
| Median                      | 0.830           | 8.277             | 5.357           | 1.869           | 5.246           |
| Min, Max                    | 0.13, 1.51      | 1.27, 11.30       | 7.22,0.63       | 0.28, 2.64      | 7.48, 0.58      |
| Relative dose intensity (%) |                 |                   |                 |                 |                 |
| Mean (SD)                   | 87.930 (25.883) | 85.611 (23.481)   | 87.639 (24.532) | 86.198 (22.063) | 91.109 (22.415) |
| Median                      | 97.550          | 96.380            | 98.235          | 95.510          | 98.640          |
| Min, Max                    | 16.02, 150.69   | 16.37,103.59      | 12.81, 121.11   | 16.19, 106.20   | 12.73, 126.80   |

Supportive safety data for the acalabrutinib safety and tolerability profile is provided from a more representative pooled data set including patients treated with acalabrutinib for various indications in hematologic malignancies ( Table 27 ).

Table 26. Safety Pools for AMPLIFY Interim Analysis Submission

|                           |         |                  |                 | Acalabrutinib monotherapy   | Combination therapy   | Combination therapy   |
|---------------------------|---------|------------------|-----------------|-----------------------------|-----------------------|-----------------------|
| Study/Protocol number     | Phase   | Indication(s)    | Treatments      | N                           | N                     | Treatm ent            |
| ACE-CL-311 (AMPLIFY)      | 3       | TN CLL           | AV, AVG, FCR/BR | NA                          | 291 284               | AV AVG                |
| ACE-CL-007 a (ELEVATE TN) | 3       | TN CLL           | GC, AG, A       | 258 [79 d ]                 | 178                   | AG                    |
| ACE-CL-309 a (ASCEND)     | 3       | R/R CLL          | A, IR, BR       | 234 [80 d ]                 | NA                    | NA                    |
| ACE-LY-004                | 2       | R/R MCL          | A               | 124                         | NA                    | NA                    |
| ACE-CL-001                | 1 and 2 | CLL/SLL. RS. PLL | A               | 301                         | NA                    | NA                    |
| ACE-CL-003                | 1b      | CLL/SLL. RS. PLL | AG, ARV, AR     | NA                          | 45                    | AG                    |
| ACE-WM-001                | 2       | WM               | A               | 106                         | NA                    | NA                    |
| 15-H-0016                 | 2       | CLL/SLL          | A               | 48                          | NA                    | NA                    |
| ACE-LY-002                | 1b      | R/R DLBCL        | A               | 21                          | NA                    | NA                    |
| ACE-LY-003 b              | 1b/2    | FL/ MZL          | A, AR           | 14/ 43                      | NA                    | NA                    |
| ACE-MY-001 b              | 1b      | R/R MM           | A, AD           | 13                          | NA                    | NA                    |
| ACE-CL-006 (ELEVATE RR)   | 3       | R/R CLL          | A               | 265                         | NA                    | NA                    |

<div style=\"page-break-after: always\"></div>

|                       |       |               |            | Acalabrutinib monotherapy   | Combination therapy   | Combination therapy   |
|-----------------------|-------|---------------|------------|-----------------------------|-----------------------|-----------------------|
| Study/Protocol number | Phase | Indication(s) | Treatments | N                           | N                     | Treatm ent            |
| ACE-LY-308 c (ECHO)   | 3     | TN MCL        | ABR, PBR   | 51 [51 d ]                  | 297                   | ABR                   |
| Total No. patients    |       |               |            | 1478                        | 1095                  |                       |

e Study has data from acalabrutinib monotherapy arms and from who underwent crossover from control arms to acalabrutinib monotherapy arm.

f Study has both acalabrutinib monotherapy and combination therapy arms. Only monotherapy patients were included in the integrated analysis of pooled data.

g Study has combination therapy arms. Only crossover patients who received acalabrutinib monotherapy were included in the integrated analysis of pooled data.

h Subset of patients who crossed over to acalabrutinib monotherapy.

Abbreviations: TN: treatment naïve; CLL: chronic lymphocytic leukaemia; R/R: relapsed/refractory; MCL: Mantle Cell Lymphoma, SLL: small lymphocytic lymphoma; RS: Richter's syndrome; PLL: prolymphocytic leukaemia; WM: Waldenström macroglobulinemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma; MM: multiple myeloma.

## Adverse events

For the safety evaluation MedDRA v26.1 was used to code all Adverse Events (AEs) to a System Organ Class (SOC) and a Preferred term (PT). Adverse event severity was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), using the CTCAE versions and severities reported in the individual studies. Study drug-related AEs were those assessed by the investigators as related in each individual study.

Treatment-emergent AEs in all studies were defined as those events that occurred or worsened on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug or until new anticancer therapy had started, whichever came first.

Study drug action due to treatment emergent adverse events (TEAEs) (i.e., discontinuation, reduction, or withholding) was based on investigator decision as recorded in the electronic case report form (eCRF).

In this section, patients with multiple occurrences are counted once per system organ class and preferred term regardless of the number of occurrences.

Similarly, a patient with multiple severity grades for the same preferred term is counted only once in the most severe grade.

<div style=\"page-break-after: always\"></div>

## Overview of Adverse Events

Table 27. Overall Summary of Adverse Events (Safety Population), study ACE-CL-311

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 28. Overview of Treatment-Emergent Adverse Events (Safety Population), study ACE-CL-311

|                                                                 | Pivotal AMPLIFY data     | Pivotal AMPLIFY data    | Pivotal AMPLIFY data         | Pooled populations                         | Pooled populations                   |
|-----------------------------------------------------------------|--------------------------|-------------------------|------------------------------|--------------------------------------------|--------------------------------------|
|                                                                 | Arm A AV (N = 291) n (%) | Arm B AVG (N=284) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Combination therapy (N = 1095) n (%) |
| Any TEAEs                                                       |                          |                         |                              |                                            |                                      |
| Any grade                                                       | 270 (92.8)               | 269 (94.7)              | 236 (91.1)                   | 1446 (97.8)                                | 1057 (96.5)                          |
| Grade ≥ 3                                                       | 156 (53.6)               | 197 (69.4)              | 157 (60.6)                   | 988 (66.8)                                 | 807 (73.7)                           |
| Serious TEAEs                                                   |                          |                         |                              |                                            |                                      |
| Any grade                                                       | 72 (24.7)                | 109 (38.4)              | 71 (27.4)                    | 753 (50.9)                                 | 509 (46.5)                           |
| Grade ≥ 3                                                       | 65 (22.3)                | 94 (33.1)               | 64 (24.7)                    | 671 (45.4)                                 | 463 (42.3)                           |
| Fatal/Grade 5 TEAEs                                             | 10 (3.4)                 | 17 (6.0)                | 9 (3.5)                      | 125 (8.5)                                  | 80 (7.3)                             |
| Treatment-related TEAEs                                         |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 230 (79.0)               | 238 (83.8)              | 215 (83.0)                   | 1103 (74.6)                                | 933 (85.2)                           |
| Acalabrutinib                                                   | 221 (75.9)               | 223 (78.5)              | 0                            | 1103 (74.6)                                | 879 (80.3)                           |
| Treatment-related Grade ≥ 3 TEAEs                               |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 117 (40.2)               | 157 (55.3)              | 143 (55.2)                   | 451 (30.5)                                 | 606 (55.3)                           |
| Acalabrutinib                                                   | 99 (34.0)                | 135 (47.5)              | 0                            | 451 (30.5)                                 | 526 (48.0)                           |
| TEAEs leading to study drug discontinuation                     |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 23 (7.9)                 | 57 (20.1)               | 28 (10.8)                    | 234 (15.8)                                 | 279 (25.5)                           |
| Acalabrutinib                                                   | 22 (7.6)                 | 39 (13.7)               | 0                            | 234 (15.8)                                 | 235 (21.5)                           |
| TEAEs leading to study drug dose reduction                      |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 41 (14.1)                | 59 (20.8)               | 29 (11.2)                    | 87 (5.9)                                   | 228 (20.8)                           |
| Acalabrutinib                                                   | 17 (5.8)                 | 18 (6.3)                | 0                            | 87 (5.9)                                   | 85 (7.8)                             |
| TEAEs leading to study drug withholding                         |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 145 (49.8)               | 184 (64.8)              | 81 (31.3)                    | 724 (49.0)                                 | 728 (66.5)                           |
| Acalabrutinib                                                   | 140 (48.1)               | 172 (60.6)              | 0                            | 724 (49.0)                                 | 663 (60.5)                           |
| TEAEs leading to infusion interruption (for infusion drug only) |                          |                         |                              |                                            |                                      |
| Any study drug                                                  | 0                        | 49 (17.3)               | 83 (32.0)                    | 0                                          | 99 (9.0)                             |

[a]  Possibly related is defined as reasonable possibility that the AE was caused by treatment, as assessed by investigator. Missing responses are counted as possibly related.

<div style=\"page-break-after: always\"></div>

## Common Treatment-emergent Adverse Events

The most common TEAEs reported in the AV and AVG arms in the AMPLIFY study were consistent with the known individual safety profiles of acalabrutinib, venetoclax, and obinutuzumab ( Table 30 ).

Table 29. TEAEs experienced by ≥ 10% of patients in any treatment arm. Safety Population, study ACE-CL-311

|                                   | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pooled populations                         | Pooled populations                   |
|-----------------------------------|--------------------------|---------------------------|------------------------------|--------------------------------------------|--------------------------------------|
| Preferred Term                    | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Combination therapy (N = 1095) n (%) |
| Patients with ≥ 1 TEAE            | 270 (92.8)               | 269 (94.7)                | 236 (91.1)                   | 1446 (97.8)                                | 1057 (96.5)                          |
| Headache                          | 102 (35.1)               | 80 (28.2)                 | 20 (7.7)                     | 539 (36.5)                                 | 12 (1.1)                             |
| Diarrhoea                         | 95 (32.6)                | 103 (36.3)                | 28 (10.8)                    | 543 (36.7)                                 | 419 (38.3)                           |
| Neutropenia                       | 90 (30.9)                | 114 (40.1)                | 99 (38.2)                    | 229 (15.5)                                 | 384 (35.1)                           |
| COVID-19                          | 55 (18.9)                | 58 (20.4)                 | 6 (2.3)                      | 110 (7.4)                                  | 249 (22.7)                           |
| Nausea                            | 43 (14.8)                | 62 (21.8)                 | 93 (35.9)                    | 322 (21.8)                                 | 301 (27.5)                           |
| Fatigue                           | 43 (14.8)                | 41 (14.4)                 | 35 (13.5)                    | 349 (23.6)                                 | 246 (22.5)                           |
| Contusion                         | 40 (13.7)                | 44 (15.5)                 | 4 (1.5)                      | 298 (20.2)                                 | 191 (17.4)                           |
| Arthralgia                        | 37 (12.7)                | 31 (10.9)                 | 9 (3.5)                      | 355 (24.0)                                 | 213 (19.5)                           |
| Pruritis                          | 32 (11.0)                | 13 (4.6)                  | 14 (5.4)                     | 99 (6.7)                                   | 114 (10.4)                           |
| Back pain                         | 31 (10.7)                | 19 (6.7)                  | 14 (5.4)                     | 191 (12.9)                                 | 148 (13.5)                           |
| Rash                              | 24 (8.2)                 | 34 (12.0)                 | 18 (6.9)                     | 182 (12.3)                                 | 150 (13.7)                           |
| Upper respiratory tract infection | 24 (8.2)                 | 18 (6.3)                  | 5 (1.9)                      | 381 (25.8)                                 | 181 (16.5)                           |
| COVID-19 pneumonia                | 21 (7.2)                 | 35 (12.3)                 | 7 (2.7)                      | 30 (2.0)                                   | 114 (10.4)                           |
| Anaemia                           | 20 (6.9)                 | 13 (4.6)                  | 25 (9.7)                     | 245 (16.6)                                 | 131 (12.0)                           |
| Myalgia                           | 20 (6.9)                 | 23 (8.1)                  | 9 (3.5)                      | 168 (11.4)                                 | 118 (10.8)                           |
| Constipation                      | 19 (6.5)                 | 23 (8.1)                  | 31 (12.0)                    | 224 (15.2)                                 | 169 (15.4)                           |
| Neutrophil count decreased        | 18 (6.2)                 | 29 (10.2)                 | 27 (10.4)                    | 38 (2.6)                                   | 117 (10.7)                           |
| Pyrexia                           | 17 (5.8)                 | 44 (15.5)                 | 47 (18.1)                    | 262 (17.7)                                 | 184 (16.8)                           |
| Vomiting                          | 16 (5.5)                 | 19 (6.7)                  | 31 (12.0)                    | 207 (14.0)                                 | 164 (15.0)                           |
| Dizziness                         | 16 (5.5)                 | 19 (6.7)                  | 8 (3.1)                      | 206 (13.9)                                 | 139 (12.7)                           |
| Cough                             | 14 (4.8)                 | 23 (8.1)                  | 13 (5.0)                     | 373 (25.2)                                 | 197 (18.0)                           |
| Thrombocytopenia                  | 13 (4.5)                 | 24 (8.5)                  | 33 (12.7)                    | 129 (8.7)                                  | 101 (9.2)                            |
| Hypertension                      | 12 (4.1)                 | 9 (3.2)                   | 6 (2.3)                      | 166 (11.2)                                 | 96 (8.8)                             |
| Pneumonia                         | 11 (3.8)                 | 15 (5.3)                  | 8 (3.1)                      | 233 (15.8)                                 | 106 (9.7)                            |
| Dyspnoea                          | 10 (3.4)                 | 16 (5.6)                  | 10 (3.9)                     | 209 (14.1)                                 | 105 (9.6)                            |
| Oedema peripheral                 | 10 (3.4)                 | 16 (5.6)                  | 8 (3.1)                      | 176 (11.9)                                 | 125 (11.4)                           |
| Insomnia                          | 9 (3.1)                  | 20 (7.0)                  | 10 (3.9)                     | 153 (10.4)                                 | 93 (8.5)                             |
| Sinusitis                         | 8 (2.7)                  | 7 (2.5)                   | 2 (0.8)                      | 168 (11.4)                                 | 73 (6.7)                             |
| Infusion related reaction         | 0                        | 56 (19.7)                 | 85 (32.8)                    | 13 (0.9)                                   | 144 (13.2)                           |

<div style=\"page-break-after: always\"></div>

In the AMPLIFY study, the treatment arm with the numerically lowest incidence of Grade ≥ 3 TEAEs was the AV arm (53.6%) followed by the FCR/BR (60.6%) and AVG arms (69.4%) ( Table 31 ).

Table 30. Treatment-Emergent CTCAE Grade ≥ 3 Adverse Events Reported in ≥ 5% of Patients in Any Treatment Arm (Safety Population), study ACE-CL-311

|                                  | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pooled populations                            | Pooled populations                |
|----------------------------------|--------------------------|---------------------------|------------------------------|-----------------------------------------------|-----------------------------------|
| Preferred Terms                  | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) (N | Combination Therapy = 1095) n (%) |
| Patients with ≥ 1 Grade ≥ 3 TEAE | 156 (53.6)               | 197 (69.4)                | 157 (60.6)                   | 988 (66.8)                                    | 807 (73.7)                        |
| Neutropenia                      | 78 (26.8)                | 100 (35.2)                | 84 (32.4)                    | 209 (14.1)                                    | 338 (30.9)                        |
| COVID-19 pneumonia               | 16 (5.5)                 | 33 (11.6)                 | 7 (2.7)                      | 28 (1.9)                                      | 99 (9.0)                          |
| Neutrophil count decreased       | 16 (5.5)                 | 29 (10.2)                 | 22 (8.5)                     | 31 (2.1)                                      | 106 (9.7)                         |
| Anaemia                          | 11 (3.8)                 | 6 (2.1)                   | 17 (6.6)                     | 140 (9.5)                                     | 60 (5.5)                          |
| COVID-19                         | 8 (2.7)                  | 19 (6.7)                  | 4 (1.5)                      | 29 (2.0)                                      | 69 (6.3)                          |
| Febrile neutropenia              | 5 (1.7)                  | 7 (2.5)                   | 24 (9.3)                     | 25 (1.7)                                      | 31 (2.8)                          |
| Thrombocytopenia                 | 4 (1.4)                  | 17 (6.0)                  | 22 (8.5)                     | 73 (4.9)                                      | 54 (4.9)                          |
| Pneumonia                        | 4 (1.4)                  | 11 (3.9)                  | 6 (2.3)                      | 128 (8.7)                                     | 57 (5.2)                          |

## Serious adverse event/deaths/other significant events

## Serious adverse event

Table 31 . Serious Treatment-Emergent Adverse Events Reported in ≥ 1% of Patients in Any Treatment Arm (Safety Population), study ACE-CL-311

|                               | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         | Pooled populations                         | Pooled populations                         | Pooled populations                   | Pooled populations                   |
|-------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------|--------------------------------------|
| System organ Class Preferred  | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Combination therapy (N = 1095) n (%) | Combination therapy (N = 1095) n (%) |
| term                          | All Grade                | Grade ≥3                 | All Grade                 | Grade ≥3                  | All                          | GradeGrade ≥3                | All Grade                                  | Grade ≥3                                   | All Grade                            | Grade ≥3                             |
| Patients with ≥1 serious TEAE | 72 (24.7)                | 65 (22.3)                | 109 (38.4)                | 94 (33.1)                 | 71 (27.4                     | 64 (24.7)                    | 753 (50.9)                                 | 671 (45.4)                                 | 509 (46.5)                           | 463 (42.3)                           |
| COVID-19 pneumonia            | 17 (5.8)                 | 16 (5.5)                 | 32 (11.3)                 | 31 (10.9)6                | (2.3)                        | 6 (2.3)                      | 28 (1.9)                                   | 27 (1.8)                                   | 101 (9.2)                            | 96 (8.8)                             |
| COVID-19                      | 9 (3.1)                  | 7 (2.4)17                | (6.0)15                   | (5.3)                     | 4 (1.5)                      | 4 (1.5)                      | 33 (2.2)                                   | 28 (1.9)                                   | 66 (6.0)                             | 57 (5.2)                             |
| Febrile neutropenia           | 5 (1.7)                  | 5 (1.7)                  | 5 (1.8)                   | 5 (1.8)                   | 21 (8.1)21                   | (8.1)22                      | (1.5)                                      | 21 (1.4)                                   | 24 (2.2)                             | 24 (2.2)                             |

<div style=\"page-break-after: always\"></div>

|                                   | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         | Pooled populations                         | Pooled populations                         | Pooled populations                   | Pooled populations                   |
|-----------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------|--------------------------------------|
| System organ Class Preferred term | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Combination therapy (N = 1095) n (%) | Combination therapy (N = 1095) n (%) |
| System organ Class Preferred term | All Grade                | Grade ≥3                 | All Grade                 | Grade ≥3                  | All                          | GradeGrade ≥3                | All Grade                                  | Grade ≥3                                   | All Grade                            | Grade ≥3                             |
| Pneumonia                         | 4 (1.4)                  | 3 (1.0)10                | (3.5)10                   | (3.5)                     | 8 (3.1)                      | 6 (2.3)                      | 122 (8.3)                                  | 113 (7.6)                                  | 60 (5.5)                             | 51 (4.7)                             |
| Anaemia                           | 3 (1.0)                  | 3 (1.0)                  | 2 (0.7)                   | 1 (0.4)                   | 3 (1.2)                      | 3 (1.2)                      | 40 (2.7)                                   | 36 (2.4)                                   | 16 (1.5)                             | 15 (1.4)                             |
| Abdominal pain                    | 2 (0.7)                  | 2 (0.7)                  | 0                         | 0                         | 1 (0.4)                      | 1 (0.4)                      | 16 (1.1)                                   | 9 (0.6)                                    | 4 (0.4)                              | 3 (0.3)                              |
| Pyrexia                           | 2 (0.7)                  | 1 (0.3)                  | 6 (2.1)                   | 3 (1.1)                   | 8 (3.1)                      | 4 (1.5)                      | 37 (2.5)                                   | 17 (1.2)                                   | 30 (2.7)                             | 13 (1.2)                             |
| Acute kidney injury               | 1 (0.3)                  | 1 (0.3)                  | 3 (1.1)                   | 3 (1.1)                   | 2 (0.8)                      | 2 (0.8)                      | 17 (1.2)                                   | 15 (1.0)                                   | 12 (1.1)                             | 11 (1.0)                             |
| Dyspnoea                          | 1 (0.3)                  | 0                        | 0                         | 0                         | 0                            | 0                            | 16 (1.1)                                   | 16 (1.1)                                   | 10 (0.9)                             | 6 (0.5)                              |
| Neutropenia                       | 1 (0.3)                  | 1 (0.3)                  | 3 (1.1)                   | 3 (1.1)                   | 2 (0.8)                      | 2 (0.8)                      | 6 (0.4)                                    | 6 (0.4)                                    | 9 (0.8)                              | 8 (0.7)                              |
| Pulmonary embolism                | 1 (0.3)                  | 1 (0.3)                  | 3 (1.1)                   | 2 (0.7)                   | 1 (0.4)                      | 1 (0.4)                      | 5 (0.3)                                    | 3 (0.2)                                    | 8 (0.7)                              | 7 (0.6)                              |
| Sepsis                            | 1 (0.3)                  | 1 (0.3)                  | 2 (0.7)                   | 2 (0.7)                   | 2 (0.8)                      | 2 (0.8)                      | 24 (1.6)                                   | 22 (1.5)                                   | 15 (1.4)                             | 15 (1.4)                             |
| Thrombocyto penia                 | 1 (0.3)                  | 1 (0.3)                  | 1 (0.4)                   | 1 (0.4)                   | 3 (1.2)                      | 3 (1.2)                      | 10 (0.7)                                   | 10 (0.7)                                   | 5 (0.5)                              | 5 (0.5)                              |
| Infusion related reaction         | 0                        | 0                        | 3 (1.1)                   | 1 (0.4)                   | 5 (1.9)                      | 5 (1.9)                      | 1 (0.1)                                    | 0                                          | 9 (0.8)                              | 4 (0.4)                              |
| Lower respiratory tract infection | 0                        | 0                        | 2 (0.7)                   | 2 (0.7)                   | 0                            | 0                            | 17 (1.2)                                   | 13 (0.9)                                   | 8 (0.7)                              | 8 (0.7)                              |
| Atrial fibrillation               | 0                        | 0                        | 1 (0.4)                   | 1 (0.4)                   | 2 (0.8)                      | 2 (0.8)                      | 23 (1.6)                                   | 19 (1.3)                                   | 12 (1.1)                             | 9 (0.8)                              |
| Neutrophil count decreased        | 0                        | 0                        | 1 (0.4)                   | 1 (0.4)                   | 3 (1.2)                      | 3 (1.2)                      | 1 (0.1)                                    | 1 (0.1)                                    | 2 (0.2)                              | 2 (0.2)                              |
| TLS                               | 0                        | 0                        | 1 (0.4)                   | 1 (0.4)                   | 6 (2.3)                      | 6 (2.3)                      | 5 (0.3)                                    | 5 (0.3)                                    | 4 (0.4)                              | 4 (0.4)                              |
| Urinary tract infection           | 0                        | 0                        | 1 (0.4)                   | 0                         | 0                            | 0                            | 24 (1.6)                                   | 21 (1.4)                                   | 8 (0.7)                              | 6 (0.5)                              |
| Cellulitis                        | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            | 15 (1.0)                                   | 13 (0.9)                                   | 12 (1.1)                             | 12 (1.1)                             |
| Respiratory tract infection       | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            | 15 (1.0)                                   | 14 (0.9)                                   | 4 (0.4)                              | 4 (0.4)                              |
| Upper respiratory tract infection | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            | 15 (1.0)                                   | 11 (0.7)                                   | 3 (0.3)                              | 2 (0.2)                              |

<div style=\"page-break-after: always\"></div>

## Deaths

Table 32. Summary of Deaths (Safety Population), study ACE-CL-311

|                                                 | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pooled populations                         | Pooled populations                   |
|-------------------------------------------------|--------------------------|---------------------------|------------------------------|--------------------------------------------|--------------------------------------|
|                                                 | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy (N = 1478) n (%) | Combination therapy (N = 1095) n (%) |
| Deaths                                          | 18 (6.2)                 | 36 (12.7)                 | 42 (16.2)                    | 355 (24.0)                                 | 187 (17.1)                           |
| Primary cause of death                          |                          |                           |                              |                                            |                                      |
| Adverse event                                   | 16 (5.5)                 | 29 (10.2)                 | 28 (10.8)                    | 142 (9.6)                                  | 110 (10.0)                           |
| Other                                           | 2 (0.7)                  | 5 (1.8)                   | 6 (2.3)                      | 37 (2.5)                                   | 25 (2.3)                             |
| Disease progression                             | 0                        | 0                         | 4 (1.5)                      | 127 (8.6)                                  | 35 (3.2)                             |
| Unknown                                         | 0                        | 2 (0.7)                   | 4 (1.5)                      | 34 (2.3)                                   | 15 (1.4)                             |
| Richter's Transformation                        | 0                        | 0                         | 0                            | 10 (0.7)                                   | 2 (0.2)                              |
| Within 30 days of last dose of study drug       |                          |                           |                              |                                            |                                      |
| Deaths                                          | 10 (3.4)                 | 11 (3.9)                  | 7 (2.7)                      | 182 (12.3)                                 | 73 (6.7)                             |
| Primary cause of death                          |                          |                           |                              |                                            |                                      |
| Disease progression                             | 0                        | 0                         | 0                            | 54 (3.7)                                   | 9 (0.8)                              |
| Adverse event                                   | 10 (3.4)                 | 11 (3.9)                  | 7 (2.7)                      | 108 (7.3)                                  | 61 (5.6)                             |
| Richter's Transformation                        | 0                        | 0                         | 0                            | 6 (0.4)                                    | 0                                    |
| Other                                           | 0                        | 0                         | 0                            | 9 (0.6)                                    | 1 (0.1)                              |
| Unknown                                         | 0                        | 0                         | 0                            | 5 (0.3)                                    | 2 (0.2)                              |
| More than 30 days after last dose of study drug |                          |                           |                              |                                            |                                      |
| Deaths                                          | 8 (2.7)                  | 25 (8.8)                  | 35 (13.5)                    | 173 (11.7)                                 | 114 (10.4)                           |
| Primary cause of death                          |                          |                           |                              |                                            |                                      |
| Disease progression                             | 0                        | 0                         | 4 (1.5)                      | 73 (4.9)                                   | 26 (2.4)                             |
| Adverse event                                   | 6 (2.1)                  | 18 (6.3)                  | 21 (8.1)                     | 34 (2.3)                                   | 49 (4.5)                             |
| Richter's Transformation                        | 0                        | 0                         | 0                            | 4 (0.3)                                    | 2 (0.2)                              |
| Other                                           | 2 (0.7)                  | 5 (1.8)                   | 6 (2.3)                      | 28 (1.9)                                   | 24 (2.2)                             |
| Unknown                                         | 0                        | 2 (0.7)                   | 4 (1.5)                      | 29 (2.0)                                   | 13 (1.2)                             |

Table 33 . Treatment-Emergent Adverse Events with a Fatal Outcome Reported for ≥ 0.3% of Patients (CTCAE Grade 5) in Any Group (Safety Population), study ACE-CL-311

<div style=\"page-break-after: always\"></div>

|                              | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pooled populations                            | Pooled populations                |
|------------------------------|--------------------------|---------------------------|------------------------------|-----------------------------------------------|-----------------------------------|
|                              | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Acalabrutinib monotherapy n (%) (N = 1478) (N | Combination therapy n (%) = 1095) |
| Patients with a Grade 5 TEAE | 10 (3.4)                 | 17 (6.0)                  | 9 (3.5)                      | 125 (8.5)                                     | 80 (7.3)                          |
| COVID-19 pneumonia           | 6 (2.1)                  | 10 (3.5)                  | 4 (1.5)                      | 5 (0.3)                                       | 34 (3.1)                          |
| COVID-19                     | 2 (0.7)                  | 5 (1.8)                   | 3 (1.2)                      | 12 (0.8)                                      | 18 (1.6)                          |
| Cardiac arrest               | 1 (0.3)                  | 0                         | 1 (0.4)                      | 3 (0.2)                                       | 1 (0.1)                           |
| Infection                    | 1 (0.3)                  | 0                         | 0                            | 0                                             | 1 (0.1)                           |
| Pneumonia                    | 0                        | 1 (0.4)                   | 0                            | 16 (1.1)                                      | 6 (0.5)                           |
| Sudden death                 | 0                        | 1 (0.4)                   | 0                            | 1 (0.1)                                       | 1 (0.1)                           |
| Septic shock                 | 0                        | 0                         | 0                            | 8 (0.5)                                       | 0                                 |
| Sepsis                       | 0                        | 0                         | 0                            | 5 (0.3)                                       | 4 (0.4)                           |
| Cerebrovascular accident     | 0                        | 0                         | 0                            | 4 (0.3)                                       | 1 (0.1)                           |
| Respiratory failure          | 0                        | 0                         | 0                            | 4 (0.3)                                       | 0                                 |
| Acute kidney injury          | 0                        | 0                         | 1 (0.4)                      |                                               |                                   |

## Events of clinical interest (ECI)

Events of clinical interest (ECI) were identified based on nonclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved BTK inhibitors. ECIs identified for acalabrutinib were: cardiac events, cytopenias, haemorrhages, hepatotoxicity, hypertension, infections, Interstitial lung disease (ILD)/pneumonitis, Second Primary Malignancies (SPMs), and Tumour Lysis Syndrome (TLS).

Adverse events of special interest associated with acalabrutinib are ventricular arrythmias (Acalabrutinib Investigator Brochure, 13th Edition, 14 March 2024). Suspected transmission of an infectious agent via product is an AESI for study treatments containing biologic products (e.g., obinutuzumab).

## Cardiac events

Table 34. Treatment-Emergent Events of Clinical Interest and Adverse Events of Special Interest: Cardiac Events (Safety Population), study ACE-CL-311

|                                        | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|----------------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI/AESI category ECI/AESI subcategory | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term                         | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Cardiac events                         | 27 (9.3)                 | 5 (1.7) a                | 34 (12.0)                 | 7 (2.5)                   | 9 (3.5)                      | 3 (1.2)                      |
| Atrial fibrillation                    | 2 (0.7)                  | 1 (0.3)                  | 6 (2.1)                   | 2 (0.7)                   | 2 (0.8)                      | 2 (0.8)                      |
| Atrial fibrillation                    | 2 (0.7)                  | 1 (0.3)                  | 6 (2.1)                   | 2 (0.7)                   | 2 (0.8)                      | 2 (0.8)                      |
| Atrial flutter                         | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            |
| Ventricular tachyarrhythmias           | 2 (0.7)                  | 0                        | 3 (1.1)                   | 0                         | 0                            | 0                            |
| Ventricular extrasystoles              | 1 (0.3)                  | 0                        | 2 (0.7)                   | 0                         | 0                            | 0                            |
| Ventricular arrhythmias                | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            |
| Ventricular fibrillation               | 0                        | 0                        | 0                         | 0                         | 0                            | 0                            |

<div style=\"page-break-after: always\"></div>

|                                                       | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|-------------------------------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI/AESI category ECI/AESI subcategory                | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term                                        | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Ventricular tachycardia                               | 1 (0.3)                  | 0                        | 1 (0.4)                   | 0                         | 0                            | 0                            |
| Other cardiac events                                  |                          |                          |                           |                           |                              |                              |
| Other cardiac events with ≥ 2% incidence in any group | 24 (8.2)                 | 4 (1.4)                  | 27 (9.5)                  | 5 (1.8)                   | 7 (2.7)                      | 1 (0.4)                      |
| Palpitations                                          | 8 (2.7)                  | 0                        | 11 (3.9)                  | 0                         | 0                            | 0                            |
| Angina pectoris                                       | 3 (1.0)                  | 0                        | 5 (1.8)                   | 1 (0.4)                   | 1 (0.4)                      | 0                            |
| Tachycardia                                           | 5 (1.7)                  | 0                        | 2 (0.7)                   | 0                         | 1 (0.4)                      | 0                            |
| Cardiac failure                                       | 1 (0.3)                  | 1 (0.3)                  | 0                         | 0                         | 1 (0.4)                      | 0                            |

a  One patient in the AV arm had a Grade 5 cardiac arrest on Study Day 391

The median time from first dose of study drug to onset of the ECI ventricular tachyarrhythmia in the AV and AVG arms was 44 days (range: 15 to 73) and 311 days (range: 100 to 332 days), respectively, and for atrial fibrillation in the AV, AVG, and FCR/BR arms it was 351 days (range: 314 to 388 days), 85 days (range: 28 to 377), and 59 days (range: 57 to 61 days), respectively.

## Cytopenias

Table 35. Treatment-Emergent Adverse Events of Events of Clinical Interest: Cytopenia in ≥ 10% of Patients in Any Group (Safety Population), study ACE-CL-311

|                              | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI category ECI subcategory | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term               | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Anaemia                      | 20 (6.9)                 | 11 (3.8)                 | 13 (4.6)                  | 6 (2.1)                   | 25 (9.7)                     | 17 (6.6)                     |
| Anaemia                      | 20 (6.9)                 | 11 (3.8)                 | 13 (4.6)                  | 6 (2.1)                   | 25 (9.7)                     | 17 (6.6)                     |
| Leukopenia                   | 109 (37.5)               | 95 (32.6)                | 147 (51.8)                | 135 (47.5)                | 140 (54.1)                   | 120 (46.3)                   |
| Neutropenia                  | 108 (37.1)               | 94 (32.3)                | 143 (50.4)                | 131 (46.1)                | 132 (51.0)                   | 112 (43.2)                   |
| Neutropenia                  | 90 (30.9)                | 78 (26.8)                | 114 (40.1)                | 100 (35.2)                | 99 (38.2)                    | 84 (32.4)                    |
| Neutrophil count decreased   | 18 (6.2)                 | 16 (5.5)                 | 29 (10.2)                 | 29 (10.2)                 | 27 (10.4)                    | 22 (8.5)                     |
| Other leukopenia             | 11 (3.8)                 | 6 (2.1)                  | 12 (4.2)                  | 6 (2.1)                   | 23 (8.9)                     | 16 (6.2)                     |

<div style=\"page-break-after: always\"></div>

|                              | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI category ECI subcategory | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term               | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| WBC count decreased          | 7 (2.4)                  | 4 (1.4)                  | 2 (0.7)                   | 0                         | 9 (3.5)                      | 4 (1.5)                      |
| Thrombocytopeni a            | 17 (5.8)                 | 6 (2.1)                  | 35 (12.3)                 | 26 (9.2)                  | 39 (15.1)                    | 28 (10.8)                    |
| Thrombocytopenia             | 13 (4.5)                 | 4 (1.4)                  | 24 (8.5)                  | 17 (6.0)                  | 33 (12.7)                    | 22 (8.5)                     |
| Platelet count deceased      | 4 (1.4)                  | 2 (0.7)                  | 12 (4.2)                  | 9 (3.2)                   | 8 (3.1)                      | 7 (2.7)                      |

## Haemorrhages

Table 36 . Treatment-Emergent Adverse Events of Clinical Interest: Haemorrhage and Major Haemorrhage Reported in ≥ 2% of Patients in Any Group (Safety Population), study ACE-CL-311

|                              | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI subcategory              | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term               | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Haemorrhage                  | 94 (32.3)                | 3 (1.0)                  | 86 (30.3)                 | 6 (2.1)                   | 11 (4.2)                     | 1 (0.4)                      |
| Contusion                    | 40 (13.7)                | 0                        | 44 (15.5)                 | 0                         | 4 (1.5)                      | 0                            |
| Haematuria                   | 3 (1.0)                  | 0                        | 8 (2.8)                   | 1 (0.4)                   | 2 (0.8)                      | 0                            |
| Haematoma                    | 17 (5.8)                 | 1 (0.3)                  | 9 (3.2)                   | 0                         | 1 (0.4)                      | 0                            |
| Conjunctival haemorrhage     | 2 (0.7)                  | 0                        | 2 (0.7)                   | 0                         | 0                            | 0                            |
| Ecchymosis                   | 8 (2.7)                  | 0                        | 11 (3.9)                  | 0                         | 0                            | 0                            |
| Epistaxis                    | 5 (1.7)                  | 0                        | 12 (4.2)                  | 0                         | 2 (0.8)                      | 0                            |
| Purpura                      | 5 (1.7)                  | 0                        | 6 (2.1)                   | 0                         | 0                            | 0                            |
| Petechiae                    | 14 (4.8)                 | 0                        | 15 (5.3)                  | 0                         | 0                            | 0                            |
| Increased tendency to bruise | 4 (1.4)                  | 0                        | 1 (0.4)                   | 0                         | 0                            | 0                            |
| Rectal haemorrhage           | 0                        | 0                        | 2 (0.7)                   | 1 (0.4)                   | 0                            | 0                            |
| Major haemorrhage            | 3 (1.0)                  | 3 (1.0)                  | 8 (2.8)                   | 6 (2.1)                   | 2 (0.8)                      | 1 (0.4)                      |

<div style=\"page-break-after: always\"></div>

Major hemorrhage was defined as any hemorrhagic event that was serious or Grade ≥ 3 in severity, or that was a CNS hemorrhage (any severity grade).

## Hepatotoxicity

Table 37. Treatment-Emergent Adverse Events of Clinical Interest: Hepatotoxicity Reported in ≥ 0.5% of Patients in Any Group (Safety Population), study ACE-CL-311

|                           | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|---------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI category              | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term            | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Hepatotoxicity            | 17 (5.8)                 | 10 (3.4)                 | 19 (6.7)                  | 8 (2.8)                   | 9 (3.5)                      | 4 (1.5)                      |
| ALT increased             | 6 (2.1)                  | 3 (1.0)                  | 10 (3.5)                  | 5 (1.8)                   | 4 (1.5)                      | 2 (0.8)                      |
| AST increased             | 5 (1.7)                  | 2 (0.7)                  | 6 (2.1)                   | 1 (0.4)                   | 2 (0.8)                      | 0                            |
| Transaminases increased   | 2 (0.7)                  | 1 (0.3)                  | 2 (0.7)                   | 2 (0.7)                   | 1 (0.4)                      | 1 (0.4)                      |
| Blood bilirubin increased | 0                        | 0                        | 1 (0.4)                   | 0                         | 1 (0.4)                      | 0                            |
| GGT increased             | 1 (0.3)                  | 1 (0.3)                  | 1 (0.4)                   | 0                         | 2 (0.8)                      | 1 (0.4)                      |

## Hypertension

Hypertension events occurred in 4.1%, 3.9%, and 2.7% of patients in the AV, AVG, and FCR/BR arms, respectively. Grade ≥ 3 hypertension events occurred in 2.7%, 2.1%, and 0.8% of patients, respectively.

Median time from first dose of study drug to onset of hypertension of any grade was 197 days (range: 16 to 442 days) in the AV arm, 197 days (range: 15 to 424 days) in the AVG arm, and 44 days (range: 1 to 142 days) in the FCR/BR arm.

## Infections

Table 38. Treatment-Emergent Adverse Events of Clinical Interest: Infections Reported for ≥ 5% Patients in Any Group (Safety Population), study ACE-CL-311

|                | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|----------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI category   | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| Infections     | 148                      | 36                       | 153 (53.9)                | 67 (23.6)                 | 82 (31.7)                    | 26 (10.0)                    |
|                | (50.9)                   | (12.4)                   |                           |                           |                              |                              |

<div style=\"page-break-after: always\"></div>

|                                   | Pivotal AMPLIFY data     | Pivotal AMPLIFY data     | Pivotal AMPLIFY data      | Pivotal AMPLIFY data      | Pivotal AMPLIFY data         | Pivotal AMPLIFY data         |
|-----------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| ECI category                      | Arm A AV (N = 291) n (%) | Arm A AV (N = 291) n (%) | Arm B AVG (N = 284) n (%) | Arm B AVG (N = 284) n (%) | Arm C FCR/BR (N = 259) n (%) | Arm C FCR/BR (N = 259) n (%) |
| Preferred term                    | All Grades               | Grade ≥ 3                | All Grades                | Grade ≥ 3                 | All Grades                   | Grade ≥ 3                    |
| COVID-19                          | 55 (18.9)                | 8 (2.7)                  | 58 (20.4)                 | 19 (6.7)                  | 6 (2.3)                      | 4 (1.5)                      |
| Upper respiratory tract infection | 24 (8.2)                 | 1 (0.3)                  | 18 (6.3)                  | 0                         | 5 (1.9)                      | 0                            |
| Pneumonia                         | 11 (3.8)                 | 4 (1.4)                  | 15 (5.3)                  | 11 (3.9)                  | 8 (3.1)                      | 6 (2.3)                      |
| COVID-19 pneumonia                | 21 (7.2)                 | 16 (5.5)                 | 35 (12.3)                 | 33 (11.6)                 | 7 (2.7)                      | 7 (2.7)                      |
| Urinary tract infection           | 9 (3.1)                  | 0                        | 17 (6.0)                  | 1 (0.4)                   | 10 (3.9)                     | 0                            |
| Herpes zoster                     | 5 (1.7)                  | 0                        | 4 (1.4)                   | 1 (0.4)                   | 4 (1.5)                      | 1 (0.4)                      |
| Bronchitis                        | 6 (2.1)                  | 0                        | 7 (2.5)                   | 0                         | 2 (0.8)                      | 1 (0.4)                      |
| Sinusitis                         | 8 (2.7)                  | 0                        | 7 (2.5)                   | 0                         | 2 (0.8)                      | 0                            |
| Nasopharyngitis                   | 4 (1.4)                  | 0                        | 3 (1.1)                   | 0                         | 5 (1.9)                      | 0                            |
| Respiratory tract infection       | 3 (1.0)                  | 0                        | 1 (0.4)                   | 0                         | 1 (0.4)                      | 0                            |
| Lower respiratory tract infection | 0                        | 0                        | 5 (1.8)                   | 2 (0.7)                   | 0                            | 0                            |

An evaluation of concomitant infection and neutropenia (based on laboratory values) was also provided. Infections and Grade ≥ 3 infections with onset 2 weeks prior to or after onset of neutropenia (any grade and Grade ≥ 3 based on laboratory values) are summarized in Table 40 .

Table 39 . Infections and Neutropenia (Safety Population), study ACE-CL-311

|                                           | Patients with any neutropenia n (%)   | Patients with neutropenia Grade ≥ 3 n (%)   | Patients without any neutropenia n (%)   |
|-------------------------------------------|---------------------------------------|---------------------------------------------|------------------------------------------|
| Patients with any infection a             |                                       |                                             |                                          |
| AV (N = 148)                              | 42 (28.4)                             | 13 (8.8)                                    | 106 (71.6)                               |
| AVG (N = 153)                             | 51 (33.3)                             | 25 (16.3)                                   | 102 (66.7)                               |
| FCR/BR (N = 82)                           | 30 (36.6)                             | 16 (19.5)                                   | 52 (63.4)                                |
| Acalabrutinib Monotherapy Pool (N = 1098) | 111 (10.1)                            | 59 (5.4)                                    | 987 (89.9)                               |
| Combination Therapy Pool (N = 724)        | 194 (26.8)                            | 93 (12.8)                                   | 530 (73.2)                               |
| Patients with any Grade ≥ 3 infection a   |                                       |                                             |                                          |
| AV (N = 36)                               | 6 (16.7)                              | 1 (2.8)                                     | 30 (83.3)                                |
| AVG (N = 67)                              | 15 (22.4)                             | 8 (11.9)                                    | 52 (77.6)                                |
| FCR/BR (N = 26)                           | 11 (42.3)                             | 7 (26.9)                                    | 15 (57.7)                                |
| Acalabrutinib Monotherapy Pool (N = 390)  | 30 (7.7)                              | 18 (4.6)                                    | 360 (92.3)                               |
| Combination Therapy Pool (N = 302)        | 52 (17.2)                             | 26 (8.6)                                    | 250 (82.8)                               |

<div style=\"page-break-after: always\"></div>

- a Treatment emergent neutropenia by laboratory within 2 weeks or on the same day of infection onset date.

Infections Grade ≥ 3 with concomitant Grade ≥ 3 neutropenia occurred at higher incidence in the AVG arm (11.9%) compared to the AV arm (2.8%).

Grade 5 infections reported in 2 or more patients included COVID-19 pneumonia (2.1%, 3.5%, and 1.5%) and COVID-19 (0.7%, 1.8%, and 1.2%). TEAEs with fatal outcome due to infection were 9 (3%) in the AV, 16 (5.6%) in AVG and 7 (2.7%) in FCR/BR arms.

## ILD/pneumonitis

Interstitial lung disease/pneumonitis of any grade occurred in 1.8% of patients in the AVG arm and 1 patient (0.4%) experienced a Grade 3 event in the FCR/BR arm. No patient had an event of ILD/pneumonitis in the AV arm.

Detailed review of the reported events of pneumonitis in AVG patients revealed that all of them reported prior events of lung infection, including pneumonia or lower respiratory tract infection.

## Second Primary malignancies (SPMs)

Table 40. Treatment-Emergent Events of Clinical Interest: Second Primary Malignancies Occurring in ≥ 2 Patients in Any Arm (Safety Population), study ACE-CL-311

<!-- image -->

|                                                    |                       | ArmB (AVG)   | ArmC(FCR/BR)      | ArmC(FCR/BR)        | ArmC(FCR/BR)      |
|----------------------------------------------------|-----------------------|--------------|-------------------|---------------------|-------------------|
| ECISubcategory ECISubcategory PreferredTerm        | ArmA (AN) N=291 n (%) | N=282 n (%)  | Total N=259 n (%) | FCRonly N=122 n (%) | BRonly N=137 (%)u |
| Secondprimarymalignancies                          |                       |              |                   |                     |                   |
| Any Grade                                          | 15 (5.2)              | 12 (4.2)     | 2 (0.8)           | 2 (1.6)             | 0                 |
| Grade≥3                                            | 5 (1.7)               | 5 (1.8)      | 0                 | 0                   | 0                 |
| BasalCell.Carcinoma                                |                       |              |                   |                     |                   |
| Any'Grade                                          | 6 (2.1)               | 4 (1.4)      | 1 (0.4)           | 1 (0.8)             | 0                 |
| Grade≥3                                            | 0                     | 1 (0.4)      | 0                 | 0                   | 0                 |
| Squamous Cell CarcinomaofSkin                      |                       |              |                   |                     |                   |
| Any Grade                                          | 4 (1.4)               | 1 (0.4)      | 0                 | 0                   | 0                 |
| Grade≥3                                            | 0                     | 0            | 0                 | 0                   | 0                 |
| MalignantMelanoma                                  |                       |              |                   |                     |                   |
| Any Grade                                          | 2 (0.7)               | 0            | 1 (0.4)           | 1 (0.8)             | 0                 |
| Grade≥3                                            | 2 (0.7)               | 0            | 0                 | 0                   | 0                 |
| Secondprimarymalignancy- excludingnon-melanomaskin |                       |              |                   |                     |                   |
| Any Grade                                          | 8 (2.7)               | 7 (2.5)      | 1 (0.4)           | 1 (0.8)             | 0                 |
| Grade≥3                                            | 5 (1.7)               | 4 (1.4)      | 0                 | 0                   | 0                 |
| MalignantMelanoma                                  |                       |              |                   |                     |                   |
| Any Grade                                          | 2 (0.7)               | 0            | 1 (0.4)           | 1 (0.8)             | 0                 |
| Grade≥3                                            | 2 (0.7)               | 0            | 0                 | 0                   | 0                 |

The median time from first dose of study drug to onset of first SPM in the AV, AVG, and FCR/BR arms was 169 days (range: 57 to 425), 193 days (range: 11 to 360 days), and 107.5 days (range: 84 to 131 days), respectively. The median time from first dose of study drug to onset of first SPM, excluding

<div style=\"page-break-after: always\"></div>

non-melanoma skin was 218.5 days (range: 57 to 351 days), 259 days (range: 37 to 360 days), and 84 days (range: 84 to 84) (see ISS Table 25.1, Module 5.3.5.3).

## Tumour Lysis Syndrome (TLS)

The incidence of TLS events in the AV and AVG arms was low. One (0.3%) patient in the AV arm and one (0.4%) patient in the AVG arm. There were 8 (3.1%) patients in the FCR/BR arm (all of whom received BR) who had TLS events. All TLS events reported were Grade ≥ 3 in severity. No Grade 5 TLS events were reported.

TLS mitigation strategies were employed per the AMPLIFY protocol because Grade 3 TLS is a known risk of venetoclax. These mitigations strategies included the following: Initiation of acalabrutinib for 2 cycles before initiation of venetoclax. A 5-week dose ramp-up schedule for venetoclax. Gradual debulking with acalabrutinib (and obinutuzumab in Arm B) prior to initiation of venetoclax. Restaging with computed tomography at Cycle 3 prior to initiation of venetoclax to determine appropriate TLS risk and initiate most appropriate prophylaxis. Optional hospitalization for observation during 1st week at investigator's discretion following re-staging at Cycle 3.

## Adverse Drug Reactions

No new ADRs were identified specific for acalabrutinib in the AV and AVG combination regimen based on the AMPLIFY study data (

Table 42 ).

Table 41. Frequency and CTCAE Grades of Acalabrutinib-Related Adverse Drug Reactions by Treatment Arms in AMPLIFY Study and in Acalabrutinib Monotherapy and Combination Therapy Pools (Safety Population), study ACE-CL-311

|                                      | Pivotal AMPLIFY (N = 834)            | Pivotal AMPLIFY (N = 834)            | Pivotal AMPLIFY (N = 834)            | Pivotal AMPLIFY (N = 834)            | Pivotal AMPLIFY (N = 834)            | Pivotal AMPLIFY (N = 834)            | Acalabrutinib                        | Acalabrutinib                        | Acalabrutinib                        | Acalabrutinib                        |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| ADR system                           | AV (N = 291)                         | AV (N = 291)                         | AVG (N = 284)                        | AVG (N = 284)                        | FCR/BR (N = 259)                     | FCR/BR (N = 259)                     | monotherapy pool (N = 1478)          | monotherapy pool (N = 1478)          | combination therapy Pool (N = 1095)  | combination therapy Pool (N = 1095)  |
| organ class/ ADR term                | All Grades                           | Grade ≥ 3                            | All Grades                           | Grade ≥ 3                            | All Grades                           | Grade ≥ 3                            | All Grades                           | Grade ≥ 3                            | All Grades                           | Grade ≥ 3                            |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders |
| Leukopenia                           | 109 (37.5%)                          | 95 (32.6%)                           | 147 (51.8%)                          | 135 (47.5%)                          | 140 (54.1%)                          | 120 (46.3 %)                         | 308 (20.8%)                          | 269 (18.2%)                          | 509 (46.5% )                         | 459 (41.9%)                          |
| Neutropenia                          | 108 (37.1%)                          | 94 (32.3%)                           | 143 (50.4%)                          | 131 (46.1%)                          | 132 (51.0%)                          | 112 (43.2 %)                         | 286 (19.4%)                          | 259 (17.5%)                          | 490 (44.7% )                         | 444 (40.5%)                          |
| Anaemia                              | 20 (6.9%)                            | 11 (3.8%)                            | 13 (4.6%)                            | 6 (2.1%)                             | 25 (9.7%)                            | 17 (6.6% )                           | 253 (17.1%)                          | 140 (9.5%)                           | 138 (12.6% )                         | 61 (5.6%)                            |
| Thrombocytopenia                     | 17 (5.8%)                            | 6 (2.1%)                             | 35 (12.3%)                           | 26 (9.2%)                            | 39 (15.1%)                           | 28 (10.8 %)                          | 170 (11.5%)                          | 92 (6.2%)                            | 155 (14.2% )                         | 81 (7.4%)                            |
| Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    | Cardiac disorders                    |
| Atrial fibrillation/flutter          | 2 (0.7%)                             | 1 (0.3%)                             | 6 (2.1%)                             | 2 (0.7% )                            | 2 (0.8%)                             | 2 (0.8 %)                            | 109 (7.4%)                           | 34 (2.3%)                            | 45 (4.1 %)                           | 19 (1.7% )                           |

<div style=\"page-break-after: always\"></div>

|                                                      | Pivotal AMPLIFY (N = 834)                            | Pivotal AMPLIFY (N = 834)                            | Pivotal AMPLIFY (N = 834)                            | Pivotal AMPLIFY (N = 834)                            | Pivotal AMPLIFY (N = 834)                            | Pivotal AMPLIFY (N = 834)                            | Acalabrutinib monotherapy                            | Acalabrutinib monotherapy                            | Acalabrutinib                                        | Acalabrutinib                                        |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| ADR system                                           | AV (N = 291)                                         | AV (N = 291)                                         | AVG (N = 284)                                        | AVG (N = 284)                                        | FCR/BR (N = 259)                                     | FCR/BR (N = 259)                                     | pool (N = 1478)                                      | pool (N = 1478)                                      | combination therapy Pool (N = 1095)                  | combination therapy Pool (N = 1095)                  |
| organ class/ ADR term                                | All Grades                                           | Grade ≥ 3                                            | All Grades                                           | Grade ≥ 3                                            | All Grades                                           | Grade ≥ 3                                            | All Grades                                           | Grade ≥ 3                                            | All Grades                                           | Grade ≥ 3                                            |
| Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             |
| Headache                                             | 102 (35.1%)                                          | 4 (1.4%)                                             | 80 (28.2%)                                           | 1 (0.4%)                                             | 20 (7.7%)                                            | 1 (0.4% )                                            | 539 (36.5%)                                          | 17 (1.2%)                                            | 369 (33.7% )                                         | 12 (1.1%)                                            |
| Dizziness                                            | 16 (5.5%)                                            | 0                                                    | 19 (6.7%)                                            | 0                                                    | 8 (3.1%)                                             | 0                                                    | 206 (13.9%)                                          | 2 (0.1%)                                             | 139 (12.7% )                                         | 4 (0.4%)                                             |
| Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      | Respiratory, thoracic and mediastinal disorders      |
| Epistaxis                                            | 5 (1.7%)                                             | 0                                                    | 12 (4.2%)                                            | 0                                                    | 2 (0.8%)                                             | 0                                                    | 118 (8.0%)                                           | 4 (0.3%)                                             | 50 (4.6 %)                                           | 0                                                    |
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Diarrhoea                                            | 95 (32.6%)                                           | 5 (1.7%)                                             | 103 (36.3%)                                          | 4 (1.4%)                                             | 28 (10.8%)                                           | 1 (0.4% )                                            | 543 (36.7%)                                          | 39 (2.6%)                                            | 419 (38.3% )                                         | 33 (3.0%)                                            |
| Nausea                                               | 43 (14.8%)                                           | 0                                                    | 62 (21.8%)                                           | 2 (0.7%)                                             | 93 (35.9%)                                           | 0                                                    | 322 (21.8%)                                          | 12 (0.8%)                                            | 301 (27.5% )                                         | 6 (0.5%)                                             |
| Constipation                                         | 19 (6.5%)                                            | 1 (0.3%)                                             | 23 (8.1%)                                            | 0                                                    | 31 (12.0%)                                           | 1 (0.4% )                                            | 224 (15.2%)                                          | 1 (0.1%)                                             | 169 (15.4% )                                         | 4 (0.4%)                                             |
| Abdominal pain                                       | 23 (7.9%)                                            | 3 (1.0%)                                             | 23 (8.1%)                                            | 2 (0.7%)                                             | 11 (4.2%)                                            | 2 (0.8% )                                            | 215 (14.5%)                                          | 18 (1.2%)                                            | 129 (11.8% )                                         | 16 (1.5%)                                            |
| Vomiting                                             | 16 (5.5%)                                            | 0                                                    | 19 (6.7%)                                            | 0                                                    | 31 (12.0%)                                           | 0                                                    | 207 (14.0%)                                          | 11 (0.7%)                                            | 164 (15.0% )                                         | 5 (0.5%)                                             |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Fatigue                                              | 43 (14.8%)                                           | 1 (0.3%)                                             | 41 (14.4%)                                           | 0                                                    | 35 (13.5%)                                           | 2 (0.8% )                                            | 349 (23.6%)                                          | 30 (2.0%)                                            | 246 (22.5% )                                         | 14 (1.3%)                                            |
| Asthenia                                             | 12 (4.1%)                                            | 0                                                    | 9 (3.2%)                                             | 0                                                    | 10 (3.9%)                                            | 2 (0.8% )                                            | 103 (7.0%)                                           | 13 (0.9%)                                            | 73 (6.7%)                                            | 4 (0.4%)                                             |
| Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   |
| Tumour Lysis Syndrome                                | 1 (0.3%)                                             | 1 (0.3%)                                             | 1 (0.4%)                                             | 1 (0.4% )                                            | 8 (3.1%)                                             | 8 (3.1 %)                                            | 7 (0.5% )                                            | 6 (0.4%)                                             | 10 (0.9 %)                                           | 10 (0.9% )                                           |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      |
| Arthralgia                                           | 37 (12.7%)                                           | 3 (1.0%)                                             | 31 (10.9%)                                           | 1 (0.4%)                                             | 9 (3.5%)                                             | 0                                                    | 355 (24.0%)                                          | 14 (0.9%)                                            | 213 (19.5% )                                         | 11 (1.0%)                                            |
| Musculoskeletal Pain                                 | 70 (24.1%)                                           | 2 (0.7%)                                             | 62 (21.8%)                                           | 3 (1.1%)                                             | 34 (13.1%)                                           | 2 (0.8% )                                            | 471 (31.9%)                                          | 27 (1.8%)                                            | 351 (32.1% )                                         | 22 (2.0%)                                            |
| Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          | Infections and Infestations                          |
| Infection                                            | 148 (50.9%)                                          | 36 (12.4%)                                           | 153 (53.9%)                                          | 67 (23.6%)                                           | 82 (31.7%)                                           | 26 (10.0 %)                                          | 1098 (74.3%)                                         | 388 (26.3%)                                          | 724 (66.1%)                                          | 302 (27.6%)                                          |

<div style=\"page-break-after: always\"></div>

|                                             | Pivotal AMPLIFY (N = 834)                   | Pivotal AMPLIFY (N = 834)                   | Pivotal AMPLIFY (N = 834)                   | Pivotal AMPLIFY (N = 834)                   | Pivotal AMPLIFY (N = 834)                   | Pivotal AMPLIFY (N = 834)                   | Acalabrutinib monotherapy                   | Acalabrutinib monotherapy                   | Acalabrutinib combination                   | Acalabrutinib combination                   |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| ADR system                                  | AV (N = 291)                                | AV (N = 291)                                | AVG (N = 284)                               | AVG (N = 284)                               | FCR/BR (N = 259)                            | FCR/BR (N = 259)                            | pool (N = 1478)                             | pool (N = 1478)                             | therapy Pool (N = 1095)                     | therapy Pool (N = 1095)                     |
| organ class/ ADR term                       | All Grades                                  | Grade ≥ 3                                   | All Grades                                  | Grade ≥ 3                                   | All Grades                                  | Grade ≥ 3                                   | All Grades                                  | Grade ≥ 3                                   | All Grades                                  | Grade ≥ 3                                   |
| Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified | Neoplasms benign, malignant and unspecified |
| SPM                                         | 15 (5.2%)                                   | 5 (1.7%)                                    | 12 (4.2%)                                   | 5 (1.8% )                                   | 2 (0.8%)                                    | 0                                           | 260 (17.6%)                                 | 99 (6.7%)                                   | 133 (12.1% )                                | 52 (4.7%)                                   |
| SPM excluding non- melanoma ski             | 8 (2.7%)                                    | 5 (1.7%)                                    | 7 (2.5%)                                    | 4 (1.4% )                                   | 1 (0.4%)                                    | 0                                           | 143 (9.7%)                                  | 81 (5.5%)                                   | 74 (6.8 %)                                  | 40 (3.7% )                                  |
| Non-Melanoma Skin Malignancy                | 9 (3.1%)                                    | 0                                           | 5 (1.8%)                                    | 1 (0.4% )                                   | 1 (0.4%)                                    | 0                                           | 146 (9.9%)                                  | 21 (1.4%)                                   | 79 (7.2 %)                                  | 13 (1.2% )                                  |
| Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      | Skin and subcutaneous tissue disorders      |
| Bruising                                    | 60 (20.6%)                                  | 0                                           | 62 (21.8%)                                  | 0                                           | 4 (1.5%)                                    | 0                                           | 457 (30.9%)                                 | 0                                           | 262 (23.9%)                                 | 1 (0.1%)                                    |
| Rash                                        | 35 (12.0%)                                  | 1 (0.3%)                                    | 46 (16.2%)                                  | 3 (1.1% )                                   | 33 (12.7%)                                  | 2 (0.8% )                                   | 300 (20.3%)                                 | 14 (0.9%)                                   | 270 (24.7%)                                 | 37 (3.4%)                                   |
| Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          | Vascular disorders                          |
| Haemorrhage/ Haematoma                      | 26 (8.9%)                                   | 2 (0.7%)                                    | 24 (8.5%)                                   | 3 (1.1% )                                   | 4 (1.5%)                                    | 0                                           | 241 (16.3%)                                 | 47 (3.2%)                                   | 149 (13.6%)                                 | 18 (1.6%)                                   |
| Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              | Investigations                              |
| Alanine aminotransferase increased          | 6 (2.1%)                                    | 3 (1.0%)                                    | 10 (3.5%)                                   | 5 (1.8% )                                   | 4 (1.5%)                                    | 2 (0.8 %)                                   | 42 (2.8% )                                  | 16 (1.1%)                                   | 50 (4.6 %)                                  | 26 (2.4% )                                  |
| Aspartate aminotransferase increased        | 5 (1.7%)                                    | 2 (0.7%)                                    | 6 (2.1%)                                    | 1 (0.4% )                                   | 2 (0.8%)                                    | 0                                           | 31 (2.1% )                                  | 9 (0.6%)                                    | 39 (3.6 %)                                  | 15 (1.4% )                                  |

## Laboratory findings

Similar incidences of haematology parameters worsening by 3 grades (from Grade 0 at baseline to Grade 3 postbaseline [maximum grade] or Grade 1 at baseline to Grade 4 post baseline [maximum grade]) were reported in the AV, AVG, and FCR/BR arms, respectively, for ALC (0%, 0.7%, and 2.3%), ANC (21.4%, 27.8%, and 24.4%), haemoglobin (0.3%, 0%, and 0%), platelets (1.0%, 5.3%, and 3.9%), and leukocytes (25.2%, 25.4%, and 21.3%).

Worsening by 4 grades from Grade 0 at baseline to Grade 4 postbaseline (maximum grade) was reported in the AV, AVG, and FCR/BR arms, respectively, for ALC (0.3%, 0%, and 1.6%), ANC (11.7%, 21.1%, and 23.3%), platelets (0%, 0.4%, and 0.8%), and leukocytes (0.7%, 1.4%, and 8.5%).

Median durations for neutropenia were 9, 12, and 15 days, for thrombocytopenia was 22, 13, and 16 days; and for anaemia was 8, 7, and 9 days in the AV and AVG and FCR/BR arms respectively.

In the AMPLIFY study, the proportion of patients with lymphocytosis (defined as ALC of &gt; 5,000 cells/µL and an increase above baseline) was higher in the AV (42.6%) and AVG (43.0%) arms compared to the FCR/BR (4.2%) arm. The median time to first onset of lymphocytosis was 4.1 weeks, 4.1, and 0.3 weeks in the AV, AVG and FCR/BR arms, respectively, and median duration was 5.3 days, 1.1 day, and 1.3 day, respectively.

<div style=\"page-break-after: always\"></div>

The incidence of patients with Grade 4 treatment-emergent abnormal ANC values trended higher in the AVG and FCR/BR arms compared to the AV arm.

## Clinical chemistry

Overall shifts in mean clinical chemistry grades over time were similar in the AV, AVG, and FCR/BR arms. The majority of patients had values that remained at Grade 0 or shifted to Grade 1 postbaseline, and the lowest percentages were for shifts from Grade 0 to Grade 3 or Grade 4. No new safety signal was observed. No notable differences between the AV, AVG, and FCR/BR arms were noted for changes in creatine, albumin, calcium, glucose, potassium, LDH, phosphate, and sodium.

The incidence of shifts from baseline across serum chemistry parameters was generally consistent between the AV and AVG arms in AMPLIFY and the Acalabrutinib Monotherapy Pool.

## Potential Hy's law

The review of liver enzymes levels for AST and ALT alongside bilirubin levels following the biochemical criteria for potential Hy's Law resulted in the identification of 1 patient in the AVG arm who fulfilled the biochemical criteria for potential Hy's law. After a comprehensive review of this patient, alternative infectious aetiology was identified, and it was concluded that this was not a Hy's Law case.

## Serum immunoglobulin

No clinically significant changes in serum immunoglobulin values from baseline to last post-baseline values were noted for patients in all treatment arms.

## Safety in special populations

There were no discernible differences in the safety profiles of AV and AVG with respect to sex, race, hepatic impairment, or renal impairment.

A trend towards more deaths at older age was observed, however, the groups are too small to draw conclusions.

## Discontinuation due to adverse events

<div style=\"page-break-after: always\"></div>

Table 42. Adverse Events Leading to Discontinuation of Study Treatment in ≥ 2 Patients in Any Treatment Arm (Safety Population), study ACE-CL-311

| PreferredTerm                                                | Arm A(AW) N=291 n (%)   | Arm B (AIG) N=284 n(%)   |
|--------------------------------------------------------------|-------------------------|--------------------------|
| Patientswith>1AEleadingtodiscontinuationof anystudytreatment | 23 (7.9)                | 57 (20.1)                |
| Patientswith≥1AEleadingtodiscontinuationof acalabrutinib     | 22 (7.6)                | 39 (13.7)                |
| COVID-19pneumonia                                            | 6 (2.1)                 | 8 (2.8)                  |
| COVID-19                                                     | 1 (0.3)                 | 11 (3.9)                 |
| Thrombocytopenia                                             | 2 (0.7)                 | 3 (1.1)                  |
| Neutrophil count decreased                                   | 0                       | 2 (0.7)                  |
| Pneumonia                                                    | 0                       | 2 (0.7)                  |
| Pneumonitis                                                  | 0                       | 2 (0.7)                  |
| Patientswith>1AEleadingtodiscontinuationof Tenetoclax        | 18 (6.2)                | 37 (13.0)                |
| COVID-19pneumonia                                            | 4(1.4)                  | 9 (3.2)                  |
| COVID-19                                                     | 1 (0.3)                 | 9 (3.2)                  |
| Thrombocytopenia                                             | 2 (0.7)                 | 2 (0.7)                  |
| Neutropenia                                                  | 1 (0.3)                 | 2 (0.7)                  |
| Acute kidney injury                                          | 0                       | 2 (0.7)                  |
| Dianhoea                                                     | 0                       | 2 (0.7)                  |
| Pneumonia                                                    | 0                       | 2 (0.7)                  |
| Patientswith≥1AEleadingtodisconhinuationof obinutuzumab      | NA                      | 27 (9.5)                 |
| COVID-19                                                     | NA                      | 6 (2.1)                  |
| Thrombocytopenia                                             | NA                      | 5 (1.S)                  |
| COVID-19pneumonia                                            | NA                      | 4 (1.4)                  |
| Neuhopenia                                                   | NA                      | 3 (1.1)                  |
| Infusionrelatedreaction                                      | NA                      | 2 (0.7)                  |

## 2.5.1. Discussion on clinical safety

Acalabrutinib, is a selective BTKi. The qualitative safety profile of BTKi is well characterised. Class related concerns include gastrointestinal (GI) disturbances (diarrhoea, nausea, and vomiting), cytopenias, bleeding events, and infections. Other toxicities that have been associated with BTKi include atrial fibrillation and hypertension.

The safety profiles of venetoclax and obinutuzumab are also well described, including e.g., GI-side effects, TLS and infections for the former, and infections for the latter. Additive or synergistic effects are anticipated with regards to cytopenias and infection.

## AMPLIFY study

A total of 834 patients (291 in AV arm, 284 in AVG arm, and 259 in FCR/BR arm) received at least one dose of any study treatment.

The evaluation of the safety profile of ABR is additionally supported by safety and tolerability data of acalabrutinib monotherapy from 1478 patients in an 11-study pool (Acalabrutinib Monotherapy Pool) and 1095 patients in a Combination Therapy Pool, with data from 4 studies, including ABR (acalabrutinib + BR) and AG (acalabrutinib + obinutuzumab) combination regimens.

## Exposure

<div style=\"page-break-after: always\"></div>

The median durations of exposure to acalabrutinib (12.9 months in Arm A and Arm B) and venetoclax (Arm A: 11.1 months and Arm B: 11.0 months). The median duration of exposure to obinutuzumab was 5.5 months in Arm B. For Arm C, the median durations of exposure were approx. 2.3 times shorter than for acalabrutinib in Arm A and Arm B, i.e. for fludarabine, cyclophosphamide, and bendamustine it was 5.6 months each and 5.5 months for rituximab.

A total of 95.9% and 93.3% of patients in the AV and AVG arms, respectively, received &gt; 6 months exposure to acalabrutinib, and 91.1% and 84.2% of patients received &gt; 12 months exposure. The median exposure to acalabrutinib was 13 months with a maximum of 18 months.

The number of patients per treatment arm and overall exposure is sufficient to characterize the safety profile of the combination of acalabrutinib with venetoclax and Obinutuzumab.

## Adverse Events and Deaths

Grade ≥ 3 TEAEs occurred in 53.6%, 69.4%, and 60.6% of patients in Arm A (AV), Arm B (AVG), and Arm C (FCR/BR), respectively. The incidence of serious TEAE of Grade ≥ 3 was similar in Arm A and Arm C (22.3% and 24.7%, respectively) but more frequent in Arm B (AVG) (33.1%).

The overall incidences of patients with CTCAE Grade ≥ 3 AEs, AEs leading to dose withholding of acalabrutinib, SAEs, and AEs leading to discontinuation of study drug were numerically higher in the AVG arm than in the AV arm.

The TEAEs by PT with the highest incidences were for the AV Arm: headache (35.1%), diarrhoea (32.6%), and neutropenia (30.9%); for the AVG Arm: neutropenia (40.1%), diarrhoea (36.3%), headache (28.2%), nausea (21.8%), and COVID-19 (20.4%); and for the FCR/BR: neutropenia (38.2%), nausea (35.9%), and infusion related reaction (32.8%).

The most common TEAEs reported in the AV and AVG arms in the AMPLIFY study were consistent with the known individual safety profiles of acalabrutinib, venetoclax, and obinutuzumab.

Patients experiencing ≥1 Grade ≥3 TEAE were; AV 156 patients (53.6%), in AVG 197 (69.4%) patients and in FCR/BR 157 (60.6%) patients. The most common Grade ≥ 3 TEAEs were neutropenia in all treatment arms with fairly similar frequencies: AV 26.8%, AVG 35.2% and FCR 29.5%, BR 35%). Grade ≥ 3 febrile neutropenia events were reported in 5 (1.7%) patients in the AV arm, 7 (2.5%) patients in the AVG arm, and 24 (9.3%) patients in the FCR/BR arm.

Overall, TE SAEs in the AMPLIFY study were reported in 24.7%, 38.4%, and 27.4% of patients in the AV, AVG, and FCR/BR arms, respectively. The SAEs with the highest incidence were in Arm A (AV) COVID-19 pneumonia (5.8%); in Arm B (AVG), COVID-19 pneumonia (11.3%) and COVID-19 (6.0%); and in Arm C (FCR/BR), febrile neutropenia (8.1%).

Deaths: In the safety population, at the DCO, 18 patients (6.2%) have died in Arm A (AV), 36 patients (12.7%) in Arm B (AVG) and 42 patients (14.5%) in Arm C (FCR/BR). The primary cause of death was due to adverse reaction; 16 patients (5.5%) in Arm A (AV), 29 patients (10.2%) in Arm B (AVG) and, 28 patients (10.8%) in Arm C (FCR/BR). In Arm A (AV) death due to adverse event within 30 days of last dose of study drug was reported for 10/16 patients (62%) and 6/16 patients (38%) died more than 30 days after last dose. In Arm B (AVG) 11/29 patients (38%) had died within 30 days of last dose and 18/29 patients (62%) died more than 30 days after last dose. In Arm C (FCR/BR) 7/28 patients (25%) had died within 30 days of last dose and 21/28 patients (75%) died more than 30 days after last dose.

The majority of deaths were reported with infection as the primary cause, mainly Covid-19 and Covid19 pneumonia. Of the 291 patients treated with AV, fatal infections occurred in 3.1% of patients (most frequently reported COVID-19 or COVID-19 pneumonia). Of the 284 patients treated with AVG, fatal

<div style=\"page-break-after: always\"></div>

infections occurred in 5.6% of patients (most frequently reported COVID-19 or COVID-19 pneumonia). In addition, for AVG there seemed to be a longer time from initiation of therapy to death when comparing to the FCR/BR arm, and 16 infectious deaths out of 24 were reported post-therapy. Thus, for the AVG combination the risk of death due to infection also longtime after therapy is of concern.

The risk of severe and potentially fatal infections is highlighted in Section 4.8 of the SmPC for both AV and AVG treated patients.

Cytopenias were also common in all three treatment arms. The rate of neutropenia in Arm A (AV) is 37.1% vs the similar rates in Arm B and Arm C, 50.4% and 51.0%, respectively.

Anaemia occurred at numerically lower incidences in the AV and AVG arms compared to the FCR/BR arm, for Grade &gt;3 anaemia it was 3.8% and 2.1% versus 6.6%, respectively.  Thrombocytopenia grade ≥ 3 was infrequent in the AV arm, 2.1% and occurred with similar rate in AVG and FCR/BR arms, 9.2% and 10.8%, respectively.

Cytopenias are covered by the present language in the SmPC section 4.2 with dose modifications in relation to grade 3 thrombocytopenia with bleeding, grade 4 thrombocytopenia or neutropenia, and other non-haematological grade 3 or greater toxicities. In the SmPC section 4.4 there is relevant information present in separate paragraphs with subheading 'Infections' and 'Cytopenias'. The haematological ADR frequencies are reflected in table 4.8 of the SmPC. Overall, the current SmPC text is considered sufficient.

Infections and cytopenia's, mainly neutropenia, are frequent in the AV regimen and further increases in frequency with the addition of obinutuzumab in the AVG regimen.

All grade haemorrhages were more frequent in the acalabrutinib containing Arm A (AV) and Arm B (AVG), 32.3% and 30.3% respectively compared to the Arm C (FCR/BR) 4.2%. Which is consistent with the known BTKi toxicity profile including increased bleeding events. The majority was of lowgrade: contusions, haematomas and petechias. The Grade ≥ 3 haemorrhages were infrequent for all treatment arms: Arm A (AV) 1.0%, Arm B (AVG) 2.1% and Arm C (FCR/BR) 0.4%. Also, the Major haemorrhages (any serious or Grade ≥ 3 or CNS haem orrhage of any severity grade) occurred at a low frequency in all arms 1.0%, 2.8% and 0.8% in the AV, AVG and FCR/BR arms respectively.

There was an exclusion of some patients at higher risk of intracranial haemorrhage in AMPLIFY study (patients with a history of stroke or intracranial haemorrhage within 6 months prior to randomisation). However, this is viewed as being standard exclusion criteria in haematological malignancies, and comparable exclusion of patients at increased risk of bleeding has been made in other BTKi registrational studies while not reflected in their respective SmPC. Thus, the current warning under the subheading 'Haemorrhage' in the Calquence SmPC, section 4.4 is considered sufficient.

Grade ≥ 3 hepatotoxicity events were reported in 3.4%, 2.8%, and 1.5% of patients. There were no fatal hepatotoxicity events in either arm. The majority of hepatotoxicity events were low grade transaminase elevations.

Cardiac events of any grade were reported in 9.3%, 12.0%, and 3.5% of patients in the AV, AVG, and FCR/BR arms, respectively and Grade ≥ 3 cardiac events were reported in 1.7%, 2.5%, and 1.2%, respectively. One patient in the AV arm died of cardiac arrest. There were no cases with ventricular fibrillation or fatal atrial fibrillation reported in the AMPLIFY study.

The incidence and severity of hypertension events was similar in AV and AVG arms and slightly less in the FCR/BR arm. Any grade hypertension occurred in 4.1%, 3.9%, and 2.7% of patients in the AV, AVG, and FCR/BR arms respectively, and Grade ≥ 3 events occurred in 2.7%, 2.1%, and 0.8% of patients, respectively.

<div style=\"page-break-after: always\"></div>

Interstitial lung disease (ILD)/pneumonitis of Grade 1 and 2 occurred in 1.8% of patients in the AVG arm and there was 1 patient (0.4%) in the FCR/BR arm who experienced a Grade 3 event. ILD/pneumonitis is not an ADR for venetoclax or obinutuzumab. No patient had an event of ILD/pneumonitis in the AV arm.

There was an overall low incidence of second primary malignancies (SPM) in all arms, likely due to the short TEAE observation period. SPM were reported in 5.2%, 4.2%, and 0.8% of patients in the AV, AVG, and FCR/BR arms, respectively.

TLS events in the AV and AVG arms was low. One patient each in the AV arm and AVG arm. There were 8 (3.1%) patients in the FCR/BR arm (all of whom received BR). All TLS events reported were Grade ≥ 3 in severity. No Grade 5 TLS events were reported. However, TLS mitigation strategies were employed in the AMPLIFY study. A lower frequency of any TLS prophylaxis was used in the FCR/BR arm (66%) compared to the AV and AVG -arms (79% and 74% respectively). TLS is listed as an ADR in the Calquence SmPC section 4.8, and now a warning has been included in the SmPC that patients considered at risk for TLS (e.g., presence of bulky disease at baseline) should be assessed for possible risk of TLS and closely monitored as clinically indicated.

The frequency of patients with &gt;1 AE leading to discontinuation of any study treatment were 7.9%, 20.1% and 10.8% in the AV, AVG and FCR/BR arms respectively. There were 7.6% in AV and 13.7% in AVG who discontinued acalabrutinib due to TEAEs. The most common TEAE was Covid-19 pneumonia in AV and Covid-19 in AVG.

## 2.5.2. Conclusions on clinical safety

The combination of acalabrutinib and venetoclax with and without obinutuzumab results in clinically relevant toxicities, particularly with respect to the risks of cytopenias and infection. The addition of obinutuzumab results in a worse side effect profile with respect to these risks.

These risks are mostly anticipated and qualitatively well-known and can be managed with the current SmPC warnings.

Overall, the safety profile of the proposed combination treatment is sufficiently characterised.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated risk management plan (RMP) version 8.2 with this application.

The CHMP received the following PRAC Advice on the submitted RMP:

The PRAC considered that the RMP version 8.2 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the RMP version 8.2 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Important identified risks   | Haemorrhage with or without association with thrombocytopenia Serious infections with or without association with neutropenia Second primary malignancy Atrial fibrillation/flutter   |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Cerebrovascular events Hepatoxicity                                                                                                                                                   |
| Missing information          | Long-term safety Use in patients with moderate to severe cardiac impairment                                                                                                           |

## Pharmacovigilance plan

| Study & status                                                | Summary of objectives                                                                                                                                                                                                                    | Safety concerns addressed                                                  | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities              | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| ACE-CL-007 Ongoing                                            | The primary objective of this study is to evaluate the efficacy and safety of CALQUENCE in treatment-naïve CLL patients (as monotherapy or combination therapy with obinutuzumab).                                                       | Long-term safety including SPM                                             | Interim report                                                | Q3 2022                                                       |
| ACE-CL-007 Ongoing                                            | The primary objective of this study is to evaluate the efficacy and safety of CALQUENCE in treatment-naïve CLL patients (as monotherapy or combination therapy with obinutuzumab).                                                       | Long-term safety including SPM                                             | Final report                                                  | Q1 2026                                                       |
| D8223C00016                                                   | The primary objective is this study is to evaluate the safety and tolerability of acalabrutinib monotherapy vs investigator's choice of treatment in patients with treatment-naïve or R/R CLL and moderate to severe cardiac impairment. | Safety in patients with pre-existing moderate to severe cardiac impairment | Protocol Submission                                           | Apr2024                                                       |
| D8223C00016                                                   | The primary objective is this study is to evaluate the safety and tolerability of acalabrutinib monotherapy vs investigator's choice of treatment in patients with treatment-naïve or R/R CLL and moderate to severe cardiac impairment. | Safety in patients with pre-existing moderate to severe cardiac impairment | Final Report                                                  | Q4 2029                                                       |

## Risk minimisation measures

| Safety concern                                                  | Risk minimisation measures                                       |
|-----------------------------------------------------------------|------------------------------------------------------------------|
| Haemorrhage with or without association with thrombocytopenia   | Routine risk minimisation measures : SmPC section(s) 4.4 and 4.8 |
| Serious infections with or without association with neutropenia | Routine risk minimisation measures : SmPC section(s) 4.4 and 4.8 |
| Second primary malignancy                                       | Routine risk minimisation measures : SmPC section(s) 4.4 and 4.8 |

<div style=\"page-break-after: always\"></div>

| Safety concern                                             | Risk minimisation measures                                       |
|------------------------------------------------------------|------------------------------------------------------------------|
| Atrial fibrillation/flutter                                | Routine risk minimisation measures : SmPC section(s) 4.4 and 4.8 |
| Cerebrovascular events                                     | None                                                             |
| Hepatotoxicity                                             | Routine risk communication: SmPC section 4.2                     |
| Long-term safety                                           | None                                                             |
| Use in patients with moderate to severe cardiac impairment | Routine risk communication: SmPC section 4.2                     |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet (PL) has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and found acceptable as the proposed changes are limited and not considered to significantly affect the readability of the package leaflet.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Chronic lymphocytic leukaemia is the most prevalent form of adult leukaemia. It is characterised by a progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin. CLL has an age adjusted incidence of 3.3-6.4 per 100000 person-years and a median age at diagnosis of 70 years.

The presently sought indication is: 'Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).'

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

CLL is an incurable disease that is clinically and biologically heterogeneous, ranging from indolent with no treatment requirement, to a very aggressive disease characterised by chemo-refractoriness and poor survival.

The choice of frontline treatment options for CLL depends on patient characteristics, such as patient's age and overall health, and disease characteristics, including the presence of certain chromosomal abnormalities and mutations.

The development of BTK inhibitors and the apoptosis regulator BCL2 antagonist venetoclax, has transformed the treatment paradigm for patients with CLL, particularly for those with high-risk disease who have inferior outcomes with chemotherapy-based regimens. Targeted treatment (BTKi or venetoclax) with or without anti-CD20 mAbs is the therapy of choice in most front-line CLL settings regardless of mutational status. However, immunochemotherapy (e.g. FCR or BR) is also indicated in young and fit patients with mutated IGHV.

## 3.1.3. Main clinical studies

Study ACE-CL-311 or AMPLIFY is a randomised, multicentre, open-label, Phase III study comparing the efficacy and safety of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemoimmunotherapy FCR or BR in patients with previously untreated CLL without del(17p) or TP53 mutation.

A total of 867 patients were randomised in the global cohort in 1:1:1 ratio into 3 arms to receive (study schema is presented in Figure 5): acalabrutinib for 14 cycles and venetoclax cycle 3-14 (Arm A), acalabrutinib for 14 cycles; obinutuzumab cycle 2-7 and venetoclax Cycle 3-14 (Arm B) or 6 cycles of either FCR or BR, according to investigator's choice (Arm C).

The primary endpoint was PFS assessed by IRC for Arm A vs Arm C. Secondary endpoints were alpha protected in a fixed hierarchical manner beginning with IRC assessed PFS for Arm B vs Arm C, followed by MRD negativity rate and OS (both tested in Arm A vs Arm C and Arm B vs Arm C, respectively).

The FAS included 291 patients in Arm A [AV], 286 patients in the Arm B [AVG]) and 290 patients in the Arm C [FCR/BR].

Due to the choice of chemoimmunotherapy (BR/FCR) as control arm, patients with a detected del17p or TP53 mutation were excluded from study enrolment.

## 3.2. Favourable effects

In the primary analysis, a PFS event was registered for 30.6% of patients in Arm A and 32.8% in Arm C. A statistically significant effect on IRC-assessed PFS was shown with a HR 0.65 (95% CI [0.49, 0.87]).

Statistically significant IRC-assessed PFS was also shown for Arm B as compared with Arm C, with HR 0.42 (95% CI [0.30, 0.59]). In this analysis, a PFS event was registered for 19.6% of patients in Arm B and 32.8% in Arm C.

Median PFS was 47.6 months in Arm C and, at the DCO, not yet reached in Arm A or Arm B.

<div style=\"page-break-after: always\"></div>

In an updated OS analyses with DCO of 30 October 2024, data maturity was 12% in the Arm A versus Arm C analysis, and 14% in the Arm B vs Arm C analysis. In the analysis of Arm A versus Arm C, the OS HR was 0.42 (95% CI: 0.25, 0.70). The OS HR for Arm B versus Arm C was 0.75 (95% CI: 0.48, 1.16).

## 3.3. Uncertainties and limitations about favourable effects

The impact of treatment on OS remains uncertain due to lack of statistical significance, as well as low maturity of data.

The study was not powered for a comparison of AV versus AVG.

## 3.4. Unfavourable effects

The main safety population included a total of 834 patients (291 in AV arm, 284 in AVG arm, and 259 in FCR/BR arm) that received at least one dose of any study treatment.

The median duration of exposure to acalabrutinib were 12.9 months in Arm A and Arm B and for venetoclax it was 11.1 and 11.0 months in Arm A and Arm B, respectively. The median duration of exposure to obinutuzumab was 5.5 months in Arm B. For Arm C, the median durations of exposure were approx. 2.3 times shorter than for acalabrutinib in Arm A and Arm B, i.e. for fludarabine, cyclophosphamide, and bendamustine it was 5.6 months each and 5.5 months for rituximab.

The most frequently reported TEAEs by PT were for the AV Arm: headache (35.1%), diarrhoea (32.6%), and neutropenia (30.9%); for the AVG Arm: neutropenia (40.1%), diarrhoea (36.3%), headache (28.2%), nausea (21.8%), and COVID-19 (20.4%); and for the FCR/BR: neutropenia (38.2%), nausea (35.9%), and infusion related reaction (32.8%).

Although neutropenia rates were high in all three arms (30.9%, 40.1% and 38.2%, in AV, AVG and FCR/BR, respectively) there were more frequent COVID-19 infections in the AV and AVG arms (18.9% and 20.4%) than in the FCR/BR arm 2.3%. This pattern was also seen for COVID-19 pneumonia (7.2% in AV, 12.3% in AVG and 2.7% in FCR/BR) and upper respiratory tract infection (8.2% in AV, 6.3% in AVG and 1.9% in FCR/BR), while the frequency of pneumonia was more similar across all arms (3.8% in AV, 5.3% in AVG and 3.1% in FCR/BR).

The most common Grade ≥ 3 TEAEs were neutropenia in all treatment arms: AV 26.8%, AVG 35.2% and FCR 29.5%, BR 35%). Grade ≥ 3 febrile neutropenia events were less frequent in AV (1.7%) and AVG (2.5%) compared to the FCR/BR arm (9.3%). Grade ≥ 3 COVID-19 and COVID-19 pneumonia were most frequently reported in the AVG arm (11.6% and 6.7%), while less frequent in the AV arm (5.5% and 2.7%) and in the FCR/BR arm only 2.7% and 1.5% experienced COVID19 pneumonia and COVID-19, respectively.

Grade 5 TEAEs, were reported for 10 (3.4%), 17 (6.0%), and 9 (3.5%) patients in the AV, AVG, and FCR/BR arms, respectively. The most frequently reported Grade 5 TEAEs were COVID-19, COVID-19 pneumonia, and suspected COVID-19, accounting for 8 of 10 deaths deemed treatment emergent in the AV arm, 15 of 17 such deaths in the AVG arm, and 7 of 9 such deaths in the FCR/BR arm, or 2.7%, 5.3%, and 2.7% of patients overall, respectively. Deaths &gt; 30 days after of the last dose of study treatment occurred in 8 (2.7%), 25 (8.8%), and 35 (13.5%) patients in the AV, AVG, and FCR/BR arms, respectively.

<div style=\"page-break-after: always\"></div>

The incidence of TEAEs leading to discontinuation of any study treatment was 7.9% in AV, 20.1% in AVG, and 10.8% in FCR/BR. The incidence of TEAEs leading to acalabrutinib discontinuation was 7.6 % in AV and 13.7% in AVG. The most frequently reported TEAEs that led to discontinuation of acalabrutinib in the AV and AVG arms were COVID-19 pneumonia (2.1% and 2.8%, respectively) and COVID-19 (0.3% and 3.9%, respectively).

## 3.5. Uncertainties and limitations about unfavourable effects

Exposure time is approximately 2.3 times longer in AV and AVG arms compared to the FCR/BR arm which complicates the direct comparison of TEAE rates between the experimental regimens and the reference arm.

## 3.6. Effects Table

Table 43. Effects Table for Calquence in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated CLL (30 October 2024).

| Effect               | Short description                                                                                       | Unit                       | Arm A AV                          | Arm B AVG                            | Arm C FCR/BR           | Uncertainties / Strength of evidence                                                                                                        | Referenc es          |
|----------------------|---------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------|--------------------------------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                                                                      | Favourable Effects         | Favourable Effects                | Favourable Effects                   | Favourable Effects     | Favourable Effects                                                                                                                          | Favourable Effects   |
| PFS                  | Time from randomisation until disease progression (according to the IWCLL 2018 criteria - IRC-assessed) | N (%) HR (95% CI) p- value | 89 (30.6) 0.65 (0.49,0.87) 0.0038 | 56 (19.6) 0.42 (0.30, 0.59) < 0.0001 | 95 (32.8) - -          | SoE: Statistically significant IRC assessed PFS for Arm A vs Arm C and for Arm B vs Arm C Consistent results with Investigator assessed PFS | AMPLIFY study        |
| OS                   | Time from randomisation to death from any cause                                                         | n (%) HR (95% CI)          | 23 (7.9) 0.42 (0.25, 0.70)        | 37 (12.9) 0.75 (0.48, 1.16)          | 44 (15.2) -            | Unc: Study not powered for OS, immature data, median not calculable for any arm                                                             | AMPLIFY study        |
| Unfavourable Effects | Unfavourable Effects                                                                                    | Unfavourable Effects       | Unfavourable Effects              | Unfavourable Effects                 | Unfavourable Effects   | Unfavourable Effects                                                                                                                        | Unfavourable Effects |
| Grade 3/4 TEAE       | Incidence: Any Infections Neutropenia Hepatotoxicity Cardiac events                                     | %                          | 53.6 12.4 32.3 3.4 1.7            | 69.4 23.6 46.1 2.8 2.5               | 60.6 10.0 43.2 1.5 1.2 | SoE: Data from adequately sized RCT Unc: Exposure time approx. 2.3 times longer in AV and AVG vs.                                           | AMPLIFY study        |
| Discontinu ation     | TEAE leading to discont- inuation of acalabrutinib                                                      | %                          | 7.6                               | 13.7                                 | -                      | FCR/BR.                                                                                                                                     | AMPLIFY study        |

Abbreviations: CLL: chronic lymphocytic leukaemia; AV: acalabrutinib and venetoclax; AVG: acalabrutinib, venetoclax and obinutuzumab FCR: fludarabine, cyclophosphamide and rituximab;  BR: Bendamustine and

<div style=\"page-break-after: always\"></div>

Rituximab;  NC: Not calculable; PFS: progression free surbvival; IWCLL: International Workshop on Chronic Lymphocytic Leukemia; IRC: independent review committee;HR: hazard ratio; CI: confidence inetval; OS: overall survival; SoE: strength of evidence; Unc: uncertainity; TEAE: Treatment Emergent Adverse Event

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Efficacy has been established in the form of a clinically meaningful prolongation of PFS with fixedduration therapy with AV or AVG as compared with investigator's choice of chemoimmunotherapy (FCR or BR). Safety concerns primarily relate to cytopenias and infection risks.

While patients with del(17p) or TP53 mutations were excluded from the AMPILFY study because of the unsuitable comparator, the efficacy of acalabrutinib and venetoclax in the claimed indication has been characterised in other studies (ELEVATE-TN, CLL14 and SAT NCT03580928). Therefore, beneficial effects of the proposed new treatment regimens may be extrapolated to these patients as well.

The addition of obinutuzumab to acalabrutinib and venetoclax results in an increased side effect burden. However, it also provides more antitumoral activity as evidenced by the reduced HR in PFS compared to acalabrutinib and venetoclax alone.

While OS data are immature, the trends are reassuring, favouring the test arms, and the levels of uncertainty acceptable. There is no indication of a detrimental effect on OS. OS data maturity and statistical robustness is not sufficient to infer any differences in survival outcomes between AV and AVG.

## 3.7.2. Balance of benefits and risks

The benefit of the longer PFS of acalabrutinib in combination with venetoclax with or without obinutuzumab is deemed to outweigh the observed increased toxicity of these combinations and which can be managed with the risk minimisation measures as reflected in the product information.

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of Calquence in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                | Type    | Annexes affected   |
|----------------------|-------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an | Type II | I and IIIB         |

Extension of indication to include CALQUENCE in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL), based on interim results from study AMPLIFY (D8221C00001);  this is a randomised, multicentre, open-label, phase 3 study of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemoimmunotherapy in subjects with previously untreated CLL without del(17p) or TP53 Mutation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.2 of the RMP was also submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion ''Calquence-EMEA/H/C/005299/II/28'